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Brain acid soluble protein 1 (BASP1) is a transcriptional corepressor of the Wilms’ 
Tumour 1 (WT1) transcription factor. Previous work from the lab demonstrated that 
N-terminal myristoylation of BASP1 facilitates an interaction with nuclear lipids such 
that PI(4,5)P2 is recruited to WT1 target gene promoters. PI(4,5)P2 is required for 
the assembly of chromatin remodelling complexes to mediate transcriptional 
repression. BASP1 also interacts with cholesterol through a cholesterol recognition 
amino acid consensus (CRAC) domain, although the role of cholesterol in BASP1-
dependent transcription regulation is unknown.  
In this study, the mechanisms of WT1/BASP1 mediated transcriptional regulation 
employing nuclear lipids were investigated. This work revealed for the first time that 
BASP1 mediates the removal of multiple activating histone modifications, H3K9Ac, 
H3K4me3 and H3K36me3 in a myristoyl-dependent manner. BASP1 was also found 
to mediate the addition of repressive histone modifications, H3K9me3 and 
H3K27me3, plus recruitment of EZH2 in a myristoyl-independent manner. 
The role of cholesterol in transcriptional repression by BASP1 was also 
investigated. Using click-chemistry and chromatin immunoprecipitation, it was 
demonstrated that BASP1 can recruit cholesterol to gene promoters. Nuclear 
cholesterol was found to be an important component of the WT1/BASP1 repression 
complex, involved in removing H3K4me3 at specific WT1/BASP1 target genes.  
The subnuclear localisation of BASP1 was investigated to explore how BASP1 
interfaces the inner nuclear membrane (INM) with chromatin modification and gene 
regulation. For the first time BASP1 was found to interact with Emerin and recruit 
several INM proteins to WT1 target gene promoters in a myristoyl-dependent 
manner. The evidence presented supports a model whereby the interaction 
between BASP1 and INM components is important for mediating transcriptional 
repression. These findings implicate PI(4,5)P2 as a linker between BASP1 and INM 
proteins. 
Together the findings reveal critical roles for PI(4,5)P2 and cholesterol in mediating 
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1.1 Gene Expression 
Every cell in the body originates from one fertilised ovum containing one DNA code. 
In humans this code is spread across 23 pairs of chromosomes, half of maternal 
and half of paternal origin [13]. As the ovum divides to produce more cells, each and 
every cell contains an identical copy of DNA code and yet it is clear that brain, heart, 
skin and every individual type of cell ultimately appears and functions quite uniquely 
[13]. The finely controlled differences in how each cell type appears and functions is 
down to its unique gene expression pattern [13]. Of the approximate 20,000 genes 
encoded in the human genome, a precise combination of genes is expressed in any 
given cell type, allowing cells to become specialized for their functions [13, 14]. 
Gene expression is the fundamental process through which a cell’s DNA code is 
translated into functioning RNA and protein molecules which work to fulfil the 
requirements of the cell. The process of gene expression is used by every known 
life form, from prokaryotes and eukaryotes to viruses [15]. The multistage process of 
gene expression begins as double stranded DNA is unwound and separated, and 
one strand of code forms a template for the synthesis of an RNA transcript (see 
Figure 1.1) [15]. In the case of protein coding genes, genes are transcribed into 
‘messenger’ RNA (mRNA) which is then edited, translated into protein, and can then 
be subject to further post translational modifications which control protein function 
[16]. 
Both transcription and translation of a gene product are essential for gene 
expression to result in protein production. Initially, this sequence of events was 
assumed to be true for all gene products, however insights such as those provided 
by large scale gene studies including the human genomes project proved that gene 
transcription occurs at a much higher level than translation, resulting in the 
production of many more RNA products than ever get translated into protein [14, 17, 
18]. There are four main types of RNA product each encoded by its own type of 
gene; transfer RNA (tRNA), ribosomal RNA (rRNA), small nuclear RNA (snRNA) 
and messenger RNA (mRNA) [19]. Only mRNA, which accounts for approximately 
1-5% of all RNA in the cell is translated into protein, but tRNA, rRNA and snRNA all 
play vital roles in the splicing, processing and translation of mRNA into protein [19]. 
MicroRNAs (miRNAs) are a further class of small non coding RNAs, which also 
contribute to regulating the expression of up to 30% of protein coding genes in 
14 
 
mammals [20]. Additional levels of gene product regulation occur outside of the 
nucleus, where mRNAs can undergo degradation, and translated products are 
subject to a range of post-translational modifications to control protein activity [15, 
16, 21, 22]. 
  
Figure 1.1 The Gene Expression Process. When a gene is expressed a copy of the 
DNA code is produced in the form of an RNA transcript (transcription). mRNA transcripts 
go through several stages of editing and processing, and mRNAs are then transported out 
of the nucleus to undergo translation into an amino acid sequence, which further folds to 
form the final 3D protein structure. Protein activity can then be altered in a variety of ways 
including through the addition or removal of protein modifications. Alternatively, cytosolic 
mRNA transcripts can also undergo degradation as an additional level of regulation of 
gene products. Control over gene products occurs at all levels from the initial production of 
an RNA transcript to RNA degradation and protein (in)activation. This multi-layered 
approach enables cells to precisely regulate gene products, and therefore respond quickly 




1.2 Gene Regulation 
Many diseases can be caused by uncontrolled gene expression whereby the cell 
experiences aberrant upregulation or downregulation of certain genes which causes 
abnormal cell function, such as the excessive growth and division that befalls 
cancer cells [23]. Therefore, it is vital that gene expression is tightly regulated on a 
number of levels to ensure it is precisely controlled. In both eukaryotes and in 
bacteria the regulation of transcription initiation is the predominant form of gene 
regulation for most genes [22]. The regulation of transcription initiation primarily 
occurs through regulating chromatin structure and regulating the assembly and 
progression of the transcription machinery. This is intricately controlled through the 
binding of transcription factors and cofactors to regulatory DNA sequences such as 
promoters and enhancers [22]. 
1.2.1 Transcription Machinery 
In eukaryotes, transcription itself is carried out by the enzyme RNA polymerase in 
concert with a number of proteins known as the general transcription factors [24]. 
The general transcription factors are responsible for the recognition of specific 
regulatory DNA sequences called gene promoters [22]. The general transcription 
factors act at the core promoter which is located ~30 base pairs (bp) upstream of 
the transcription start site (TSS). The general factors are also responsible for 
responding to additional regulatory factors and mediating the appropriate changes 
in RNA polymerase protein conformation to allow correct RNA polymerase activity 
throughout the transcription process [15, 24]. Bacteria and archaea have one RNA 
polymerase enzyme, however most eukaryotes use three enzymes to synthesise 
different types of RNA (RNA polymerase I-III) [24]. The RNA polymerase II 
transcription machinery is the most complex of the eukaryotic transcription 
machineries, with a total of almost 60 components [24]. It is also RNA polymerase II 
which is responsible for the synthesis of mRNA [15]. Although there are many more 
subunits which comprise eukaryotic RNA polymerase II than bacterial RNA 
polymerase, the catalytic subunits are homologous and display similar structure and 





Figure 1.2 The Molecular Basis of Transcription Initiation, Elongation and Termination. A, Assembly begins with the binding of transcription factor 
TFIID to the TATA box.  TFIID comprises the TATA-binding protein (TBP) plus associated factors (TAFs) shown as one large symbol. TFIIA then binds the 
TFIID promoter complex, followed by TFIIB, followed by binding of a preformed TFIIF/RNA Polymerase II complex. Finally, the other factors TFIIE and 
TFIIH bind and complete the preinitiation complex. B, The DNA helicase activity of TFIIH separates strands of the template DNA and RNA polymerase II 
(Pol II) begins to transcribe the first 8-9 nucleotides. The protein kinase activity of TFIIH (CDK7 subunit) phosphorylates serine 5 residues (S5) in the C-
terminal repeat domain (CTD) of Pol II. This allows Pol II to transcribe beyond the immediate promoter region (promoter clearance). S5 phosphorylation 
also recruits capping enzymes to cap the 5’ end of the nascent transcript. TFIIE is then released from initiation complex. Next, as the pre-mRNA chain 
grows, the P-TEFb complex (CDK9 subunit) phosphorylates Serine 2 (S2) residues in the Pol II CTD, allowing it to move freely along the DNA template. 
Then TFIIH dissociates. Finally, Pol II reaches termination signals (stop codons) in the DNA sequence and factors that cleave the transcript from the CTD, 








The sequence of events that underlies the assembly of the general transcription 
machinery beginning with the formation of the preinitiation complex followed by 
transcription initiation, RNA polymerase II pausing, transcription elongation and 
finally transcription termination are depicted in Figure 1.2 [26-29]. Commonly, the 
RNA polymerase II mediated transcription process is triggered by the binding of 
regulatory transcription factors to the gene promoter and enhancer sequences 
which directly recruit components of the transcription machinery, starting with the 
TATA binding protein (TBP) [15]. Transcription factors can be repressors or 
activators of transcription initiation, and in eukaryotes a single gene promoter may 
be regulated by the simultaneous binding of multiple transcription factors at multiple 
additional regulatory DNA sequences to provide extra regulatory control [22]. 
Transcription factors are commonly modular proteins comprising distinct functional 
domains including a DNA binding domain which can take one of a number of 
structures; commonly either a homeodomain, basic leucine zipper, helix-loop-helix 
or a zinc finger structure [30]. Transcription factors also contain one or several 
activation and/or repression domains which interact with cofactors to stimulate or 
repress transcription [30]. Some transcription factors also form heterodimers which 
enables them to bind more DNA sites and interact with more cofactors to control 
transcription [30]. The transcriptional output following binding of a transcription 
factor to a target gene promoter depends on the particular cofactors recruited and 
the influence of other regulatory sequences such as enhancers.  
Enhancers help determine spatiotemporal and quantitative gene transcription 
programmes during development and in response to environmental stimuli [31]. 
Like promoters, enhancers are also bound by transcription factors and cofactors 
which results in modulation of the local chromatin environment and alters the 
accessibility of promoter sequences [32]. Enhancers can be located several 
thousand base pairs upstream or downstream of target gene promoters but can 
activate gene expression through DNA looping [32]. More recently enhancer 
sequences have also been found to be pervasively transcribed into enhancer 
RNAs (eRNAs) [31]. Whilst further evidence is needed to fully understand the 
function of eRNAs, early work suggests they may further support transcription 
activation of target coding genes by modifying chromatin structure to make promoter 
sequences more accessible, stabilising enhancer-promoter interactions, trapping 
transcription factors at genomic sites and regulating the pause and release of 




1.2.2 DNA and Chromatin Structure 
Gene expression is further regulated through the control of DNA compaction. The 
billions of base pairs of DNA code that make up eukaryotic genomes is not free 
inside the nucleus, instead it is tightly associated with an approximately equal mass 
of protein [21]. Together DNA and the associated proteins form a structure known 
as chromatin [21]. A dynamic chromatin structure determines the ability of 
transcription factors and the transcription machinery to interact with DNA sequences 
[21]. The basic structural component of chromatin is the nucleosome, consisting of 
146bp of DNA tightly wrapped around the surface of a core histone octamer, in a left 
handed superhelix of almost two turns [33, 34]. Nucleosomes are then condensed 
together into 10nm and then 30nm fibres, and form highly organised coils and loops 
which are finally packed ever more densely into chromosomes (Figure 1.3) [21, 35]. 
Chromatin is categorised into euchromatin, a looser structure that permits gene 
expression, and heterochromatin, a very dense structure that is less accessible to 
external proteins, including the transcription machinery, and is associated with 
transcriptional silencing [21].  
 
A more recent study has argued that chromatin organisation is not quite as 
simplistic as this text-book model, and that at least some regions of chromatin are 
comprised of a flexible and disordered granular chain of between 5 and 24nm [36]. 
The visualisation of chromatin via a DNA labelling method enabled these authors to 
determine that chromatin structure differs in nuclei in different states, with 
interphase nuclei displaying more extended chromatin structure, and mitotic nuclei 
displaying more compact loops [36]. Exactly how changes in chromatin structure are 
regulated is an ongoing area of research. 
Figure 1.3 Packaging of DNA into Nucleosomes and Chromosomes.  Exactly 146bp 
of double stranded DNA is wrapped around a central histone octamer, consisting of two 
H3/H4 and two H2A/H2B heterodimers [1]. Additional linker DNA connects to the adjacent 
nucleosome [9]. Nucleosomes can then progressively form more compact structures; a 
10nm fibre, which condenses into a 30nm fibre, which further condenses into 100-200nm 




1.2.3 Epigenetics  
Regulatory factors can modify how tightly DNA binds to its local histone 
environment, thereby modifying local chromatin structure and controlling access of 
the transcription machinery to DNA sites [24]. The density of the DNA-histone 
binding is controlled by the charge of both components [37]. DNA itself can be 
modified by methylation whilst the lysine rich N-terminus of each histone, which 
extends out from the surface, is exposed to reversible acetylation, phosphorylation, 
methylation and ubiquitination (Figure 1.4) [34]. These modifications are placed and 
removed in a dynamic manner by specific enzymes [38]. Methylation and 
acetylation of histone tails, and methylation of DNA directly effects the stability of 
nucleosome particles by altering the charge attracting the two elements together 
[34, 39]. The more the charges are neutralised the more nucleosomal DNA is 
unwrapped and the more accessible the DNA becomes [34]. Furthermore, modified 
histone tails serve as binding sites for proteins that specifically recognise the post-
translationally modified histone, including chromatin remodelling proteins, which are 
crucial for translocating nucleosomes along the DNA sequence to further control 
accessibility of DNA sequences [34, 40]. Large scale and small scale shifts in the 
density of different chromatin regions is vital to control gene expression in response 
to environmental stimuli and through the key regulatory processes of development 






Figure 1.4 Euchromatin and Heterochromatin.  Euchromatin (open chromatin) is 
permissive of gene expression. Histone acetylation by HATs (histone acetyl transferases) 
and methylation of active lysine residues by HMTs (histone methyl transferases) ensures 
an open chromatin structure accessible to the transcription machinery (TBP – TATA 
binding protein, TAFs – TBP associated factors, TFs – transcription factors, RNA 
polymerase II). Heterochromatin (condensed chromatin) contains silenced genes. 
Histone deacetylation by HDACs (histone deacetylases), methylation of repressive lysine 
residues by HMTs, removal of active lysine methylation marks by KDMs (lysine 
demethylases), and methylation of DNA by DMNT (DNA methyltransferase) ensures 
close association of DNA and histone proteins, and blocks access of the transcription 




1.3 Wilms’ Tumour Suppressor Protein 1 (WT1) 
1.3.1 Introduction to WT1 
The transcription factor Wilms’ tumour protein 1 (WT1) is a major regulator of genes 
involved in a range of important cellular functions; including tissue development, 
growth, differentiation, and apoptosis [42]. During mammalian development WT1 is 
essential for the correct development of a range of tissues and organs including the 
kidneys, spleen, liver, heart and blood vessels, blood cells, body muscle, nervous 
system, eye and lungs [42-44]. WT1 is also a major regulator of adult homeostasis, 
particularly of mesenchymal derived tissues such as bone and fat [45]. The nature 
of WT1 function has been greatly studied over the last two decades, revealing great 
complexity and highlighting the importance of WT1 function in regulating the 
transcription, epigenetic landscape and protein function of its targets for 
development and adult tissue maintenance. 
The importance of WT1 during development is highlighted by the range of 
developmental disorders that result from mutations affecting WT1 function and 
expression levels. Intergenic mutations in DNA-binding domains of WT1, often exon 
8 or 9, leads to developmental abnormalities such as Denys-Drash syndrome, 
Meacham syndrome, gonadal dysgenesis, nephropathy and Wilms’ tumour 
predisposition [46]. Further WT1 point mutations which affect splice sites and the 
balance of WT1 isoforms leads to Frasier syndrome [46]. Mutations leading to loss 
of WT1 function, or deletion of the WT1 gene from chromosome 11, leads to 
aniridia, genitourinary abnormalities and mental retardation (WAGR) syndrome [47]. 
WT1 mutations are also associated with lung, prostate, breast, ovarian cancers and 
leukaemias, plus the formation of tumours including the paediatric nephroblastoma 
Wilms’ tumour (after which it is named) [48-51].  
1.3.2 WT1 Protein Isoforms, Structure and Modifications  
The human WT1 gene is located on human chromosome 11 (band p13) and spans 
approximately 50kb including 10 exons [52]. The region can generate at least 24 
different WT1 protein isoforms through a combination of alternative splicing, RNA 
editing, and use of alternative translation start sites [52]. The two major exons that 
undergo alternative splicing are exon 5 and exon 9, where the entirety of exon 5 (17 
amino acids) and a lysine-threonine-serine (KTS) sequence of exon 9, can be either 
inserted or excluded [53]. The +KTS and -KTS isoforms perform different functions 




most important variations [54]. The +KTS form is known to bind RNA more strongly 
than DNA and is associated with the post-transcriptional regulation functions of WT1 
[54, 55]. Mouse models have also demonstrated that the +KTS form is essential for 
male sex determination and development of the olfactory system [43, 56]. The -KTS 
form of WT1 preferentially interacts with DNA and is generally considered the main 
form of WT1 that regulates transcription. Human and rat WT1 transcripts have been 
identified with either a thymidine or cytosine residue at position 839 in exon 6, 
proposed to be caused by RNA editing and which leads to the incorporation of 
leucine or proline at amino acid 280, respectively. The resulting proteins appear to 
target promoters with differing efficiencies and each play important roles during 
development [57]. Additionally, an alternative (CTG) translation start site 204bp 
upstream of the major ATG start site, and another ATG downstream have also been 
reported and result in the translation of longer and shorter in-frame versions of WT1 
[52, 58, 59].  
 
A schematic depicting the key functional domains and modifications of WT1 is 
shown in Figure 1.5 The WT1 protein contains functionally independent domains 
which enable activation and repression of target genes. Residues 71-180 comprise 
the transcriptional repression domain, and residues 180-250 the transcriptional 
activation domain [60, 61]. Two domains at amino acids 1-45 and 157-253 permit 
protein self-association, although a physiological role for this has not been 
Figure 1.5. Wilms’ Tumour 1 Protein Functional Domains and Modifications. A linear 
schematic of the WT1 protein is shown. Amino acids are numbered, with alternative start 
sites and sumoylation and phosphorylation sites indicated above. Alternative splice sites 
are indicated below. Regions involved in self-association, nuclear export and nucleic acid 
binding are shown. N, N-terminus; SD, suppression domain; R, repression domain; A, 




determined [62]. There are also domains involved in nuclear export, and four zinc 
fingers at the C terminus involved in DNA binding [61].  
The complexity of WT1 function is increased further through post-translational 
modifications and the binding of an array of cofactors. Phosphorylation of WT1 by 
protein kinase A (PKA) or protein kinase C (PKC) at serine 365 and serine 393, 
within the second and third zinc finger domains, blocks DNA (but not RNA binding) 
[63, 64]. Phosphorylation therefore directly effects transcription and decreases 
transcriptional repression. Sumoylation of WT1 at Lysine 73 and Lysine 177, within 
the repression domain, has also been identified although the effect of this 
modification on the transcriptional regulation function of WT1 remains undetermined 
[65].  
Evidence suggests that mutant forms of WT1 can exert a dominant negative effect 
on other WT1 isoforms through self-association, highlighting the necessity to better 
understand the individual functions of WT1 isoforms and their role in disease [66]. 
Ultimately, despite advances in our knowledge of the importance of different WT1 
isoforms, determining the precise roles of individual isoforms for gene regulation, 
development and disease remains a considerable challenge. Further studies in 
mouse models are perhaps the best means to provide insight into isoform functions.  
1.3.3 WT1 as a Transcriptional Regulator 
Transcriptional regulation by WT1 is highly complex largely due to the fact that it 
can function as both a transcriptional activator or repressor towards its targets 
depending on its interaction with specific cofactors [67]. Indeed, WT1 can interact 
with the histone acetyl transferase (HAT) CBP to acetylate histone tails at target 
gene promoters and promote transcription activation, or it may associate with the 
co-repressor brain acid soluble protein 1 (BASP1) and recruit histone deacetylases 
(HDAC), or the CTCF protein to modulate chromatin structure [3, 67-69]. 
Furthermore, WT1 can recruit DNA methyltransferase 1 (DNMT1) which can modify 
both histone tails and DNA itself through methylation [70]. Additionally, WT1 can 
bind DNA directly or it can be recruited to gene promoters by binding to other DNA-
binding proteins including p53 [67, 71]. Thus, WT1 has multiple activities which 
contribute to the state of the local chromatin environment at its target genes. WT1 
activity is further complicated by its multiple splice forms which display distinct 




1.3.4 WT1 and Cancer 
Wilms’ tumour is the most common paediatric renal tumour, accounting for around 
85% of all childhood renal cancers. It affects 1 in 10,000 children, with the median 
age of children at diagnosis being just over 3 years old [72]. The disease occurs at 
significantly higher frequencies in individuals with a genetic predisposition such as 
heritable WT1 mutations [72].   
The tumour driving effect of aberrant WT1 in Wilms’ tumour arises from its essential 
role in kidney development. WT1 is essential for the mesenchymal to epithelial 
transition (MET) of the developing kidney metanephric mesenchyme into the 
epithelial nephron [72, 73]. Work with WT1 mutant mice has highlighted that the 
timing of WT1 mutation is critical in determining the effect of the mutation. WT1 
mutations occurring very early or very late in renal development often do not lead to 
tumour formation, instead often leading to a complete lack of kidney and gonad 
development (early mutations), or glomerular sclerosis (late mutations) [72]. It is 
most likely that WT1 mutation alone is not sufficient to induce tumourigenesis, but 
when the dysregulation of differentiation is combined with mutations leading to 
aberrant proliferation, such as Igf2 overexpression, renal tumour formation can 
occur [72, 74].  
Somatic WT1 mutations occur in between 5-25% of sporadic Wilms’ tumours, 
making WT1 one of the most frequently mutated genes in this cancer type [72, 75]. 
Other common mutations include WTX (18%), TP53 (5%) and MYCN (3.8%). All of 
these are related to WT1, in that WTX is associated with WT1 transcriptional 
control, p53 interacts directly with WT1 to modulate activation of their both target 
genes, and WT1 controls MYCN expression [71, 76, 77]. These findings highlight 
that WT1 can affect multiple pathways in tumour development and progression.  
WT1 mutations are also associated with several types of leukaemia, affecting both 
children and adults, and other adult cancers including lung, prostate, breast and 
ovarian cancers [48, 50, 51]. As WT1 functions to both activate and repress target 
genes it can act as both an oncogene and a tumour suppressor depending on 
cellular context, giving it a highly complex role in tumourigenesis [54, 78]. WT1 is 
expressed at relatively low levels in normal human bone marrow and in leukaemia 
WT1 mutations are relatively uncommon, but aberrant overexpression of WT1 
protein is common, with 80% of immature leukaemia cells expressing higher levels 
of WT1 than more mature cells [79]. The effect of excessive WT1 expression in 




haematopoietic cells, such that when overexpression of WT1 is combined with other 
mutations that block differentiation, like the AML-ETO gene fusion, excessive 
proliferation of immature cells can occur. Therefore, in leukaemia, WT1 
overexpression is associated with poorer prognosis and can be used as an 
independent prognostic factor for survival in acute myeloid leukaemia (AML), acute 
promyelocytic leukaemia (APL) and T-lymphoblastic leukaemia patients [72]. 
In summary, WT1 plays a significant role in a variety of cancers, largely due to its 
significant and far reaching role in development. WT1 mutations predominantly 
affect childhood and adolescent cancers, although WT1’s involvement in some adult 
cancers and solid tumours is also significant. The consequence of WT1 changes is 
highly dependent upon the tissue, the timing and the effect of the mutation on WT1 
expression levels. The complex interactions and functions of WT1 are continually 
being better understood, however there remains poor understanding of how cancer 





1.4 Brain Acid Soluble Protein 1 (BASP1) 
1.4.1 Introduction to BASP1 
BASP1 was initially identified as an N-terminally myristoylated protein from the 
cytoplasm of brain cells [80]. At the time it was grouped with three other proteins, 
BASP2-1, BASP2-2 and BASP3 which shared properties such as a molecular 
weight of 20-24kDa, abnormally low migration via SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE), and very acidic isoelectric points (pI 4.3-4.6) [80]. 
Later BASP2-1 and BASP2-2 were identified as two forms of the neuronal protein 
GAP-43. BASP1 is now commonly regarded as belonging to a family of growth-
associated proteins including GAP-43 and myristoylated alanine rich protein kinase 
C substrate (MARCKS) [81]. Although these proteins do not share sequence 
similarity, they do share several properties including high hydrophilicity, N-terminal 
myristoylation and subsequent linkage to the plasma membrane, preferentially 
within lipid rafts [81]. BASP1, GAP-43 and MARCKS also all share a highly basic 
region which facilitates an interaction with acidic phospholipids, including 
phosphatidylinositol-4,5-bisphosphate (PIP2), Ca2+ bound calmodulin and actin 
filaments. All these interactions are perturbed by PKC-mediated phosphorylation 
[81]. 
In accordance with its expression in neuronal cells, BASP1 has been described as 
being essential for neuronal development [81]. BASP1 expression levels are 
particularly high during brain development, and high levels are maintained into 
adulthood in selected brain regions [81]. During neuronal development BASP1 
causes sequestering of PIP2 in the plasma membrane in a cholesterol dependent 
manner, producing PIP2 rich lipid rafts and cholesterol-depleted domains. The 
formation of these membrane domains and lipid rafts in the plasma membrane are 
essential for subsequent neurite outgrowth [82, 83]. BASP1 is also often reported to 
be involved in axonal growth and guidance [81]. Similarly, overexpression of BASP1 
in adult neurons also promotes sprouting, and is entirely independent of well-
characterised NCAM-mediated neurite outgrowth, which GAP-43 is known to 
contribute to [81, 84]. These findings lead to the conclusion that the primary function 
of BASP1 in neuronal tissues is the regulation of cell morphology, through the 
organisation of lipid rafts prior to neurite outgrowth.  
In addition to its described role as a neuronal membrane protein, BASP1 has been 
identified as a transcriptional regulator. This function of BASP1 was revealed 




binds to the WT1 suppression domain and mediates WT1 target gene repression 
[49]. Further investigation of BASP1 expression in vivo confirmed it is expressed in 
multiple tissues throughout the developing embryo including the heart, lungs, 
thymus, liver, tongue and central nervous system [49]. Importantly, BASP1 is 
spatially and temporally coexpressed alongside WT1 in many of these tissues, 
including the kidney, implicating it as an important regulator of WT1 during 
development [49]. 
1.4.2 BASP1 Protein Structure and Modifications 
BASP1 protein exists in multiple forms due to differences in proteolytic processing 
and post-translational modifications [3, 49, 85, 86]. Several BASP1 isoforms are 
commonly present and the ratio of isoforms varies between BASP1 expressing cell 
types. Myristoylation at the N-terminus of BASP1 is the most notable modification; 
this occurs co-translationally, mediated by N-myristoyltransferase1, and has been 
identified in multiple tissues and cell lines [3]. Myristoylation is critical for BASP1’s 
function as it is the sole source of the protein’s hydrophobic properties which allow it 
to effectively interact with cell membranes and function as a transcriptional 
repressor [3, 80, 81, 86]. After myristoylation, phosphorylation likely has the greatest 
effect on BASP1 function. Phosphorylation at the N-terminal serine 6 residue, a 
PKC target site, causes redistribution of BASP1 within the cell through disruption of 
the positive charge at the N-terminus [3]. This results in unfavourable electrostatic 
forces near the myristoyl motif and disrupts the interaction with lipids resulting in the 
release of BASP1 from membranes [3, 80, 87]. The same PKC mediated 
phosphorylation of the N-terminal region of the MARCKS protein is also known to 
cause its release from membranes [80].  
BASP1 can also undergo sumoylation at lysine residues 78 and 83, causing 
redistribution of BASP1 from chromatin to the nuclear matrix, including to within 
PML bodies, and potentially enhancing its WT1 corepressor function [85]. Extensive 
methylation and/or acetylation of the lysine-rich N-terminus of BASP1 has also 
recently been identified in the Roberts’ lab (unpublished) and most likely also 
regulates lipid and membrane interactions. The transient nature of most 





The majority of known modifications to BASP1 occur within the N-terminus (see 
Figure 1.6). This region is also the most highly conserved in amino acid sequence 
across mammals, birds, amphibians and fish. Overall, the human BASP1 sequence 
is 80%, 70% and 45% similar to bovine, rat and chicken, respectively, indicating the 
importance of its function [80]. The N-terminus is also the location of the nuclear 
localisation sequence and the cholesterol recognition amino acid consensus 
(CRAC) domain. The CRAC domain, a L/V-X(1-5)-Y-X(1-5)-R/K amino acid 
sequence, allows an interaction with cholesterol [88]. Additionally, BASP1 contains 
several PEST sequences, a feature of proteins that undergo high turnover. The 
conservation of these PEST sequences across species implies their significance for 
protein function [80]. Many of BASP1’s phosphorylation sites fall within these 
conserved PEST sequences, suggesting the stability of BASP1 could be under the 
control of a set of kinases which modify the PEST sequences and affect BASP1 
degradation. PEST sequences have also been identified in GAP-43 and MARCKS, 
and transmembrane NCAM which has a role in learning and memory formation [80]. 
1.4.3 BASP1 as a Transcriptional Regulator 
The function of BASP1 as a transcriptional regulator has most often been studied, 
and is best understood, in the context of it binding the WT1 suppression domain. 
Figure 1.6. Brain Acid Soluble Protein 1 (BASP1) Functional Domains and 
Modifications. A linear schematic of the BASP1 protein. The N-terminal myristoyl group is 
shown in purple. Amino acids are numbered 1-243. The highly conserved sequence of the 
first 25 amino acids is written below. This contains a purple G residue which represents the 
Glycine to which the myristoyl group is added. The cholesterol recognition amino acid 
consensus sequence (CRAC) is also indicated in red. PKC targeted phosphorylation sites 
(purple arrows) and sumoylation targeted residues (red arrows) and indicated. The PIP2 
binding region and the methylation/acetylation rich region are also indicated above (black 




The function of BASP1 as a WT1 cofactor will be discussed in section 1.5. It is also 
important to consider the evidence that BASP1 likely regulates many other proteins. 
Microarray analysis of K562 cells that ectopically express BASP1 versus control 
K562 cells revealed that across the genome over 1000 genes were regulated by 
BASP1 (Figure 1.7) [2]. This indicated that BASP1 function is not limited to the 
regulation of WT1 targets and therefore that BASP1 has a wider role in 
transcriptional regulation. Furthermore, BASP1 has also recently been implicated as 
a cofactor for the oestrogen receptor α (ERα), for which it is also responsible for the 
repression of ERα target genes [89]. Moreover, a recent report implicated BASP1 as 
a major regulator of Lin28 and Oestrogen Related Receptor Beta (ESRRB) during 
the differentiation of pluripotent stem cells, suggesting BASP1 plays a major role in 
cell fate [90].  
 
1.4.4 BASP1 and Cancer 
BASP1 mediated repression of WT1 target genes, which are involved in cell growth 
and differentiation, implicates it as a tumour suppressor [1]. Recent establishment of 
BASP1 as co-repressor of ERα further demonstrates BASP1 functions as a tumour 
suppressor in breast cancer [89]. A range of other evidence also implicates BASP1 
as a tumour suppressor including that the BASP1 gene is silenced via promoter 
methylation in a broad range of cancer types [91]. Additionally, a genome wide 
Figure 1.7.  BASP1 Regulates the Expression of Over a Thousand Genes in K562 
Cells. Microarray analysis was performed with K562 cells that ectopically express BASP1 
(B) versus control K562 cells (V) and data were analysed as described in [2]. Red areas 
show significant changes in gene expression. B cells show an equivalent number of 
repressed and activated genes. The majority of altered WT1 target genes (blue dots) are 
repressed. Grey areas indicate small changes below the level of significance. Full details 




association study of melanoma identified a polymorphism that results in the 
suppression of BASP1 expression as a key risk factor for melanoma development 
[92]. Furthermore, BASP1 is known to inhibit cellular transformation by oncogenic 
Myc and inhibit the proliferation and migration of thyroid cancer cells [91, 93].  
In addition to K562 cells, BASP1 protein has recently been identified as lacking 
detectable expression in a range of CML cell lines (Figure 1.8). K562, KCL-22, 
LAMA-84, KU-812, KYO-01, JURL-MK1 cell-lines, all of which are derived from 
CML in blast crisis, display lack of BASP1 protein expression via western blotting 
(Jörg Hartkamp, unpublished). WT1 expression is apparent in all lines except KU-
812. In contrast, BASP1 is expressed in the analysed AML cell lines (HEL, HL-60, 
NB-4, U937, MV4-11, MOLM-13) suggesting lack of BASP1 expression is specific to 
CML. It is possible that BASP1 expression is lost in CML, suggestive of a tumour 
suppressive function for BASP1 in CML. Alternatively, knowing that clinically AML is 
the more severe disease with poorer patient prognosis and survival rates, it is 
possible that BASP1 expression in AML could be contributing to more severe 
disease and could therefore be suggestive of an oncogenic function for BASP1 [94]. 
Interestingly, the first evidence that BASP1 acts in an oncogenic manner was 
recently reported whereby BASP1 is upregulated and promotes the proliferation and 
tumourigenicity of cervical cancer cells [95]. Further work is required to establish 
whether BASP1 may function as an oncogene or tumour suppressor in myeloid 
leukaemias, as well as investigating further the role of BASP1 in other cancers. 
 
Figure 1.8. BASP1 Protein Expression in CML and AML Cell Lines. A panel of 
chronic myelogenous leukaemia (CML) and acute myeloid leukaemia (AML) cell lines 
were assessed for their expression of BASP1 and WT1 protein. GAPDH is shown as a 
loading control. All CML lines examine are absent of BASP1 expression, whilst WT1 





1.5 WT1/BASP1 Mediated Gene Regulation 
1.5.1 Mechanism of WT1/BASP1 Mediated Gene Repression  
The molecular mechanism of BASP1 mediated repression of WT1 target genes has 
become increasingly clear in recent years (see Figure 1.9). Following the first 
mechanistic data which showed that BASP1 binds to the WT1 suppression domain 
at the promoters of WT1 regulated genes, BASP1 was shown to recruit several 
proteins including prohibitin, BRG1 and HDAC1 to the repression complex, in a 
myristoyl motif dependent manner [3, 49, 85, 96]. The myristoyl motif allows BASP1 
to interact directly with the phosphoinositide PI(4,5)P2 (hereafter referred to only as 
PIP2) and this interaction occurs at the target gene promoter, as demonstrated 
through chromatin immunoprecipitation (ChIP) assays [3]. The presence of PIP2 at 
WT1/BASP1 bound target gene promoters is essential in order to recruit further 
complex components. The recruitment of HDAC1 results in the removal of 
negatively charged acetyl groups from sites such as histone 3 lysine 9 (H3K9), 
therefore inducing a stronger DNA-histone association and limiting access for the 
transcription machinery, leading to gene repression [3]. The WT1/BASP1 repression 
complex also recruits prohibitin, a well characterised corepressor to the WT1-
BASP1 repression complex, in a myristoyl-dependent manner [96]. Furthermore, 
recruitment of prohibitin is followed by recruitment of BRG1, the catalytic subunit of 
the chromatin remodelling SWI/SNF complex to mediate transcriptional repression 
at WT1 target promoters [96]. 
 
Experiments utilising wild type BASP1 (wtBASP1) expressing K562 cells, and a 
PIP2 binding mutant form of BASP1 (G2A-BASP1) expressing cells were used to 
elucidate the mechanisms described above. The G2A mutant form of BASP1 
consists of a glycine-2 to alanine mutation which positions the alanine residue in 
place of the N-terminal glycine to which the myristoyl motif is cotranslationally 
Myristoyl 
group 
Figure 1.9. Transcriptional Repression by 
BASP1 Through Interaction with Nuclear 
Lipids. Myristoylation of the N terminal 
glycine of BASP1 facilitates an interaction 
with PI(4,5)P2 at the promoters of WT1 target 
genes. Subsequent recruitment of chromatin 
remodelling factors such as HDAC1 
mediates target gene repression through the 





added. This forms a myristoyl null form of BASP1 which is known to be deficient in 
PIP2 binding [3]. As well as showing that the myristoyl modification is essential for 
recruiting components of the repression complex, gene expression analysis 
confirmed that G2A-BASP1 is defective at repressing WT1 target gene expression 
[3]. This work implicated PIP2 as a vital component for WT1/BASP1 mediated gene 
repression. To date, BASP1 is the only promoter-localised transcriptional regulator 
known to require a direct interaction with a lipid to carry out its transcription 
regulation function. BASP1 therefore provides a unique means by which to 
investigate the role of lipids in transcription. 
1.5.2 WT1/BASP1 and Differentiation  
WT1 and BASP1 are known to be spatially and temporally coexpressed in multiple 
tissues in the embryo, including the kidney, spleen, heart, ovary and testis [49]. 
Their coexpression in a variety of tissues suggests BASP1 may be an important 
regulator of WT1 through development and differentiation. In cultured cells, 
expression of BASP1 causes the differentiation of K562 cells to be diverted from a 
megakaryocyte lineage to a neuron-like lineage following treatment with the phorbol 
ester PMA [2]. Induction of K562 cell differentiation in culture by various agents had 
never previously lead to their differentiation to anything other than a blood cell type; 
yet PMA treatment of BASP1 expressing cells was sufficient to divert towards a 
neuronal-like state complete with neuron-like morphology, neuronal marker gene 
expression, and some functional properties of neurons [2, 97]. Further, BASP1 
controls WT1 target gene expression through the differentiation of cultured 
podocytes, altering promoter occupancy and gene repression as differentiation 
progresses [85]. BASP1 and WT1 have recently been found to be coexpressed at 
the terminal stages of taste cell differentiation in the mouse. BASP1 is critical to 
maintain the differentiated cell state of these neuroepithelial cells through repression 
of WT1 target genes (unpublished). Also, as mentioned previously, BASP1 was 
recently implicated as a major regulator of pluripotent stem cell fate through its 
repression of Lin28 and ESRRB target genes in cooperation with WT1 [90]. These 
studies indicate that BASP1 is a major transcriptional regulator of multiple 
transcription factors during development, differentiation and maintenance of the 





1.6 Nuclear Lipids 
1.6.1 Introduction to Nuclear Lipids 
Lipids are a broad class of largely non-polar organic molecules which play multiple 
fundamental roles in mammalian cells; they are key structural components of the 
plasma membrane and cellular compartments such as the endoplasmic reticulum, 
the golgi apparatus, vesicles, lysosomes and the nuclear membrane [98]. Lipids 
also provide energy reserves and serve as biologically active molecules in their own 
right, with fundamental roles in cell signalling [99, 100]. The roles of lipids in the 
plasma membrane and in the cytoplasm are well documented, however, the role of 
nuclear lipids remains much less well understood [101]. Decades of biochemical 
evidence plus more recent studies have established that as well as residing in the 
nuclear membrane, nuclear lipids are present outside of membranes [102-105]. It is 
now widely accepted that approximately 70-80% of all nuclear lipids are present in 
the nuclear membrane, and the remaining 20-30% are known to be associated with 
the nuclear matrix, chromatin and interchromatin granules [101, 106, 107].  
Figure 1.10 Common Nuclear Lipids. The diagrams depict A, the structures of the 
phosphophatidic acid (PA) and the major phospholipid derivatives of PA, 
phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidylethanolamine (PE) and 
phosphatidylcholine (PC). The hydrophilic head groups (-H, inositol, serine, ethanolamine 
and choline) attached to the basic phospholipid structure are shown in red. B, the structures 
of the other most common nuclear lipids. Top; an example of a fatty acid structure, with the 
characteristic –COOH group (in red box). Fatty acid tails vary in length and in their level of 
saturation. Also shown is the structure of a basic sphingosine molecule, a cholesterol 

















The pool of nuclear lipids consists of phospholipids, sphingolipids, gangliosides, 
cholesterol and fatty acids [108]. Phospholipids are the most abundant in 
membranes, where their polar head groups align and allow the hydrophobic 
hydrocarbon tails to be shielded within the bilayer membrane structure [109]. The 
most abundant phospholipids in the nucleus are phosphoinositides (PI), 
phosphatidylethanolamine (PE), phosphatidylcholine (PC) and phosphatidylserine 
(PS) [108]. The structures of these phospholipids and the other most common lipids 
in the nucleus are shown in Figure 1.10 [4-8]. The nuclear pool of lipids is further 
diversified through modifications to these lipids, such as the addition of phosphate 
groups to the carbons of the inositol ring of PI or the differing length and saturation 
of fatty acid tails, to create a highly diverse pool of nuclear lipids each with distinct 
functions [108]. 
The intranuclear pool of lipids is further regulated through controlled cycles of lipid 
metabolism by lipid regulating enzymes in the nucleus. The inositide cycle, 
controlled by phosphoinositol-3-kinase (PI3K) and phospholipase C (PLC) controls 
levels of differentially phosphorylated forms of PIs as well as the fundamental 
secondary messengers Ins[3,4,5]P3 and diacylglyceride (DAG)  [108]. Cycles of 
sphingomyelin (SM) production by sphingomyelin-synthase and degradation by 
sphingomyelinase into phosphocholine and ceramide regulates nuclear levels of 
ceramide and DAG [108]. Ceramide is further hydrolysed into free fatty acid and 
sphingosine, plus sphingosine can undergo conversion to sphingosine phosphate 
[108]. Such metabolism of intranuclear lipids is distinct from the metabolism of 
plasma membrane lipids adding to evidence that they form a uniquely functional 
group of lipids [102, 110]. It is now widely accepted that intranuclear lipids are 
regulated in accordance with cell behaviour; from cell growth to survival, 
differentiation and apoptosis [101, 111]. Cross-talk between the activity of enzymes 
such as sphingomyelinase, sphingomyelin-synthase and PLC also regulates the 
ratio of different lipids, primarily PC:SM:cholesterol in different subnuclear locations, 
creating distinct pools of lipids within the nucleus, which carry out distinct functions 
[112]. The levels of many PI metabolising enzymes are also known to vary in 
response to a range of stimuli, including DNA damage, oxidative stress, UV 
irradiation, growth factor stimulation, cell cycle progression and differentiation [113]. 
This results in different patterns of PIs and second messengers within the nucleus 
that ultimately regulates cellular response [114]. PI levels are particularly tightly 
regulated during differentiation and cell cycle progression; indicating their particular 




1.6.2 Intranuclear Lipids  
It is now appreciated that nuclear lipids exist within the nucleoplasm and evidence 
suggests they are associated with many nuclear structures. Firstly, many PI 
regulating enzymes have been shown to produce and degrade PIs at the inner 
nuclear membrane (INM) [115]. This supports evidence that the nucleus does not 
simply only passively receive lipids from the endoplasmic reticulum and outer 
nuclear membrane, as once thought, and implicating the INM as a site of dynamic 
lipid metabolism [115]. In membranes the hydrophobic tails of phospholipids are 
buried within the bilayer structure and the polar head group is exposed allowing 
lipids to recruit proteins and function in signalling [116]. In the nucleoplasm 
however, it is still not well understood how the hydrophobic tail is shielded from the 
aqueous inner nuclear environment. It is predominantly proposed that inner nuclear 
lipids must exist as lipid droplets and associate with protein complexes and nuclear 
bodies. Nuclear lipids have been shown to associate with protein complexes 
involved in a diverse range of nuclear processes including RNA processing, 
chromatin remodelling and gene transcription [101, 107, 113, 117, 118]. Still, the 
molecular detail of how lipid tails are accommodated by such associations and the 
molecular mechanisms through which lipids are involved in nuclear processes 
remains largely unknown.  
Lipid droplets have been well characterised in the cytoplasm, and have now also 
been identified in the nucleus, acting as storage repositories and functioning to 
modulate lipid metabolism, thereby contributing to several physiological processes 
[119]. In addition to lipid, these droplets contain and interact with numerous proteins 
[119]. It has been suggested that the interaction of lipids with lipid binding proteins 
and protein complexes in this way may enable shielding of the lipid tail. Certainly, 
some nuclear proteins do contain lipid binding domains which can accommodate 
binding by several phospholipid ligands, such as the transcription factor NR5A1 
(Steroidogenic factor 1 receptor) which can engulf the acyl chain of 
phosphatidylinositol 4,5‐bisphosphate (PIP2) and phosphatidylinositol 3,4,5‐
trisphosphate (PIP3) but leave the polar head group exposed [120].  
Additionally, since the reporting of BASP1-PIP2 mediated gene regulation, the 
myristoylated alanine-rich C-kinase substrate (MARCKS) protein has been 
implicated in nuclear PIP2 storage [121]. In the cytoplasm MARCKS is well known to 
have roles in cell motility, phagocytosis, membrane trafficking, mitogenesis and to 




phosphorylation which releases and re-sequesters PIP2, respectively [121, 122]. 
More recent data showing that MARCKS colocalises in nuclear speckles with PIP2 
and is involved in altering nuclear PIP2 levels has implicated it as a regulator of 
nuclear PIP2 [121]. Like BASP1, MARCKS is N-terminally myristoylated, which 
provides a valid potential biochemical mechanism by which to shield the 
hydrophobic tail of PIP2 [3, 85]. As well as myristoylation MARCKS shares several 
other properties with BASP1, including an identical lysine rich sequence, found 
within the nuclear localisation sequence of BASP1, and the effector domain of 
MARCKS, which further mediates PIP2 binding [121]. The similarity of BASP1 and 
MARCKS raises the possibility that BASP1 could also have a role in regulating the 
storage, release and levels of nuclear PIP2. Furthermore, work from the Roberts’ lab 
has demonstrated that BASP1 colocalises with PIP2 in nuclear speckles (Figure 
1.11) [3]. BASP1 is also known to form oligomers and multimeric structures which 
could further aid the shielding and sequestering of lipids in the nucleus [123, 124].  
 
Other nuclear proteins that are known to interact with lipids include the nuclear 
receptors, such as Oestrogen Receptor (ERα) and Progesterone Receptor (PR), 
which are transcription factors activated by steroid hormones and other lipid-soluble 
signals, such as retinoic acid and oxysterols [102, 125]. Ligands of these receptors 
remain bound during the receptors trafficking through the cytoplasm and through the 
nucleus onto target DNA sites, thus these receptors are also able to shield their lipid 
ligand from the nuclear environment. It has also been shown that, similarly to 
membrane bound PI function, the binding of PI(4,5)P2 and PI(3,4,5)P3 to NR5A 
nuclear receptors regulates the interface between NR5A1 (Steroidogenic factor 1 
receptor) and its cofactors, resulting in increased coactivator recruitment [126]. This 
Figure 1.11. BASP1 and PIP2 Colocalisation in 
Nuclear Speckles. Confocal microscopy of U2OS 
cell nuclei subjected to coimmunofluorescence with 
BASP1 and PIP2 antibodies shows their 
colocalisation in nuclear speckles. Comparable 




demonstrates that lipid binding to nuclear receptors permits their movement 
throughout the cell and regulates receptor activity. 
The nuclear structures within which lipids have been visualised can correspond to 
the nucleolus and a number of nuclear bodies including PML bodies and Cajal 
bodies. Many of these nuclear structures have been proposed to accommodate lipid 
tails [127]. Nuclear speckles are predominantly associated with mRNA maturation, 
are rich in splicing machinery, poly adenylating polymerases and enzymes 
responsible for post‐transcriptional modifications to mRNAs [102, 128]. The 
association of lipids with such structures implicates a role for them in mRNA 
maturation. 
The bulk of nuclear lipid content is still provided by the lipids of the nuclear 
membrane [108]. Biochemical isolation of nuclear membranes has demonstrated 
the existence of lipid microdomains within the membrane which have particular roles 
in regulating nuclear function [122]. Typically these microdomains are characterised 
by a PC:SM:cholesterol ratio of 1:1:1 [101]. These microdomains are typically 
associated with lamin B, signal transducer and activator of transcription-3 (STAT-3) 
and newly synthesized RNA indicating they are involved in transcription regulation 
and could serve as a transcription factor resting place and scaffolds for RNA 
synthesis [122, 129]. It is also hypothesised that these lipid microdomains could act 
as sites of chromatin anchorage [122]. Such evidence suggests that even within the 
nuclear membrane distinct clusters of lipids have roles beyond simply providing 
membrane structure.  
There remains much to learn about the function and storage of lipids in the nucleus. 
Lipids’ binding to large protein complexes remains the most commonly proposed 
mechanism by which they can behave and function in the intranuclear environment. 
Profiling of all myristoylated proteins in human cells has so far revealed around 100 
myristoylated proteins, but the knowledge of nuclear myristoylated proteins and their 
contribution to nuclear lipid biology is significantly lacking [130]. Further work is 
much needed to better understand nuclear lipid activity. More debatable is the 
existence of intranuclear membranes, with some work showing evidence of their 
formation following overexpression of nuclear lipidated protein [131]. The context of 





1.6.3 The Role of Lipids in Gene Regulation 
Chromatin bound phospholipids account for 10% of all nuclear lipids and increasing 
evidence suggests that phospholipids such as PIs, sphingosine-1-phosphate plus 
inositol phosphates and pyrophosphates are essential for healthy cell function 
through epigenetic regulation of the genome [101, 119, 132]. The nuclear lipid 
compartment can also broadly affect chromatin structure through regulating fluidity 
of the nuclear membrane and nuclear matrix [112]. Chromatin lipids also participate 
in signal transduction pathways, and many transcriptional regulators and chromatin 
remodelling factors interact with lipid regulating enzymes, such as PIPkinase, to 
locally generate lipids in a spatially and temporally controlled manner [113]. The 
levels of cholesterol-sphingomyelin-protein complexes in chromatin are also 
changed by altered lipid synthesis and metabolism during key cellular processes 
such as cell proliferation, indicating their importance for gene expression 
[133]. Furthermore, nuclear lipids also contribute to the maturation of RNA in 
intranuclear complexes [112, 114, 134]. It therefore appears that lipids play an 
important role in many stages of gene regulation. 
One of the ways in which lipids contribute to gene regulation is through modulation 
of transcription factors. For example, cholesterol based molecules such as steroids 
and oxysterols, fatty acids, and some phospholipids can contribute to transcriptional 
regulation by serving as hormone‐like ligands for the nuclear receptors including 
PPARs, Liver X Receptor (LXR), Farnesoid X Receptor (FXR) and Oestrogen 
Receptor (ERα) [135-138]. Many of these receptors control both transcriptional 
activation and repression of their target genes [102]. Furthermore, the association of 
SM with the nuclear lamina, a mesh of intermediate filaments that internally 
supports the nuclear membrane and associates it with chromatin, contributes to the 
sequestering of transcription factors away from chromatin [99, 101]. Thus, it is clear 
that many lipids can regulate cell function through binding transcription factors 
present in the nucleus.  
As well as regulating transcription lipids have been heavily implicated in the 
regulation of chromatin structure. The nuclear matrix, defined as the nuclear 
component that remains insoluble following extraction with non-ionic detergents, 
salts and treatment with nuclease, harbours dynamic pools of lipids including PC 
and PI [101, 108]. The main function of the nuclear matrix is in the organisation of 




as well as serving as parent molecules of lipid second messengers and other 
phospholipids, PC and PI may have a role in chromatin organisation [101, 108].  
Recently, direct binding of cholesterol to chromatin was demonstrated and 
cholesterol shown to contribute to the formation of mononucleosomes and 
compaction of chromatin fibres [139]. Cholesterol can bind to six residues in key 
nucleosome regions, such as the histone 4 (H4) tail, the acidic patch on the 
nucleosome surface, and the docking domain between the histone 3-histone 4 (H3-
H4) and histone 2A-histone 2B (H2A-H2B) clusters [139]. Many of the other small 
lipid molecules are present in the nucleus are hypothesised to directly bind 
nucleosomes and modulate chromatin structure [135]. 
Studying the recruitment of PIP2 to the promoters of WT1 target genes, via BASP1, 
provided some of the first mechanistic information regarding the role of PIP2 in 
transcriptional regulation at gene promoters [3]. This work revealed a direct role for 
PIP2 in recruiting HDAC1 to mediate removal of activating H3K9 acetyl marks at 
target gene promoters [3]. In a similar way, PIP2 regulates the interaction of the 
chromatin remodelling BAF complex and regulates its recruitment to chromatin and 
the nuclear membrane [118, 140]. Further evidence has also shown that PIP2 can 
specifically bind to C terminal histone tails of H1 and H3 and reverse H1 mediated 
repression of transcription [141]. These findings indicate that PIP2 influences 
chromatin structure in a number of ways.  
Other PIs have also been shown to bind chromatin remodelling complexes and 
regulate their nuclear localisation. ING2, a core component of the Sin3a‐HDAC1 
chromatin remodelling complex, binds multiple PIs, with highest specificity for 
phosphatidylinositol‐5‐phosphate (PI5P) [142, 143]. This interaction is thought to 
help localise ING2 to the nuclear matrix, as downregulation of nuclear PI5P levels 
by PI4‐kinase results in ING2 release from the matrix fraction [143]. Furthermore, 
production of PI5P, through dephosphorylation of plasma membrane PI(4,5)P2, 
leads to the specific recruitment of ING2 to the membrane, suggesting that PI5P is 
also important for membrane localisation of ING2 [144]. 
PIP2 is not alone in its ability to the regulate histone acetylation. Inositol phosphates 
have also been reported to bind HDAC complexes and regulate histone acetylation 
[145]. HDAC1 and HDAC3 are regulated through the binding of IP4, IP5 or IP6, to 
the interface between the HDACs and their co-repressors, metastasis-associated 




sphingosine has also been found to regulate histone acetylation through inhibiting 
the activity of HDAC1 and HDAC2, leading to increased acetylation of H3K9, H4K5 
and H2BK12 [148, 149]. This activity is promoted through sphingosine kinase 2 
activity, which interestingly also inhibits HDAC activity resulting in reduced p53 
activation of p21 [102]. These examples demonstrate how multiple lipids can 
regulate gene transcription through modulation of epigenetic regulators.  
Several further examples of lipids contributing to epigenetic gene regulation have 
been documented. Nuclear PI(4,5)P2 interacts directly with histone lysine 
demethylase PHD finger protein 8 (PHF8) and represses PHF8 activity through 
inducing a conformation change in the protein [150]. This PI(4,5)P2 activity caused 
reduced demethylation of H3K9me2, but not other substrates of PHF8, 
exemplifying the highly precise nature of this regulation [150]. This work also 
implicates PIP2 also as a regulator of rRNA gene transcription at the epigenetic 
level. PI(4,5)P2 further influences RNA polymerase I transcription and ribosomal 
RNA processing through its interactions with UBF, RNA polymerase I and fibrillarin 
[151].  
Currently all published data on PIP2 functions suggest that PIP2 activity is 
dependent on the interacting partner; seeing as nuclear PIP2 has in excess of 250 
possible protein-interacting partners it is highly likely that PIP2 influences the 
epigenome through other chromatin modifying proteins and subsequently affects 
many cellular functions [119, 152, 153]. A further study also suggested that PI5P 
may regulate the interaction of the E3 ubiquitin-protein ligase UHRF1 with H3 and 
different H3 modifications, primarily H3K9me3 [154]. This suggests that PI5P may 
also regulate the epigenetic state of chromatin. Furthermore, UHRF1 recognises 
and binds hemimethylated DNA and recruits the methyltransferase DNMT1, 
suggesting that PI5P-UHRF1 possibly contributes to the inheritance of genome 
wide DNA methylation patterns [154]. As a further example of lipids contributing to 
epigenetic gene regulation, the activity of inositol hexakisphosphate kinase 1 
(IP6K1), responsible for the dynamic metabolism of inositol pyrophosphates, has 
been shown to be required for the association of Lysine Demethylase 4C (KDM4C) 
with chromatin [119]. IP6K1 tightly associates with chromatin and specifically 
interacts with H3K9me3 and not other KDM4C substrates [119, 155].  
Clearly nuclear phospholipids and inositol phosphates contribute to nuclear 
processes such as transcription, chromatin remodelling, and epigenetics. 




mechanisms underlying the functions of nuclear lipids. Further mechanistic data is 
much needed to answer crucial questions such as how one lipid can act as both a 
repressor and an activator, whether lipid function depends strictly on protein 
binding partners and whether inducing a conformational change in protein binding 
partners could be a general mechanism by which lipids contribute to transcription 
control.  
1.6.4 Lipids and Cancer 
Hanahan and Weinberg outlined “deregulating cellular energetics” as a hallmark of 
cancer [156]. Lipid metabolism is significantly altered in a range of human diseases 
including liver disease, insulin resistance, obesity and cancer [157]. The reactivation 
of lipid biosynthesis is frequently observed in tumour tissue where it causes altered 
cell signalling, gene expression and enhanced proliferation [158]. Changes in lipid 
metabolism even contribute to the predisposition of obese patients to developing 
cancer. 20% of all cancers and 50% of endometrial and oesophageal cancers are 
attributed to obesity, frequently due to increased insulin and IGF-1 release and the 
enhancement of cell proliferation and cell survival [159].  
The contributions of many lipid metabolising enzymes to cancer initiation and 
progression have been described. Several deregulated PLC isoforms are known to 
play important roles in cell proliferation, migration and survival. For example, PLCβ1 
increases phosphorylation of retinoblastoma tumour suppressor protein (pRb) and 
activates expression of the E2F transcription factor, both of which are hallmark 
events of upregulated progression through the G1 cell cycle phase [160]. Also, 
PLCβ2 is highly expressed in a large number of breast cancers, where its 
expression is correlated with tumour size, tumour grade, proliferation index, and 
poor prognosis [161]. Similarly, upregulation of PLCγ expression is correlated with 
activation of the oncogenic ERK pathway and rapid proliferation [162].  
Additionally, one of the most significant nuclear phospholipid signalling enzymes is 
the tumour suppressor phosphatase and tensin homolog (PTEN), which 
dephosphorylates PI substrates and switches off the cell survival, growth and 
proliferation driving PI3K pathway [102]. PTEN is very commonly mutated in 
tumours, with more than 60% of primary tumours displaying loss or mutation of at 
least one PTEN allele [102]. Low expression of another PI regulating enzyme, 
phosphatidylinositol kinase PIP4Kβ, is correlated with reduced patient survival in 
breast cancers, largely due to reduced E-cadherin expression [102]. Reduced E-




progression to metastasis [102]. PIP4Kβ expression is strongly correlated with 
histological grade, tumour size and poor prognosis [163].  
The composition of the pool of DNA bound lipids in transformed cells is known to 
significantly differ from that of healthy cells [164]. The quantity of chromatin 
associated SM in peripheral blood lymphocyte nuclei of patients with chronic 
lymphocytic leukaemia is significantly reduced compared to healthy lymphocytes 
[108]. Conversely, the content of SM is higher in the nuclei of hepatoma cells than in 
normal rat liver [108]. 
The role of the PI3K/PI(3,4,5)/AKT cascade in tumorigenesis is well documented 
[165]. Furthermore, PI-PLC and PI3K have been implicated in causing defective 
control of nucleoskeleton assembly during granulocytic maturation, suggesting they 
are responsible for dysregulated cell maturation or differentiation in myeloid 
leukaemia [108]. It is possible that PI-PLC and PI3K may affect the nucleoskeleton 
assembly of other cell types, meaning that these enzymes not only caused 
deregulated transcription of their downstream targets but may also more globally 
affect transcription by causing defective nucleoskeleton assembly and defective 
chromatin organisation.  
Cholesterol is increasingly thought to contribute to the progression and severity of 
multiple cancer types, with both hypocholesterolaemia and hypercholesterolaemia 
associated with tumour progression [89, 166-168]. Furthermore, DAG, LPA and 
prostaglandins can act as promigratory factors, whilst blocking enzymes of the 
SREBP lipid biogenesis pathway has been shown to block the invasive morphology 
of breast cancer cells in 3D culture [169]. It is therefore evident that changes in 
nuclear lipid levels can affect expression of the genome in many ways; including 
histone modifications, transcription rates, RNA maturation and RNA export, and 
contribute to disease progression at many stages of cancer [102]. Further study of 
lipid regulation, and its effects on cell signalling and gene regulation will advance 
our understanding of gene regulation and will provide insights into how lipids 
contribute to aberrant gene expression in cancer. Lipid signalling pathways are 
highly complex, thus regulation is highly specific and could offer new targets for 





1.7 Gene Regulation at the Nuclear Periphery 
Much evidence suggests that the 3D organisation of the genome and the inner 
nuclear space plays a role in gene regulation. Early electron microscopy studies of 
eukaryotic nuclei revealed that heterochromatin is enriched at the nuclear periphery 
and around nucleoli, whilst euchromatin is predominantly present in the nuclear 
interior [170]. Similarly, fluorescence in situ hybridization (FISH) experiments have 
shown that chromosomes are confined to specific nuclear territories [171, 172]. 
Regions with a high density of active genes are more likely to be located in the 
centre of the nucleus, and those with a low density of active genes more likely to 
reside at the nuclear periphery [170, 173]. Cells undergoing division or 
differentiation experience significant changes to the 3D organisation of 
chromosomes as genes become activated and repressed, and several associations 
between gene position and expression level have been demonstrated [174-178]. To 
understand how genome organisation in the nucleus contributes to gene regulation 
it is important to first understand nuclear structure. 
1.7.1 Introduction to Nuclear Structure 
As well as the DNA, packaged into chromosomes, the nucleus is comprised of a 
number of structures and domains which contribute to key nuclear processes 
including transcription, RNA processing and ribosome assembly [174]. These 
include the nuclear membrane, the nuclear lamina, a number of nuclear bodies and 
the nuclear matrix.  
The nuclear membrane is a highly organised double membrane that defines and 
contains the nuclear compartment and connects it to the surrounding cytoskeleton  
[170, 179]. The inner and outer nuclear membranes are contiguous with the 
endoplasmic reticulum (ER), although each leaflet is comprised of a uniquely 
diverse group of proteins that are typically not enriched in the ER [179, 180]. The 
nuclear membrane is punctuated with nuclear pore complexes (NPCs), aqueous 
channels that allow bidirectional transport of proteins, RNA and ribonucleoprotein 
complexes between the nucleus and the cytoplasm [179, 181]. The outer nuclear 
membrane includes proteins which contain a KASH domain, allowing them to 
directly interact with the actin cytoskeleton, such as nuclear envelope spectrin 
repeat (nesprin) -1 and -2 [182]. This is important for nuclear positioning, particularly 
during cell polarisation and migration [182]. The INM contains an array of largely 




LEM-domain containing proteins; emerin, MAN1, LAP2, plus LAP1 and Lamin B 
receptor (LBR), all of which have been shown to contribute to nuclear functions 
such as chromatin organisation, gene expression and DNA metabolism [129, 170, 
179]. 
The nuclear lamina is a meshwork system of intermediate filaments and proteins 
that underpins the INM and stabilises the whole nuclear structure [183]. It is 
predominantly formed of the two types of lamin filaments; A-type lamins and B-type 
lamins, encoded by the LMNA, LMNB1 and LMNB2 genes [183]. There are two B-
type lamins, B1 and B2, and two splice variants of A-type lamins named lamin A 
and C [184]. In most mammalian cell types all the lamins reside at the nuclear 
lamina, but A-type lamins are also present in the nucleoplasm [184]. The lamin 
proteins bind many proteins of the INM including emerin, LAP1, LAP2, MAN1, 
barrier-to-autointegration (BAF) and LBR, as well as nuclear pore complexes, 
making the lamina contiguous with the nuclear membrane [185]. 
A catalogue of interactions between proteins of the INM and lamin filaments helps to 
form a stabilising structure which connects the INM with chromatin [183]. BAF is one 
protein of the INM which interacts with a plethora of nuclear lamina proteins 
including the LEM domain containing proteins, A- and B-type lamins and Nemp1. 
BAF also directly binds DNA and therefore acts as a bridging factor to link chromatin 
to the nuclear membrane [184, 186-188]. As well as serving as an anchoring point 
for chromatin, the nuclear lamina is bound by transcription factors and plays an 
important role in signal transduction [170, 189-191].  
Mutations in genes encoding components of the nuclear lamina and lamina 
interacting proteins which affect protein localisation or function lead to a huge 
variety of clinical problems; including neuropathies, muscle dystrophies, and 
lipodystrophies, collectively termed laminopathies [170, 185, 192]. Classic 
laminopathy patients have mutations in the LMNA gene leading to loss of function of 
the Lamin A/C protein, mostly famously in Hutchinson-Gilford Progeria syndrome, 
where the unstable nuclear envelope causes progressive nuclear damage and 
premature cell ageing [185]. This has generated considerable interest in nuclear 
lamina biology in order to understand the disease biology and attempt to develop 
treatments.  
The existence of a filamentous backbone inside the nuclear space which provides a 




cytoskeleton, has been considerably debated but it is now largely accepted that 
such a structure in fact does not exist [193, 194]. Instead, it has now been proposed 
that the chromatin fibres of interphase chromosomes themselves define the inner 
nuclear domains, such that the inner nucleus can simply be divided into the 
intrachromatin domain and the interchromatin domain [193].  
Although the existence of a defined filamentous nuclear matrix has been denied, 
undoubtedly a protein network of sorts does exist in the interchromatin domain. 
Furthermore there is evidence that various noncoding RNAs have skeletal functions 
during the assembly of different nuclear compartments [193]. Plus sphingomyelin is 
also reported to play a role in the organisation of the intranuclear space, highlighting 
that the structural organisation of the nucleus is likely achieved through the 
cooperation of a wide variety of nuclear compounds [193, 195]. The nuclear matrix 
can instead be thought of as a tightly packed body of protein, RNA and lipid that 
together act as a scaffold for the attachment of both heterochromatin and 
euchromatin [196]. Specific chromosome regions, termed scaffold/matrix 
attachment regions (S/MARs), bind to proteins of the nuclear matrix which stabilises 
the organisation of interphase chromosomes within the nucleus, aids the regulation 
of transcription, RNA processing and DNA replication [196-199]. Therefore, the 
attachment of chromosomes to the nuclear matrix impacts on nuclear organisation 
and function.  
Found abundantly in the nuclear matrix are the lamin proteins, A, B and C, 
nucleophosmin and components of core heterogeneous nuclear ribonucleoproteins 
(hnRNPs) [196, 200]. Also abundantly present are the Matrins, a group of 8 proteins 
ubiquitously present within the nucleoplasm but excluded from nucleoli [183, 200]. 
Of all the matrin proteins (matrin 3, matrin 4, matrins D-G, matrin 12, matrin 13) 
matrin 3 is the most studied, and appears to play an important role in connecting the 
nuclear matrix with the nuclear periphery, primarily through an interaction with lamin 
A [183, 201]. Interestingly, mutations in the MATR3 gene, which encodes matrin 3, 
disrupt matrin 3 interactions and lead to distal myopathies, amyotrophic sclerosis, 
skeletal muscle degeneration and neurodegenerative disorders, similarly to 
mutations in LMNA and lamina interacting proteins [202-204]. Interestingly, another 
abundant nuclear matrix protein is nuclear mitotic apparatus protein 1 (NuMa), a 
protein which in vitro forms 3D space filling structures, leading to speculation that it 




This is supported by evidence that altered NuMa expression leads to changes in 
nuclear shape and chromatin organisation [206].  
Also in the nuclear matrix resides a number of membrane-less subnuclear 
organelles that dynamically respond to basic physiological processes, stress, 
metabolic state and cell signalling, known as nuclear bodies (Figure 1.12) [10]. 
Nuclear bodies include nucleoli, Cajal bodies, histone locus bodies, nuclear 
speckles, Polycomb bodies, and paraspeckles [10, 207]. Each nuclear body 
contains its own subset of proteins, has its own morphology and can often be 
biochemically isolated from other nuclear compartments [208-210]. Nuclear bodies 
coordinate with noncoding RNAs, chromatin modifying proteins and other nuclear 
machinery to carry out a range of functions including sequestering and modifying 
proteins, processing RNAs, assembling ribonucleoprotein complexes and epigenetic 
regulation of gene expression [10]. 
Figure 1.12. Nuclear Bodies. Schematic representation of nuclear bodies in an 
interphase mammalian nucleus. The interchromatin space harbours multiple nuclear 
bodies, Cajal bodies, clastosomes, histone locus bodies, nuclear speckles, nucleoli, 
paraspeckles, perinuclear compartments, PML bodies and Polycomb bodies. The 
nucleolus consists of three main compartments; the fibrillar centre, a dense fibrillar 
component and a granular component. The nucleolus is bordered by perinucleolar 





The nucleolus is the largest nuclear body and is the site of ribosomal RNA (rRNA) 
transcription, rRNA processing and of ribosome assembly [211]. Morphologically, 
nucleoli consist of three distinct subregions; the fibrillar centre, a dense fibrillary 
component, and a granular component [211]. The nucleolus is centred around 
clusters of ribosomal DNA (rDNA) on human chromosomes 13, 14, 15, 21 and 22, 
which contain the genes for rRNAs 5.8S, 18S and 28S [208]. Transcription of a 
single 45S rRNA precursor from these genes by RNA polymerase I occurs primarily 
at the fibrillar centre boundary [211]. The 45S precursor is processed to form the 
5.8S, 18S and 28S ribosomal subunits, which are assembled with ribosomal 
proteins to form almost complete preribosomal subunits, ready for export to the 
cytoplasm [211].  
Another nuclear body, Cajal bodies are small spherical structures, typically 
appearing as a mesh of coiled fibrillar strands of 40-60nm diameter [212]. There are 
commonly 1-5 Cajal bodies per nucleus, and each contains multiple components 
including spliceosomal small nuclear ribonucleic particles (snRNPs), U3, U7, U8, 
U14 small nucleolar RNAs (snoRNAs), TFIIF, TFIIH, cleavage-stimulation factor, 
cleavage and polyadenylation specificity factor, as well as nucleolar components 
fibrillarin, protein B23 and Nopp140 [213]. The precise role of Cajal bodies is still 
unclear, although they have been implicated in multiple processes including snRNP 
and snoRNA processing, assembly, modification and maturation, as well as 
processing of pre-mRNAs, recycling of spliceosome components and telomerase 
biogenesis [214-216]. It is also thought that Cajal bodies and the nucleolus are 
functionally connected [215]. Cajal bodies have almost always been seen within the 
nuclear matrix, but they have also been reported within the nucleolus of human 
breast carcinoma cells, brown adipocytes and hepatocytes in hibernating mice [208, 
217, 218]. Within the nuclear matrix Cajal bodies are predominantly associated with 
the periphery of chromosome territories at the interface of multiple chromosomes 
[215]. Cajal bodies are also known to interact with loci enriched with highly 
expressed histone genes and snRNP and snoRNA loci [215].  
PML bodies are small spherical structures of 0.1-1.0µm diameter found scattered 
throughout the interchromatin space in most cell types, with approximately 10-30 
PML bodies per nuclei [219]. PML bodies are characterised by the presence of the 
PML protein, a member of the TRIM/RBCC protein family, which largely contains 
ubiquitin ligases which generate subcellular structures through autoassembly [220, 
221]. PML is the key organiser of PML bodies and it recruits a huge variety of 




domains in response to different cell stresses [220]. PML bodies often recruit 
sumoylated proteins, including BASP1 [85]. Although a wide range of proteins are 
known to be recruited to PML bodies, allowing these proteins to be sequestered, 
modified and degraded, the precise function of these nuclear bodies remains largely 
unknown [220]. 
Nuclear speckles, otherwise known as splicing factor compartments or 
interchromatin granule clusters, consist of fibres known as perichromatin fibrils 
[208]. These differing size fibres are strands of nascent transcripts together with 
snRNPs, spliceosome components and other pre-mRNA splicing machinery [222]. 
Nuclear speckles range in size from one to several µm in diameter, with often 20-50 
present per nuclei [222]. Nuclear speckles are thought to function primarily to store 
and assemble the spliceosomal components, rather than being the primary sites of 
pre-mRNA splicing as most active genes are found at the periphery of nuclear 
speckles, not within them [208, 223].  
The final nuclear domain to be mentioned here are the discrete sites at which 
transcription occurs, named transcription factories. Transcription factories are 
composed of approximately 4-30 RNA polymerase molecules plus a host of other 
proteins including transcription factors, coactivators, chromatin remodellers, histone 
modification enzymes, RNPs, splicing and processing factors and RNA helicase 
[224, 225]. Transcription factory size varies from around 40nm to 200nm, likely 
according to the genes within the factory and their level of transcription activity 
[224]. Transcription factories consist of a protein rich core, with DNA templates and 
nascent RNA transcripts laying on the surface [224]. The number of transcription 
factories per cell varies widely depending on cell type and species, but usually 
ranges from a few hundred to a thousand per nucleus [224].  
1.7.2 Nuclear Compartments and Gene Regulation 
Chromatin structure, organisation, and interaction with nuclear structures all 
contribute to regulation of the genome. Several studies have now demonstrated that 
gene position is related to gene expression, with thousands of genes known to 
reposition during differentiation, correlated with changes in transcription and 
replication timing [175-178]. It is not always clear whether changes in gene 
expression are a cause or consequence of gene repositioning and vice versa. Most 
often, tethering of reporter genes or endogenous genes to the INM has been 
sufficient to induce gene repression, whilst detachment from the nuclear lamina has 




A specific range of large genomic regions, approximately ~10kb to ~10Mb, directly 
interact with proteins of the nuclear lamina [184]. These regions, termed lamina 
associated domains (LADs), together comprise approximately 40% of the genome 
[184]. Approximately 50% of LADs are consistent between mammalian cell types, 
named constitutive LADs (cLADs), whilst others are cell type specific, named 
facultative LADs (fLADs) [174, 226]. cLADs are often AT-rich in sequence, rich in 
long interspersed nuclear elements, poor in short interspersed nuclear elements, 
and are less gene dense than fLADs [226]. cLADs genomic positions and sizes are 
strongly conserved between the human and mouse genomes, although the precise 
DNA sequences are not [226]. It is hypothesised that cLADs form the structural 
backbone of chromosomes tethering to the nuclear lamina at defined positions and 
therefore help guide the overall folding of interphase chromosomes [186]. fLADs on 
the other hand are generally the more gene dense and their positions are less 
conserved between species [226].  
All LADs are commonly enriched in the heterochromatic histone modifications in 
H3K9me2, H3K9me3 and H3K27me3 marks and exhibit low levels of transcriptional 
activity [186, 227, 228]. The methylation of H3K9 is particularly critical for the 
anchoring of chromatin to the nuclear periphery. It has been shown to be involved in 
targeted specific loci, such as the β-globin locus to the nuclear lamina [229]. Plus 
knockdown of H3K9 methyltransferases, such as G9a, reduces the interaction 
between LADs and the nuclear lamina, and lower levels of H3K9me2 are observed 
when LADs are located in the nuclear space [174, 184, 227, 228, 230, 231]. Such 
evidence suggests that H3K9 methylation does at least partly drive contact with the 
nuclear lamina. Similarly, knockdown of the Polycomb group (PcG) protein EZH2, 
the methyltransferase that deposits H3K27me3 marks, was shown to reduce nuclear 
lamina interactions of an ectopically integrated LAD fragment [232]. Additionally, 
following artificial tethering of the DNA-binding factor Ying-Yang 1 (YY1) to a 
reporter locus, H3K27me3 marks accumulated and the locus was relocated to the 
nuclear periphery [232]. The nuclear lamina therefore contributes to the spatial 
organisation of the genome and appears to have an important role in gene 
repression.  
Several proteins of the nuclear lamina, including the lamin proteins, emerin, BAF 
and LBR, are important contact points for LADs and also interact with transcription 
factors and chromatin modifying enzymes [186, 226, 233]. The nuclear periphery is 
thereby cohabited by chromatin and its regulatory factors making it a major site of 




HP1 and the repressive histone mark H4K20me3 [234]. Knockout of LBR and Lamin 
A/C has been found to result in heterochromatin amassing in the nuclear interior, 
similarly to what is seen in retinal rod cells which express neither Lamin A/C nor 
LBR [186, 235]. Similarly, ectopic expression of LBR in rod cells results in the 
relocation of heterochromatin to the nuclear periphery [186]. Loss of Lamin A/C 
expression causes mislocalisation of PcG proteins, including EZH2, preventing their 
repressive action and causing chromatin detachment from the nuclear periphery 
[170, 191]. This has been shown to lead to accelerated differentiation of myoblasts 
into myotubes [191]. Lamin A/C is also particularly important for maintaining the 
peripheral location of nuclear factors; for example, together with emerin, it regulates 
the nuclear translocation and downstream signalling of the mechanosensitive 
transcription factor megakaryoblastic leukaemia 1 (MKL1) [236].  
Emerin also tethers chromatin to the nuclear lamina through its interaction with 
chromatin binding proteins including BAF [237]. The mislocalisation or knockdown 
of emerin results in changes in chromosome positioning and partial replacement of 
histone marks H3K9me2, H3K9me3 with H3K27me3, indicating that emerin is 
important for chromosome positioning and maintenance of a repressive state [186]. 
This is further evidenced by the binding of emerin to LAP2β and the histone 
deacetylase HDAC3, which enhances HDAC3 enzymatic activity, leading to 
increased gene repression [190, 238]. Other less well characterised NET proteins 
of the INM including NET5, NET29, NET39, NET45 and NET47 have also been 
associated with the relocation of specific loci to the nuclear periphery [239]. It is 
therefore evident that the nuclear lamina tethers chromatin to the INM through a 
wide variety of components, regulating the localisation of chromatin, and its 
interaction with a host of chromatin modifying enzymes. All of these components 
can be individually regulated giving huge complexity and flexibility to gene 
regulation at the nuclear periphery. The implications of this potential complexity on 
transcription or cell behaviour are only just beginning to be understood. 
There is also evidence that a number of nuclear bodies can also contribute to gene 
regulation. Cajal bodies, for example, have been associated with gene positioning 
events observed for chromosome 1 [215]. Disruption of Cajal body assembly by 
RNA interference also disrupts gene clusters targeting Cajal bodies resulting in 
the repression of snRNA, snoRNA and histone genes [215]. Such evidence 
implicates Cajal bodies in genome organisation, with global effects on gene 
expression and RNA splicing. The nucleolus also binds specific genomic regions 




with LADs [240, 241]. It has been shown that loci located at the nuclear periphery 
in mother cells can locate either to the nuclear periphery or the nucleolar 
periphery in daughter cells following mitosis [172, 227]. Therefore, it is possible 
that both the nuclear lamina and the nucleolus are sites at which repressed 
genomic domains locate. 
Furthermore, both nuclear speckles and transcription factories have been 
suggested to contribute to the formation of chromatin loops and clustering of 
coregulated genes that may be located megabases apart on the same or different 
chromosomes [224, 242-245]. FISH studies have suggested that active genomic 
regions are often located on the borders of chromosome territories, as loops of DNA 
making contact with the nuclear matrix and are associated with transcription 
factories [171, 172, 243, 244]. “Looping out” of DNA is seen in only a proportion of 
alleles and it is unclear whether this occurs due to the dynamic movement of DNA in 
and out of the chromatin territory but live cell analysis has suggested that looping 
out occurs in order for genes to interact with transcription factories and nuclear 
speckles and aids transcription activation [171]. Therefore, nuclear speckles and 
transcription factories may have roles in genome organisation and gene regulation, 
although their exact contribution requires further investigation.  
Proteins within the nuclear matrix have also been shown to have roles in gene 
regulation through their interaction with S/MARs. Matrin 3 has been reported to 
contribute to gene regulation through a number of means; firstly, it appears to play 
an important role in connecting the nuclear matrix with the nuclear periphery, 
primarily through an interaction with lamin A [183, 201]. Matrin 3 also has a reported 
role in localising transcriptional regulators, such as the Pit1 transcription factor, to 
their target genes [246]. Pit1 requires this matrix interaction to recruit further 
transcription factors β‐catenin and SATB1 to specific enhancer loci in order to 
activate transcription [196]. Further evidence suggests matrin 3 may also function in 
alternative splicing and RNA stability [196].  
Interestingly, it has been noted that many membrane-less nuclear compartments 
share similar properties to liquid droplets [247-250]. The structure of the nucleus 
has subsequently been thought of as an emulsion of many phase separated 
droplets of DNA and protein [247]. It has been argued that phase separation could 
aid the compartmentalisation of chromosomes into discrete nuclear territories, and 
that liquid-liquid phase separation drives the assembly of liquid-like nuclear bodies 




physical means to control gene expression throughout the nucleus by controlling 
the interplay between different liquid-like components [251]. Several nuclear 
proteins, including many proteins of the eukaryotic transcription machinery such 
as the Mediator transcriptional coactivator and RNA polymerase II have been 
shown to behave as biomolecular condensates [251, 252]. HP1α also condenses 
DNA into liquid-like droplets which has been suggested to be a robust mechanism 
of heterochromatin formation and gene silencing [249, 253]. Such evidence 
supports the possibility that the organisation and expression of the genome may 
be regulated through phase separation. These mechanisms could explain how 
chromatin bodies can act as dynamic spherical structures which coalesce and 
constantly and rapidly exchange components with the surrounding nucleoplasm. 
Work to understand how these properties contribute to gene organisation and 





1.8 Project Aims  
The study of BASP1, as a transcriptional regulator that interacts with PIP2 and 
cholesterol, provides a unique opportunity to investigate the contribution of nuclear 
lipids to the regulation of WT1/BASP1 target genes. Very little is currently known 
about the role of nuclear lipids in gene regulation and molecular data is particularly 
lacking. How BASP1 uses cholesterol in its mechanism of gene regulation is 
currently unknown. Furthermore, BASP1 is an established cofactor of other 
transcriptional regulators, including ERα, and is known to regulate over a thousand 
genes in K562 cells, so it possible that mechanisms of gene regulation employed by 
BASP1 at WT1 target genes could extend to a multitude of regulated genes [2, 89]. 
Moreover, nuclear myristoylated proteins are very poorly understood and so study 
of BASP1 will enhance our understanding of the function and behaviour of these 
proteins. It is important to understand more about how BASP1-lipid complexes 
regulate chromatin remodelling in transcriptional regulation. 
The study of BASP1 also provides an opportunity to examine the importance of the 
WT1/BASP1 repression complex localisation on its function. BASP1 is a 
transcriptional corepressor with the capacity to interact with membranes, but that is 
also found localised together with PIP2 in nuclear speckles [3]. Examination of the 
localisation of the WT1/BASP1/PIP2 repression complex could give insight into 
potential mechanisms of gene repression at the nuclear periphery and improve 
understanding of how lipids interact with proteins within the nucleoplasm. As the 
only known transcription regulator that requires lipidation for its transcription 
function, BASP1 provides a means to explore and better understand the 
mechanisms through which lipids contribute to transcriptional regulation and 
chromatin organisation.  
Moreover, BASP1, WT1 and many lipids have all been implicated in a variety of 
cancers. Improved understanding of the behaviour of the WT1/BASP1/PIP2 complex 
will in turn improve the wider understanding of the mechanisms gene regulation and 





2 Materials and Methods 
2.1 General Chemicals  
The following chemicals were purchased from Sigma-Aldrich (Dorset, UK): 
Phosphate Buffered Saline (PBS), Triton X-100, phorbol 12-myristate 13-acetate 
(PMA), Lovastatin (Mevinolin), Lithium Chloride, Sodium Deoxycholate, Ammonium 
Acetate, Trizma, Acetonitrile, Azide-PEG3-biotin, Tetrakis(acetonitrile)copper(I) 
tetrafluoroborate (CuBF4), Paraformaldehyde (PFA). 
The following chemicals were purchased from Thermo Fisher Scientific 
(Loughborough, UK): Methanol, Ethanol, Agarose, Glycerol, Glycine, Tris, 
Ammonium Persulphate, sodium dodecyl sulfate (SDS), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), Tween, Bromophenol Blue, 
Ethylenediaminetetraacetic acid (EDTA), Sodium Pyruvate, Sodium Bicarbonate. 
Sodium Chloride, Potassium Chloride and Magnesium Chloride were purchased 
from VWR Chemicals (Leicestershire, UK). Urea and NP-40 were purchased from 
Millipore (Watford, UK). Potassium Hydroxide and Dithiothreitol (DTT) was 
purchased from Santa Cruz Biotechnology. TEMED was purchased from Flowgen 
Bioscience. Trypan Blue was purchased from Invitrogen. DMSO was purchased 
from Corning. 
 
2.2 Tissue culture 
K562 cells were maintained in RPMI 1640 (Life Technologies, Inc.) supplemented 
with 10% (v/v) FCS, 1% (v/v) Pen-Strep and 1% (v/v) L-glutamine (all from Life 
Technologies, Inc.). MCF7 cells were maintained in DMEM (Life Technologies, Inc.) 
supplemented with 10% (v/v) FCS and 1% (v/v) Pen-Strep. shN (shNegative 
control) and shB (shBASP1) stable MCF7 lines were additionally supplemented with 
1mg/ml G418 (Melford Laboratories). All cells were kept at 37°C in humidified 95% 
air and 5% CO2 atmosphere. 
 
2.3 Vectors and transfection of stable cell lines 
Stable K562 cell lines were prepared as described previously [2]. Essentially, K562 
cells were stably transfected using Effectene (Qiagen) transfection reagent and 




vectors were; pc-DNA3 vector only (V-cell lines), pc-DNA3 vector containing wild 
type BASP1 sequence (B-cell lines), pc-DNA3 vector containing Y12L-BASP1 
sequence (Y-cell lines) or pc-DNA3 containing G2A-BASP1 sequence (G-cell lines). 
All BASP1 sequences were followed by a hemagglutinin (HA) tag sequence to tag 
BASP1 protein with HA at the C terminus. pc-DNA3, pc-DNA3-BASP1 and pc-
DNA3-Y12L-BASP1 vectors were obtained from previous laboratory members. 
Mutant derivative G2A-BASP1 was generated via cloning of the mutant G2A-BASP1 
sequence into digested pc-DNA3 vector as described below.  
2.4 Transfection of siRNA  
Mission(R) esiRNA against emerin (Sigma Aldrich) or Mission(R) esiRNA control 
siRNA (#SIC003, Sigma Aldrich) was transfected into shN (shNegative control) and 
shB (shBASP1) stable MCF7 cell lines using Hiperfect transfection reagent 
(Qiagen). Transfected cells were analysed 48 hours post transfection for western 
blotting and RNA analysis. 
 
2.5 Cloning 
2.5.1 PCR Reaction 
A PCR reaction of the following components was assembled: 
1µl 10mM dNTPs 
4µM G2A-BASP1 primers [Fwd:5’-CTCGGATCCATGGCAGGCAAGCTCAGC-3’] 
[Rev: 5’-GCTGAGCTTGCCTGCCATGGATCCGAG-3’] 
5µl NEB standard 10x buffer 
2ng pc-DNA3-BASP1 template 
1.5µl DMSO 
ddH2O up to 50µl 
 
0.25µl (1.25 units) Taq polymerase (NEB) was then added immediately prior to PCR 
reaction. A negative control containing ddH2O in place of pc-DNA3-BASP1 template 
was also set up and run on a Techne TC3000 thermocycler.  
The following cycling parameters were set up: 
95°C for 30s, followed by 40 cycles of 95°C for 30s, 45°C for 30s, 68°C for 1min, 




2.5.2 Agarose Gels 
DNA products or fragments were resolved on a 1.5% (w/v) agarose gel dissolved in 
TAE buffer (Thermo Fisher Scientific) (40mM Tris, 20mM acetic acid, 1mM EDTA) 
and containing 0.5 µg/ml ethidium bromide (VWR). DNA loading dye (Thermo 
Fisher Scientific) was added to each sample prior to loading. Samples were loaded 
and electrophoreised at 100V in TAE buffer for ~45mins alongside an appropriate 
DNA ladder (GeneRuler Low Range DNA ladder – Thermo Fisher Scientific, or 1kb 
DNA ladder – Sigma Aldrich). Bands were visualised under UV light. 
2.5.3 Product digestion 
A small sample of PCR product was resolved on a 1.5% (w/v) agarose gel to 
validate successful production of ~700bp product. Following this, PCR product and 
pc-DNA3 were each digested for 2 hours at 37°C via addition of 1µl (10 units) 
BamHI, 1µl (10 units) EcoRI, 1µl 10x Buffer R (Thermo Fisher Scientific #ER0051, 
#ER0271, #BR5) 1µg DNA. Digested products were then resolved on a 1.5% (w/v) 
agarose gel and DNA extracted using a Qiaquick gel extraction kit (Qiagen).  
2.5.4 Gel Extraction 
Digested G2A-BASP1 PCR product, and digested pc-DNA3 were extracted from 
agarose gels using the Qiaquick gel extraction kit (Qiagen) according to 
manufacturer’s instructions. This involved excising the region of agarose gel 
containing the relevant DNA product from the gel using a scalpel blade and freezing 
in a clear bag for 20 mins at -80°C. Slices were squeezed by hand to release DNA, 
which was collected by pipetting. 
2.5.5 Ligation 
Enzyme-cleaved G2A-BASP1 PCR product and linearised pc-DNA3 were then 
ligated together using the following conditions: 
100ng pc-DNA3 vector, 170ng G2A-BASP1 PCR product, 1µl T4 DNA Ligase buffer 
(Promega #C126B), 1µl T4 DNA Ligase (1 unit) (Promega #M180A) up to 10µl with 
nuclease free water. Samples were incubated overnight at 15°C in a thermocycler 




2.5.6 Bacterial Transformation 
Thawed OneShot TOP10 (Thermo Fisher Scientific) competent cells were 
transformed with ligated PCR product. This was achieved via incubation of 1.5µl 
ligated DNA product with 45µl of competent cells on ice for 30 mins. Competent 
cells were heat shocked at 42°C for 30s, cooled on ice, and plated onto 100µg/ml 
ampicillin/LB plates. Water controls containing competent cells incubated with water 
only were also heat shocked and plated. Agar plates were incubated at 37°C 
overnight.  
The next day, individual colonies of ampicillin resistant transformed bacteria were 
picked and grown again in 3ml LB broth containing 100µg/ml ampicillin overnight, 
shaking at 37°C. 
2.5.7 Qiagen Mini Preps 
DNA from a 3ml overnight culture was extracted using a QiaPrep Miniprep kit 
(Qiagen) according to manufacturer’s instructions. This involved collecting bacteria 
via centrifugation for 5 mins at 3000 x g followed by step by step completion of the 
QiaPrep Miniprep protocol. DNA was eluted and the concentration measured on a 
NanoDrop Lite spectrophotometer (Thermo Fisher Scientific).  
2.5.8 DNA Sequencing 
All plasmids were sequenced using the Source Bioscience Sanger sequencing 
service (1 Orchard Place, Nottingham Business Park, Nottingham) 
 
2.6 Colony Formation Assay 
V-K562, B-K562 and G-K562 cells were seeded onto agar bases (0.7% (w/v) LMP 
Agarose, 10% (v/v) FBS, 1% (v/v) Pen Strep, 1% (v/v) L-glutamine in DMEM media 
supplemented with 0.15% (v/v) NaHCO3, 200µM sodium pyruvate and 800µM 
NaOH at a density of 2x105 cells per ml of agar. Agar dishes were fed with 
additional agar (2ml) on days 7 and 14 post seeding. The colony formation 
efficiency (%CFE) was calculated 7, 14 and 21 days post seeding via counting 
colonies consisting of greater than 50 cells, in a minimum of ten 15.89mm2 fields of 
view per 60mm2 dish. Average colony area was measured using ImageJ software. 




2.7 Gene Expression Analysis 
RNA samples were isolated from pellets of cells using an RNeasy Mini Kit (Qiagen) 
according to manufacturer’s instructions. RNA samples were quantified using a 
NanoDrop™ Lite spectrophotometer (Thermo Fisher Scientific) and diluted to 
0.5µg/µl to complete cDNA reaction using iScript cDNA synthesis kit (Bio-Rad) 
according to manufacturer’s instructions. cDNA was then prepared for q-PCR 
reactions with appropriate gene primers using iTaq Universal SYBR Green 
Supermix (Bio-Rad). 
Components for each q-PCR reaction consisted of: 
2µl cDNA 
10µl SYBR Green Supermix 
1µl forward primer (10µM stock) 
1µl reverse primer (10µM stock) 
6µl H2O 
The following cycling parameters were set up: 
95°C for 3 mins, followed by 40 cycles of 95°C for 20s, 60°C for 30s, 72°C for 30s, 
plate read.  
A melt curve was then initiated using the following parameters: 
95°C for 10s, followed by 65.0°C for 5s, then temperature of increases 0.5°C every 
0.5s, plus plate read, up to 95°C. 
2.7.1 Primers for Gene Expression Analysis 
Gene Forward Primer 5’-3’ Reverse Primer 5’-3’ 
AREG TGGATTGGACCTCAATGACA  ACTGTGGTCCCCAGAAAATG 
ETS-1 AAACTTGCTACCATCCCGTACGT  ATGGTGAGAGTCGGCTTGAGAT 
REN GAAAGCCTGAAGGAACGA  GTACTGGGTGTCCATGTAGTT 







2.8 Subnuclear Fractionation 
V-K562, B-K562 and G-K562 cells were collected and washed once in PBS. Nuclei 
were isolated using the Nuclei EZ Prep kit (Sigma) according to manufacturer’s 
instructions (15ml of cell suspension per 4ml Nuclei EZ lysis buffer). Briefly, cells 
were incubated in lysis buffer on ice for 5 mins, then centrifuged at 500 x g for 5 
mins. Lysis and centrifugation were repeated twice. To fractionate, the nuclei pellet 
was resuspended in 100µl CSK buffer (10 mM Pipes pH 6.8, 100mM NaCl, 300mM 
sucrose, 3mM MgCl2, 1mM EGTA, 1mM DTT, 0.5% (v/v) Triton X-100) plus 
protease inhibitors (Calbiochem). After extraction for 5 mins on ice, soluble proteins 
were recovered following separation from the insoluble fraction by centrifugation at 
5000 x g for 3 mins. The pellet was resuspended in CSK buffer with 30 units 
DNAse1 (RNase-free) (Thermo Fisher Scientific) and incubated at 37°C for 30 mins. 
The chromatin fraction was extracted by 5 mins incubation on ice following addition 
of 0.25M ammonium sulphate (final concentration) and then centrifuging at 500 x g 
for 5 mins. The resulting pellet was treated with 2M NaCl in CSK buffer on ice for 5 
mins, and this matrix fraction solubilised in 8M Urea. Protein concentrations were 
estimated via incubation with Bradford protein assay reagent (Bio-Rad) and 
measurement of absorption at 595nm on a spectrophotometer. Protein samples 
were then heated at 95°C in SDS-loading buffer (50mM Tris-Cl pH 6.8, 100mM 
DTT, 2% (w/v) SDS, 0.1% (w/v), Bromophenol Blue, 10% Glycerol) and analysed by 
western blot. 
 
2.9 Western Blotting 
Prepared western samples were loaded into wells of prepared denaturing 
polyacrylamide gels (37.5mM Tris pH 8.8, 0.1% (w/v) SDS, 7.5-12.5% (w/v) 
Acrylamide/Bis gel mix). Proteins were separated by resolving gels in SDS-PAGE 
buffer (25mM Tris, 192mM Glycine, 0.1% (w/v) SDS) at ~200 V until the 
bromophenol dye front reached the bottom of the gel. Separated proteins were then 
transferred onto methanol activated Immobilon-FL polyvinylidene difluoride 
membranes (Millipore) in transfer buffer (25mM Tris, 192mM Glycine, 20% (v/v) 
Methanol) using semi-dry blotting apparatus (Bio-Rad). Transfer was usually 
conducted for 45mins at 25V depending on the molecular weight of proteins being 
analysed. Following transfer, membranes were blocked in 5% (v/v) dried Milk 
(Marvel) in PBST (1 x PBS containing 0.1% (v/v) Tween), followed by overnight 




After washing four times for 5 mins each in PBST/5%(v/v) dried milk, membranes 
were incubated with horseradish peroxidase-conjugated secondary antibody diluted 
in 5% (v/v) milk in PBST for 1 hour at room temperature. Washes were repeated as 
before. Detection was carried out using a chemiluminescence system (Thermo 
Fisher Scientific) and CL-X PosureTM films (Thermo Fisher Scientific) developed 
using a Konica Minolta™ SRX-101A Film Processor.  
 
 




Antibody Species Source Dilution 
BASP1 Rabbit Pacific Immunology, California 1:1000 
WT1 Rabbit Pacific Immunology, California 1:1000 
β-actin Mouse Sigma, #A5316 1:10000 
Emerin Mouse Santa Cruz Biotech, #sc-25284 1:1000 
Lamin A/C Mouse Santa Cruz Biotech, #sc-20681 1:1000 
Prohibitin Rabbit Santa Cruz Biotech, #sc-28259 1:1000 
EZH2 Rabbit Abcam #ab186006 1:1000 
BAF Mouse Abcam #ab88464 1:1000 
LAP2α Rabbit Abcam #ab5162 1:1000 
MARCKS Goat Santa Cruz #sc-6455 1:500 
HDAC1 Mouse Cell Signalling, #5356 1:1000 
TGN46 Sheep GeneTex #GTX74290 1:1000 
Anti-Rabbit HRP Goat Jackson ImmunoResearch Laboratories 1:5000 
Anti-Mouse HRP Goat Jackson ImmunoResearch Laboratories 1:5000 




2.10 Chromatin Immunoprecipitation (ChIP) 
K562 cells were collected and resuspended to a density of 1x106 cells/ml in PBS. 
Crosslinking was achieved by adding formaldehyde into the PBS to a final 
concentration of 1.42% (v/v), and incubating, rocking, at room temperature for 15 
mins. When ethylene glycol bis(succinimidyl succinate) (EGS) (#E3257, Sigma) 
was also used to aid crosslinking, EGS at 1mM, 2mM or 3mM (final concentration) 
was added to samples following this 15mins incubation in 1.42% PFA and left for a 
further 15 mins rocking, at room temperature. Formaldehyde was quenched with 
ice-cold 125mM glycine for 5 mins at room temperature. Cells were collected by 
centrifugation at 2000 x g for 5 mins at 4°C and washed with ice cold PBS. Cells 
were resuspended to a concentration of 1x107 cells/ml, and lysed in 1ml IP buffer 
(150mM NaCl, 50mM Tris-HCl (pH 7.5), 5mM EDTA, 0.5% (v/v) NP-40 and 1% (v/v) 
Triton X 100) plus protease inhibitors (Calbiochem), for 15 mins on ice. Lysed 
samples were centrifuged at 2000 x g for 5 mins at 4°C, supernatant removed and 
the pellet resuspended in 1ml IP buffer plus protease inhibitors for sonication. 
Chromatin was sheared via sonication using a QSonica Q500 at 60% amplitude. 
Successful sonication giving fragments 200-500bps in length was confirmed by 
resolving a small (decrosslinked) sample on a 1.5% (w/v) agarose gel.  Following 
sonication the lysate was cleared by centrifugation at 12000 x g for 10 mins at 4°C. 
Samples were precleared by incubating with 10µl Mag-G beads (Life Technologies) 
for 1 hour, rotating at 4°C. 5µl Mag-G beads, 600µl IP buffer, 1µl 10mg/ml 
acetylated BSA (Sigma) and appropriate antibody were also incubated together in 
one microtube per desired chromatin immunoprecipitation for a minimum of 4 hours, 
rotating at 4°C. 200µl of pre-cleared chromatin was then added to the incubated 
microtube of antibody and beads and rotated at 4°C overnight. A 2% input sample 
was also stored for later decrosslinking and processing.  
Immunoprecipitated samples were then magnetised, supernatant discarded and 
beads sequentially washed once in IP buffer, high salt IP buffer (500mM NaCl, 
50mM Tris-HCl (pH 8.0), 5mM EDTA, 0.5% (v/v) NP-40, 1% (v/v) Triton X 100), LiCl 
buffer (10mM Tris-HCl (pH 8.0), 250mM LiCl, 1mM EDTA, 1% (v/v) NP-40, 1% 
(w/v) Sodium Deoxycholate), and TE buffer (10mM Tris-HCl (pH 8.0), 1mM EDTA). 
After the final wash beads and 2% input samples were resuspended in 100µl of PK 
buffer (125mM Tris-HCl (pH 8.0), 10mM EDTA, 150mM NaCl, 1% (w/v) SDS) and 
placed at 65°C overnight. Samples were then incubated with 1µl of 20mg/ml 




purified using Qiaquick PCR purification kit (Qiagen) according to manufacturer’s 
instructions. Eluted DNA was placed at 95°C for 10 mins and prepared for qPCR. 
Components for each q-PCR reaction consisted of: 
2µl DNA sample 
10µl SYBR Green Supermix 
1µl forward primer (10µM stock) 
1µl reverse primer (10µM stock) 
6µl H2O 
The following cycling parameters were set up: 
95°C for 3 mins, followed by 40 cycles of 95°C for 10s, 60°C for 10s, 72°C for 30s, 
plate read.  
A melt curve was then initiated using the following parameters: 
95°C for 10s, followed by 65.0°C for 5s, then temperature of increases 0.5°C every 
0.5s, plus plate read, up to 95°C. 
 
2.10.1 ChIP Antibodies 
 
Antibody Species Source Volume per IP 
BASP1 Rabbit Pacific Immunology, California 50μl 
WT1 Rabbit Pacific Immunology, California 50μl 
H3K4me3 Rabbit Millipore #07-473 4μl 
H3K36me3 Rabbit Abcam, #ab9050 4μl 
H3K27me3 Mouse Abcam, #ab6002 4μl 
H3K9Ac Rabbit Abcam, #ab10812 4μl 
H3K9me3 Rabbit Abcam #ab8898 4μl 
RNA polymerase II Rabbit Abcam #ab817 4μl 
RNA polymerase II S5 Rabbit Abcam #ab5408 4μl 
PI(4,5)P2 Mouse Abcam, #ab11039 3μl 
HDAC1 Mouse Cell Signalling #5356 2μl 




BAF Mouse Abcam #ab88464 4μl 
CDK7 Mouse Santa Cruz Biotech 4μl 
Lap2α Rabbit  Abcam #ab5162 4μl 
EZH2 Rabbit Abcam #ab186006 4μl 
Normal IgG Rabbit Cell Signalling #2729 1μl 




2.10.2 ChIP Primers 
 
Gene Forward Primer 5’-3’ Reverse Primer 5’-3’ 
AREG TTTAAGTTCCACTTCCTCTCA GGTGTGCGAACGTCTGTA 
ETS-1 CCTAAAGAGGAGGGGAGAGC AGGGGAAGTTGGCACTTTG 
REN GCTTAACCTCCTAGGTCTTG GTGGAGGAAGTCTGTAAATC 
JUNB 
 
  GGTCCTGGTATTTGTCCCAG 
  
  CTCGCGTCACTGTCAGGAAG  
 
VDR  CACCTGGCTCAGGCGTCC  
 
  GCCAGGAGCTCCGTTGGC  
 
18S  GTAACCCGTTGAACCCCATT  
 
  CCATCCAATCGGTAGTAGCG  
 
BAX internal CTGACGGCAACTTCAAC GGTGCACAGGGCCTT 
Control CAGCTCAGTGCTGTTGGTGG ACCATCCAACCCTGGAGATC 







2.11 Protein Immunoprecipitation (IP) 
All protein immunoprecipitation was carried out using nuclear extracts. To prepare 
nuclear extracts K562 cell lines were collected via centrifugation for 3 mins at 1400 
x g. The packed cell volume (PCV) was estimated, and the pellet incubated with 2/3 
PCV of NE1 buffer (10mM HEPES pH 8.0, 1.5mM MgCl2, 10mM KCL, 1mM DTT) 
for 15 mins on ice, with protease inhibitors. Cells were then passed through a 23 
gauge needle 4-5 times, and microfuged at full speed for 30 secs to isolate nuclei. 
The supernatant was discarded and remaining pellet resuspended in one PCV of 
NE2 buffer (20mM HEPES pH 8.0, 1.5mM MgCl2, 25% (v/v) Glycerol, 420mM NaCl, 
0.2mM EDTA, 1mM DTT and 0.5mM PMSF) on ice for with regular stirring for 30 
mins, with protease inhibitor cocktail. Nuclear debris was pelleted by 5 mins 
microfuge at full speed. The supernatant (nuclear extract) was dialysed against 
Buffer D (20mM HEPES pH 8.0, 100mM KCl, 0.2mM EDTA, 20% (v/v) Glycerol and 
0.5mM DTT) for 2 hours at 4°C. Dialysed samples were cleared by centrifugation at 
13,000 x g for 5 mins at 4°C and precleared by incubation with 10μl Protein-G 
beads and appropriate IgG antibody for 1-2 hours at 4°C. Following the preclear, 
samples were divided as necessary onto fresh Protein G beads, IP buffer (20mM 
HEPES pH 8.0, 100mM KCl, 0.2mM EDTA, 20% (v/v) Glycerol, 0.5mM DTT and 
0.05% (v/v) NP-40) and the appropriate antibody. Samples were rotated at 4°C 
overnight. Lastly, magnetic beads were collected and washed 3 times in 1ml IP 
buffer. To western blot, beads were resuspended in 10μl 1 x SDS loading buffer per 
gel and boiled at 95°C for 3 mins before loading SDS-PAGE gels and performing 
western blotting as previously described. 
 
2.11.1 IP Antibodies 
Antibody Species Source Volume per IP 
BASP1 Rabbit Pacific Immunology, California 50μl 
HA Rabbit Cell Signalling #3724S 4μl 
Emerin Mouse Santa Cruz #sc25284 10μl 
Normal IgG Rabbit Millipore #12-370 1μl 





2.12 TMT Mass Spectrometry 
To carry out Tandem Mass Tag (TMT) mass spectrometry of K562 cell lines, protein 
immunoprecipitation samples were collected as described above. The washed 
protein-bound magnetic beads were processed by the Faculty of Life Science 
Proteomics Facility, University of Bristol. Samples were differentially labelled with 
TMT reagents such that V-K562, B-K562 and G-K562 samples were 
distinguishable. Samples were mixed, fractionated and analysed by high resolution 
Orbitrap LC-MS/MS to identify present peptides. Only proteins with a minimum of 
95% confidence that all peptides were present in the sample (<5% false discovery 
rate) were assumed to be genuine interactors based on a human-specific protein 
database. The abundance of peptides from each sample is then calculated 
according to relative abundance of reporter ions. 
 
2.13 Immunofluorescence and Confocal Imaging 
K562 cells grown in suspension culture were collected via centrifugation at 1400 x g 
for 3 mins. Nuclei were isolated using the Nuclei EZ Prep nuclei isolation kit (Sigma) 
according to manufacturer’s instructions. Nuclei were collected via centrifugation at 
500 x g for 5 mins. Nuclei were fixed in 4% (v/v) PFA and rotated at room 
temperature for 15 mins. Nuclei were incubated with 50mM NH4Cl for 15 mins, 
rotating, then washed three times in PBS, and blocked in blocking buffer (2% (w/v) 
BSA, 0.25% (w/v) Gelatin, 0.2% (w/v) Glycine, 0.2% (v/v) Triton X-100 in PBS) for 1 
hour, rotating at room temperature. Primary antibody was diluted in PBS with 1% 
(w/v) BSA, 0.25% (w/v) gelatin and 0.2% (v/v) Triton X-100 and incubated for 1 
hour, rotating at room temperature. Nuclei were washed three times with washing 
buffer (0.2% (w/v) Gelatin in PBS). Fluorescent secondary antibody was then 
applied for 45 mins in the same buffer as the primary antibody, and samples were 
rotated in the dark. Nuclei were washed three times in washing buffer before 10 
mins incubation with DAPI (Thermo Fisher Scientific) solution. Nuclei were 
resuspended in a minimum volume of DABCO (Sigma) mounting media to mount 
onto poly-lysine coated slides. Samples were viewed using a Leica SP5-II AOBS 
confocal laser scanning microscope attached to a Leica DM I6000 inverted 
epifluorescence microscope with oil 63x lens. Images were processed using ImageJ 




2.13.1 Immunofluorescence Antibodies 
 
Antibody Species Source Dilution 
BASP1 Rabbit Pacific Immunology, California 1:300 
BASP1 Sheep SAPU, Edinburgh, Scotland 1:100 
HA-tag Rabbit Cell Signalling #3724S 1:500 
PI(4,5)P2 Mouse Abcam, #ab11039 1:200 
Prohibitin Rabbit Santa Cruz Biotech, #sc-28259 1:500 
HDAC1 Mouse Cell Signalling #5356 1:250 
Emerin Mouse Santa Cruz Biotech, #sc-25284 1:500 
Lamin A/C Mouse Santa Cruz Biotech, #sc-20681 1:500 
AlexaFluor Anti-rabbit 
secondary (488) 

















2.14 Click Chemistry 
K-562 and MCF7 cells were incubated in lipid free media (RPMI and DMEM, 
respectively) containing 10µg/ml of alkyne-Myristic Acid (Caymen Chemical #13267) 
or alkyne-Cholesterol (Avanti #700143) for 16 hrs. Samples were washed once in 
PBS, and either whole cells or nuclei (obtained using EZ Prep nuclei kit according to 
manufacturer’s instructions) were fixed in 3.7% (v/v) formaldehyde in Buffer A [0.1M 
HEPES/KOH (pH 7.4)] for at least 16 hrs. Samples were washed once in 155mM 
ammonium acetate, and twice in Buffer A. For detection, 50µM Azide-PEG3-biotin 
conjugate (Aldrich #762024) was dissolved in prewarmed Buffer A and added to 
samples. The click reaction was initiated via addition of 2mM CuBF4 in 2% (v/v) 
acetonitrile, and the reaction was left to proceed at 43oC for 30 mins with gentle 




2.14.1 Click Chemistry Immunofluorescence: 
If samples were being costained for BASP1, they were next incubated in IF blocking 
buffer (2% (w/v) BSA, 0.25% (w/v) Gelatin, 0.2% (w/v) Glycine, 0.2% (v/v) Triton X-
100 in PBS) for 60 mins, rotating at room temperature. Primary BASP1 antibody 
was then diluted 1:300 in PBS with 1% (w/v) BSA, 0.25% (w/v) gelatin and 0.2% 
(v/v) Triton X-100 and incubated for 1 hour, rotating at room temperature. Nuclei 
were washed three times with washing buffer (0.2% (w/v) Gelatin in PBS). Samples 
were next incubated with fluorescent secondary antibody (Thermo Fisher Scientific, 
#a21206) (1:500 dilution in Buffer A) and fluorescent streptavidin antibody 
(AlexaFluor #S32356) (1:400 dilution in Buffer A) and rotated for 45 mins at room 
temperature in the dark. Samples were then washed in Buffer A before 10 mins 
incubation with DAPI solution. Nuclei were resuspended in minimum volume of 
DABCO (Sigma) mounting media to mount onto poly-lysine coated slides for 
visualisation.  
If samples were not being costained, they were simply incubated with fluorescent 
streptavidin antibody (as described above) immediately following completion of the 
click reaction. Samples were then washed in Buffer A, incubated for 10 mins with 
DAPI solution and mounted using DABCO (Sigma) mounting media (as above). 
All samples were viewed using a Leica SP5-II AOBS confocal laser scanning 
microscope attached to a Leica DM I6000 inverted epifluorescence microscope with 
oil 63x lens. Images were processed using ImageJ or Volocity 6.3 software. 
2.14.2 Click Chemistry Immunoprecipitation:  
Following completion of the click chemistry reaction at 43oC for 30 mins (described 
above), nuclear extracts were prepared by resuspending samples in one PCV of 
NE2 buffer (20mM HEPES pH 8.0, 1.5mM MgCl2, 25% (v/v) Glycerol, 420mM NaCl, 
0.2mM EDTA, 1mM DTT and 0.5mM PMSF) and incubating on ice with regular 
stirring for 30 mins. Nuclear debris was pelleted by 5 mins microfuge at full speed. 
The subsequent nuclear extracts were then subjected to immunoprecipitation using 
streptavidin magnetic beads (Invitrogen) and IP buffer (20mM HEPES pH 8.0, 
100mM KCl, 0.2mM EDTA, 20% (v/v) Glycerol, 0.5mM DTT and 0.05% (v/v) NP-40) 
overnight at 4°C. Magnetic beads were collected and washed 3 times in IP buffer, 
and prepared for western blotting by resuspending in 10μl SDS loading buffer per 
gel and heating to 95°C for 5 mins before loading SDS-PAGE gels and performing 




2.14.3 Click Chemistry Chromatin Immunoprecipitation: 
5x106 K-562 cells were incubated in lipid free media containing 10µg/ml of alkyne-
Myristic Acid (Caymen Chemical #13267) or alkyne-Cholesterol (Avanti #700143) 
for 16 hrs. Samples were washed once in PBS and crosslinked in 3.7% (v/v) 
formaldehyde in PBS for 15 mins (Myristic Acid) or 4 hours (Cholesterol). Cells were 
collected by centrifugation at 2000 x g for 5 mins and washed once in 155mM 
ammonium acetate and twice in Buffer A. The click reaction was performed by 
resuspending the cell pellet in 50µM Azide-Reporter in prewarmed Buffer A, 
followed by the addition of 2mM CuBF4 in 2% (v/v) acetonitrile. The reaction was left 
to proceed at 43oC for 30 mins with gentle agitation. Samples were then extensively 
washed in Buffer A. Next, samples were fixed again in 3.7% (v/v) formaldehyde in 
PBS for 15 mins, and formaldehyde quenched with ice-cold 125mM glycine for 5 
mins at room temperature and cells collected by centrifugation at 2000 x g for 5 
mins. 
Cell pellets were resuspended to a concentration of 5x106 cells/ml, and lysed in IP 
buffer (150mM NaCl, 50mM Tris-HCl (pH 7.5), 5mM EDTA, 0.5% (v/v) NP-40 and 
1% (v/v) Triton X 100) plus protease inhibitors (Calbiochem), for 15 mins on ice. 
Chromatin was sheared via sonication of 5x106 cells in 1ml IP buffer, using a 
QSonica Q500 at 60% Amplitude. Successful sonication giving fragments 200-
500bps in length was confirmed by resolving a small (decrosslinked) sample on a 
1.5% (w/v) agarose gel.  Following sonication the lysate was cleared by 
centrifugation at 12000 x g for 10 mins at 4°C. 
500µl of cleared lysates were incubated with 10µl streptavidin beads (Invitrogen) 
with 100µl IP buffer, rotating at 4°C overnight. Samples were then magnetised, 
supernatant discarded and beads sequentially washed once in IP buffer, high salt 
IP buffer (500mM NaCl, 50mM Tris-HCl (pH 8.0), 5mM EDTA, 0.5% (v/v) NP-40, 
1% (v/v) Triton X 100), LiCl buffer (10mM Tris-HCl (pH 8.0), 250mM LiCl, 1mM 
EDTA, 1% (v/v) NP-40, 1% (w/v) Sodium Deoxycholate), and TE buffer (10mM Tris-
HCl (pH 8.0), 1mM EDTA). After the final wash beads were resuspended in 100µl of 
PK buffer (125mM Tris-HCl (pH 8.0), 10mM EDTA, 150mM NaCl, 1% (w/v) SDS) 
and placed at 65°C overnight. Samples were then incubated with 1µl of 20mg/ml 
Proteinase K for 3-4 hours at 55°C. Finally, samples were purified using Qiaquick 
PCR purification kit (Qiagen). Eluted DNA was placed at 95°C for 10 mins and 




Components for each q-PCR reaction consisted of: 
2µl DNA sample 
10µl SYBR Green Supermix 
1µl forward primer (10µM stock) 
1µl reverse primer (10µM stock) 
6µl H2O 
The following cycling parameters were set up: 
95°C for 3 mins, followed by 40 cycles of 95°C for 10s, 60°C for 10s, 72°C for 30s, 
plate read. 
A melt curve was then initiated using the following parameters: 
95°C for 10s, followed by 65.0°C for 5s, then temperature of increases 0.5°C every 
0.5s, plus plate read, up to 95°C. 
 
2.15 Transmission Electron Microscopy 
B-K562 and G-K562 cells were frozen onto TEM gold grids using a Leica EM 
PACT2 high pressure freezing system. Grids were then placed into a Leica EM 
ASF2 freeze substitution processor for automated low temperature embedding and 
resin (lowicryl) polymerisation. Once embedded in lowicryl resin, samples were 
sectioned at thickness of 70nm and subjected to immunogold labelling. Labelling 
was achieved by incubating grids in blocking solution (0.1% (w/v) BSA in PBS) for 
15 mins, followed by 1 hour incubation with primary antibody in blocking solution. 
Grids were then washed three times in blocking solution before a 30 min incubation 
with secondary antibody in blocking solution. Finally, grids were washed three times 
in blocking solution, and six times in distilled H2O. Images were obtained using an 
FEI Tecnai T12 TEM microscope. 
2.15.1 Antibodies for Immunogold Labelling 
 
Antibody Source Dilution 
HA (mouse) Kind gift from Paul Verkade 1:5 
Emerin (rabbit) Millipore #06-1052 1:5 
Anti-mouse Gold 6nm Kind gift from Paul Verkade 1:50 




3 Results Chapter 1: Molecular Mechanism of Gene Repression by the 
WT1/BASP1/PIP2 Complex 
3.1 Introduction 
Previous work from our laboratory established a PIP2 dependent mechanism of 
transcriptional repression mediated by the WT1/BASP1 complex [3]. This work 
provided the first evidence for the recruitment of PIP2 directly to gene promoters, 
and implicated PIP2 as an essential factor for the recruitment of the chromatin 
modifying protein HDAC1, and subsequent gene repression. Very little is known 
about the role of lipids in gene regulation, and currently the WT1/BASP1 repression 
complex is the only transcription regulating complex known to require PIP2 binding 
for its repression mechanism. Recently the N-terminally myristoylated MARCKS 
protein has also been shown to bind nuclear PIP2, suggesting protein lipidation 
could be a more widespread requirement for transcription regulation [121]. The 
experiments presented in this chapter were conducted to gain further insights into 
the BASP1 mechanism of action and the roles of lipid interaction in transcription. 
Here the effect of BASP1-PIP2 on the local chromatin environment at WT1 target 
gene promoters was examined. The aim was to build upon previous findings by 
studying the effects of PIP2 binding on additional active chromatin marks. It has also 
previously been suggested that BASP1 could also have a role in generating an 
increase in the repressive H3K27me3 mark at WT1 target gene promoters [69]. 
Thus, here it was also aimed to examine a role for BASP1 in mediating an increase 
in repressive chromatin marks and establish whether this activity was lipid 
dependent. These experiments serve to provide better understanding of how the 
WT1/BASP1/PIP2 complex mediates the alterations in the local chromatin 
environment that ultimately lead to transcriptional repression.  
In order to achieve this aim, generation of stable BASP1 expressing K562 cell lines 
and optimisation of the chromatin immunoprecipitation (ChIP) method was first 
necessary. The ChIP method was optimised through examination of BASP1 and 
WT1 recruitment to WT1 target gene promoters in the K562 cell lines. The levels of 
active and repressive chromatin marks at bound promoters was subsequently 
studied. Additionally, the effects of BASP1-PIP2 on transcriptional activation events 
downstream of chromatin changes were also studied to gain new insights into how 




3.2 Generation of Stable K562 Cell Lines  
K562 cells endogenously express WT1 but do not endogenously express BASP1, 
so stable K562 cell lines were generated that express either wild type BASP1 
protein (hereafter referred to as wtBASP1), a glycine-2 to alanine (G2A) mutant 
BASP1 protein, or control vector for use throughout this study. A pcDNA3 vector as 
shown in Figure 3.1A was used. The BASP1 sequence was inserted in the pcDNA3 
vector between the BamHI and EcoRI restriction sites, under the control of the CMV 
promoter (Figure 3.1A). A pcDNA3-BASP1 vector was previously generated in the 
laboratory. The G2A-BASP1 derivative was generated using G2A-BASP1 primers 
and the pcDNA3-BASP1 plasmid. The glycine residue mutated in the G2A mutant 
BASP1 is highlighted in the schematic in Figure 3.1B. The previously characterised 
G2A mutation removes the glycine residue to which the myristoyl motif is added by 
N-myristoyltransferase 1, completely abrogating myristoylation and disrupting the 
BASP1-PIP2 interaction [3, 81, 254, 255]. G2A-BASP1 PCR product was most 
efficiently produced following the addition of 3% DMSO to the PCR reaction (Figure 
3.1C). The PCR product and pcDNA3 vector were digested with BamHI and EcoRI 
enzymes and ligated together before being transformed into E. coli. Diagnostic 
digestion of plasmid DNA isolated from E. coli colonies with BamHI/EcoRI confirmed 
the insertion of a 700bp fragment in the pcDNA3 vector (Figure 3.1D). Presence of 
the G2A mutation was confirmed by sequencing.  
K562 cells were transfected with either unmodified pcDNA3 vector (V-K562 control 
cell line), pcDNA3-BASP1 sequence (B-K562 cell line), or pcDNA3-G2A-BASP1 
sequence (G-K562 cell line). Positively transfected cells were selected with 2µg/ml 
G418. Three sets of V-K562, three sets of B-K562 and two sets of G-K562 
derivative cell lines were generated via stable transfection and selection of G418 
resistant cells. The expression of BASP1 and mutant derivatives in these cell lines 





Figure 3.1. Generation of Stable BASP1 Expressing K562 Cell Lines. A, Map of the pcDNA3 mammalian expression vector. The BASP1 coding 
sequence is inserted between the BamHI and EcoRI sites (highlighted in red boxes), under the control of the CMV promoter. B, Schematic of BASP1 
protein and the N-terminal amino acid sequence. Glycine-2 is highlighted in purple; this amino acid is mutated to alanine in this study. The attachment of 
the myristoyl group is shown via the zig-zag purple line. C, Agarose gel of G2A-BASP1 product from PCR amplification. %DMSO added to PCR reaction 
mix is shown above, or W for water control. Base pair markers (bp) are shown at left. D, Agarose gel of undigested and digested (-/+) DNA from picked 
colonies of E. coli transformed with pcDNA3-G2A-BASP1. DNA was digested with BamHI and EcoR1 enzymes. E, V-K562 (V), B-K562 (B) and G-K562 
(G) cells were generated by stably transfecting K562 cells with the appropriate pcDNA3-based vector, selected with 2µg/ml G418 and tested for BASP1 
expression via western blotting. Molecular weight markers (kDa) are shown at left. β -actin was probed as a loading control 
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3.3 Gene Expression Analysis of WT1 Target Genes in V-K562, B-K562 and 
G-K562  
The stable K562 cell lines were tested for their expression levels of a selection of 
WT1 target genes. Total RNA and then cDNA were prepared from V-K562, B-K562 
and G-K562 cells and expression quantified using real time quantitative PCR. 
Multiple WT1 target genes that have previously been identified as repressed by 
BASP1 were examined including AREG (Amphiregulin), ETS-1 and REN (Renin) 
(Figure 3.2) [2, 3, 96]. In agreement with these previous reports wtBASP1 repressed 
these target genes. Transcriptional repression was not observed in G-K562 cells; 
indeed the ETS-1 gene was even upregulated in the G-K562 cells compared to V-
K562 cells. These results recapitulate previous findings from our laboratory and 
support a role for BASP1 in mediating repression of WT1 target genes in a 
myristoyl-dependent manner. Since myristoylation is required for the BASP1-PIP2 
interaction this implicates PIP2 as being important for the repression mechanism at 
these target genes. 
 
3.4 PMA Treatment of V-K562, B-K562 and G-K562 Cells 
It is well established that PMA treatment induces the differentiation of K562 cells 
towards a megakaryocyte lineage [2, 256, 257]. Our lab has previously shown that 
this PMA induced differentiation pathway is entirely diverted in K562 cell line 
derivatives that express wtBASP1, whereby cells instead differentiate into neuron-
like cells [2]. The stable K562 cell lines generated for this project were similarly 
tested (Figure 3.3). Upon PMA treatment the V-K562 cells adhere to the culture dish 
and retain a round morphology. B-K562 cells also adhere to the culture dish, and 
some arborisation was observed indicative of neuron-like differentiation. 
Furthermore, also in accordance with previous reports, G-K562 cells adhere to the 
culture dish but remain round in morphology, reminiscent of the V-K562 cells [3]. No 
arborisation of G-K562 cells was evident. These observations confirm that the K562 
cells used in this study differentiate in the presence of PMA similarly to previous 
reports and again demonstrate that myristoylation of BASP1 is essential for the 
BASP1 mediated differentiation of K562 cells into neuron-like cells. This in turn 
implicates the PIP2 interaction as being important for the BASP1 mediated effect on 


































































Figure 3.2. WT1 Target Genes are Repressed in Wild Type BASP1 Expressing K562 Cells. Relative expression of 
WT1 target genes in V-K562, B-K562 and G-K562 cell lines was analysed, compared to control gene GAPDH. The 
expression levels of three target genes; AREG, ETS-1 and REN are shown. Error bars representative of the standard 
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Figure 3.3. PMA Treatment Causes Neuronal-like Differentiation in B-K562 Cells. V-K562, B-K562 and G-K562 cells were treated 
with DMSO (control) or 100nm PMA for 72 hours in 6 well plates and examined for the presence of differentiating cells. All DMSO 
treated cells remained in suspension. Black arrows highlight adherent cells with neuron-like protrusions. Images representative of cells 




3.5 Soft Agar Colony Formation Efficiency of Stable K562 Cell Lines 
Our laboratory has previously demonstrated that expression of wtBASP1 leads to 
growth suppression of K562 cells in culture [2]. Given that the G2A mutation of 
BASP1 is sufficient to abolish transcriptional repression by BASP1, it was 
hypothesised that G2A-BASP1 expression in K562 cells may lead to loss of growth 
suppression. K562 cells can be used in soft agar assays as a measure of 
tumorigenicity [258, 259]. The K562 cell line derivatives generated here were 
therefore tested in soft agar assays to establish their ability to form anchorage 
independent colonies.  
The number of V-K562, B-K562 and G-K562 colonies greater than 50 cells in size 
were counted over a three-week period (Figure 3.4). Expression of wtBASP1 lead to 
a significant decrease in the colony forming ability of K562 cells (Figure 3.4B). 
Images taken to qualitatively assess differences in colonies, and subsequent 
measurement of the average area of colonies revealed that as well as forming fewer 
colonies, B-K562 cells form significantly smaller colonies (Figure 3.4C). Expression 
of G2A-BASP1 also lead to a significant decrease in the colony forming ability of 
K562 cells (Figure 3.4B). However, the average area of G-K562 colonies did not 
significantly differ to that of V-K562 colonies. This result suggests that BASP1 
reduces anchorage independent colony formation of K562 cells. This result also 
suggests that myristoylation, and subsequently interaction of BASP1 with PIP2, is 
not required to suppress formation of anchorage independent colonies but does 





Figure 3.4. BASP1 Expression Leads to Reduced Colony Formation in K562s. V-K562, B-K562 and G-K562 cells were seeded into 
agar dishes and colony formation efficiency was assessed at days 7,14 and 21. A, Representative images of V-K562, B-K562 and G-K562 
cells after 21 days growth in soft agar. B, Colony formation efficiencies (CFE) for both BASP1 expressing cell lines are significantly lower at 
all time points compared to V-K562 control. There is no significant difference between B-K562 and G-K562 colony formation efficiency. Error 
bars representative of the standard deviation of the mean across 3 independent experiments. C, Box and Whisker plot of average colony 
area after 21 days growth of V-K562, B-K562 and G-K562 cells in agar. *p<0.05, **p<0.005, n.s. (no significant difference) by Student’s t 

























































3.6 Development and Optimisation of the Chromatin Immunoprecipitation 
Method for K562 Cells 
As previously described our laboratory has demonstrated a BASP1-PIP2 dependent 
mechanism of transcriptional repression of WT1 target genes [3]. PIP2 is an 
essential component of the repression complex which recruits histone deacetylase 1 
(HDAC1) to target gene promoters [3]. HDAC1 subsequently mediates the removal 
of acetyl groups from histone 3 lysine 9 (H3K9Ac) and thus produces a more 
repressive chromatin environment. To further explore how BASP1-PIP2 mediates 
changes in chromatin dynamics at WT1 target gene promoters chromatin 
immunoprecipitation (ChIP) experiments were conducted to examine the levels of 
other activating histone marks, as well as repressive histone marks at WT1- and 
WT1/BASP1-bound promoters.  
Previous studies using ChIP experiments in our laboratory have found that 
considerable optimisation of the crosslinking and fragmentation steps in particular 
are required for K562 cells. Firstly, several methods were tested to establish the 
most efficient and reproducible method to produce high quality DNA fragments 
(Figure 3.5).  Prior to fragmentation, cells were crosslinked in 1.42% PFA, lysed and 
nuclear extracts collected via centrifugation. The first method of DNA fragmentation 
tested was via digestion by the micrococcal nuclease (Mnase) enzyme. Mnase 
enzyme digestion of the collected DNA reliably produced a dense band of DNA 
fragments of approximately 300bp, and a smaller band of approximately 150bp 
(Figure 3.5A). This indicated digestion of DNA into di and mono nucleosomes, 
respectively. Additionally, partially digested DNA was detected as a diffuse smear 
above these bands on agarose gels. Longer mnase digestion times (10, 15, 20, 30 
mins) and changes in initial crosslinking times (15, 20, 25 mins) did not greatly 
affect the production of dinucleosomes, mononucleosomes or significantly reduce 
the proportion of partially digested DNA. Optimal DNA fragmentation using the 
Mnase digestion method was achieved when samples were digested for 30 mins. 
Secondly, identically prepared DNA samples placed in a bioruptor to fragment DNA 
resulted in poor DNA fragmentation (Figure 3.5B). Despite identifying a band of 
DNA fragments of approximately 400-500bp when samples were resolved on 
agarose gels, all biorupted samples contained a large proportion of unfragmented 
DNA that did not migrate out of the loading wells. Increasing the number of bioruptor 




Thirdly, DNA fragmentation via sonication was also examined. 16 pulses of 
sonication for 30 seconds (s), followed by 30s on ice was recommended by 
previous lab members as a starting protocol. Sonication using this method produced 
DNA fragments of approximately 300bp, however a large proportion of sample 
remained several thousands of base pairs in length as seen on agarose gels (Figure 
3.5C). It was predicted that a larger number of shorter sonication pulses would more 
efficiently fragment the DNA and give higher quality fragments. To this end, shorter 
sonication pulses of 3x3s at 60% amplitude, with 2s on ice between each pulse was 
trialled. This shorter sonication protocol reliably produced fragments of 
approximately 400bp, even at the lowest number of pulses (16) (Figure 3.5D). This 
method was also most effective at fragmenting the whole DNA sample, with minimal 
DNA detected above 400bp on agarose gels. To ensure maximum optimisation of 
the sonication protocol different amplitudes were also tested (Figure 3.5E). Using 
50% or 60% amplitude for sonication had no determinable effect on the size of 
fragments produced.  
From these results it was concluded that the optimal method of DNA fragmentation 
was sonication, and that the best DNA fragmentation was achieved using 16 pulses 
of 3x3s sonication, with 2s on ice between each. Therefore, using this method the 
enrichment of BASP1 and WT1 protein at the AREG promoter in V-K562 and B-
K562 cells was then examined (Figure 3.5F). No enrichment of BASP1 or WT1 
could be detected in the B-K562 cell line regardless of the number of sonication 
pulses. Both BASP1 and WT1 signal was enriched at the AREG promoter in the V-
K562 cells. Given that BASP1 is not expressed in these cells it is reasonable to 
conclude that the signal obtained in this experiment was not specific and that further 
optimisation of the ChIP method was required.  
Simultaneously to experiments exploring the optimal DNA fragmentation method for 
ChIP, experiments examining a variety of crosslinking times and methods were also 
conducted in order to improve the reliability of protein enrichment. Direct 
comparison of ChIP signal from V-K562 and B-K562 cells crosslinked in 1.42% 
paraformaldehyde (PFA) for different lengths of times was examined. Having 
already found 20 mins of crosslinking to result in high levels of background signal, 
crosslinking for 10 and 15 mins with 1.42% PFA was tested (Figure 3.6A and 3.6B). 
Detection of both BASP1 and WT1 signal above that of IgG control was limited in 
both crosslinking conditions. Whilst the fold enrichment for BASP1 was greater in B-
K562 than V-K562 cells after 10 mins of crosslinking, this is also true for WT1. WT1 




was successful only in one of the two cell lines. After 15 mins crosslinking both 
BASP1 and WT1 were detected at similarly low levels in both cell lines. Following 
these results it was concluded that neither ChIP experiment had resulted in 
successful pull down of BASP1 and WT1 and therefore that further optimisation was 
required. 
V-K562, B-K562 and G-K562 cells were next crosslinked using either 1.42% PFA 
alone, or in combination with 1mM, 2mM or 3mM ethylene glycol bis(succinimidyl 
succinate) (EGS) (Figure 3.6C-G). EGS has previously been used to enhance the 
crosslinking of proteins not directly bound to DNA but bound as part of protein 
complexes [260, 261]. Fragmentation of DNA via sonication was unaffected by 
addition of EGS as a crosslinker (Figure 3.6C). Detection of BASP1 protein at the 
REN promoter was unimproved by the addition of EGS at any concentration. 
Conversely, in this experiment BASP1 was more reliably detected in the absence of 
EGS (Figure 3.6D). It was therefore concluded that samples for further ChIP 
experiments would be crosslinked using only 1.42% PFA. It was also found that 
crosslinking with PFA in phosphate buffered saline (PBS) gave more efficient 
crosslinking than adding PFA directly to the culture medium.  
Based on the unimproved ChIP signal following any of the crosslinking conditions 
tested it was determined that optimisation of other stages of the ChIP protocol was 
necessary in order to gain reliable ChIP signal. To proceed it was decided that a 15 
min crosslinking was the most appropriate to use whilst further optimising the ChIP 
protocol in order to ensure the best capture of target proteins. Only upon combining 
the optimally devised sonication protocol with the 15 mins 1.42% PFA crosslinking 
method was reliable and convincing detection of BASP1 and WT1 bound to target 
gene promoters achieved. It proved essential that both high quality crosslinking and 
sonication were achieved in order to gain successful protein capture and DNA 
detection. This detection was further improved through additional protocol 
adaptations which included the use of acetylated bovine serum albumin (BSA) 
during pre-blocking of dynabeads, lengthening the immunoprecipitation stage to 
approximately 20 hours, decrosslinking in the presence of Ambion Proteinase K 
(#AM2548), testing multiple aliquots of BASP1 and WT1 antibodies, and using 
always freshly made IP and washing buffers throughout. Once optimisation of all 
these aspects of the protocol were combined successful detection of BASP1 and 
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Figure 3.5. Testing Methods of DNA Fragmentation for ChIP. Gel electrophoresis showing sizes of DNA fragments following different DNA 
fragmentation protocols. Base pair markers are shown at left. A, size of fragments following varying times of Mnase enzyme digestion of crosslinked 
B-K562 for 15, 20 or 25 mins. B, size of fragments achieved following 5-10 pulses of 30s in a bioruptor after 15 mins crosslinking (B-K562). C, 
Crosslinked K562 cells (V-, B-, Y- and G-) were sonicated using an amplitude of 50%, for 16 pulses of 30s sonication, 30s on ice. D, size of 
fragments following pulses of sonication for 3s, followed by 2s on ice for increasing number of rounds (16-32) in V-K562 and B-K562 crosslinked for 
15 mins. E, V-K562 and B-K562 cells were sonicated at 50% or 60% amplitude, respectively, for either 16, 24 or 32 pulses of 3s sonication, 2s on 






Figure 3.6. Optimising PFA + EGS Crosslinking for ChIP. ChIP was performed on V-K562 and B-K562 cells following crosslinking with PFA for 
either A, 10 mins or B, 15 mins. BASP1 and WT1 immunoprecipitates were analysed for signal above IgG control at the AREG gene compared to 
negative control region. B-K562 cells were crosslinked with either PFA plus DMSO (control), PFA plus 1mM EGS, PFA plus 2mM EGS, or PFA 
plus 3mM EGS (C,1,2,3 in C). C, Gel electrophoresis showing size of DNA fragments following PFA + EGS crosslinking and sonication. Base pair 
markers (bp) are shown at left. D-G, ChIP signal obtained at the REN promoter, after crosslinking V-K562, B-K562 and G-K562 cells with PFA plus 
DMSO (control), PFA plus 1mM EGS, PFA plus 2mM EGS, or PFA plus 3mM EGS, sonication, and incubation with BASP1 antibody overnight. 
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3.7 Chromatin Immunoprecipitation of BASP1 and Repression Complex 
Components to the Promoters of WT1 Target Genes 
Having optimised the protocol for ChIP in K562 cells, detection of BASP1 and WT1 
at the promoters of WT1 target genes was performed.  V-K562, B-K562 and G-K562 
cells were subjected to ChIP using antibodies against BASP1, WT1 or IgG control 
(Figure 3.7). Both wtBASP1 and G2A-BASP1 were bound at the AREG, ETS-1, 
REN, VDR and JUNB promoters. As would be predicted, BASP1 enrichment was 
statistically significantly greater in B-K562 and G-K562 cells than in V-K562 cells as 
determined using a Student’s t test (Figure 3.7A). Further, the enrichment of BASP1 
at these sites was also statistically significantly greater than the enrichment of IgG. 
Therefore, both wtBASP1 and G2A-BASP1 were detected at these WT1 target gene 
promoters above the level of background signal. Similarly, WT1 was detected above 
the level of background signal in all three cell line derivatives, indicating that WT1 
was bound to its target gene promoters regardless of BASP1 expression (Figure 
3.7B). There was no statistically significant difference in the binding of WT1 at these 
sites between V-K562, B-K562 and G-K562 cells as determined using a Student’s t 
test. These findings indicate that WT1 was successfully detected bound to WT1 
target gene promoters in V-K562, B-K562 and G-K562 cells, whilst wtBASP1 and 
G2A-BASP1 were successfully detected bound to WT1 target gene promoters in the 







Figure 3.7. Recruitment of BASP1 and WT1 to AREG, ETS-1, REN, VDR and JUNB Promoters in K562 Cells. The presence of (A) 
BASP1 and (B) WT1 at the promoters of AREG, ETS-1, REN, VDR and JUNB was examined using chromatin immunoprecipitation in V-
K562, B-K562 and G-K562 cells. Error bars representative of the standard deviation of the mean, A) n=6, B) n=10 *p<0.05 by Student’s t 
test comparing B-K562 or G-K562 with control line V-K562. 
AREG REN VDR ETS-1 JUNB A 




3.8 Chromatin Immunoprecipitation of Active and Repressive Chromatin 
Marks at WT1 Target Gene Promoters in V-K562, B-K562 and G-K562 
Cells 
Following successful detection of BASP1 and WT1 bound to target gene promoters 
in the K562 cell lines via ChIP, examination of BASP1-dependent changes in 
histone modifications at these sites was next conducted. As described, our lab has 
previously demonstrated a decrease in histone H3 lysine 9 (H3K9) acetylation at 
BASP1 bound sites in a PIP2-dependent manner [3]. Therefore, ChIP was 
conducted in V-K562, B-K562 and G-K562 cells to verify that changes in H3K9Ac 
levels could be detected using the optimised ChIP protocol (Figure 3.8). In 
agreement with previous findings H3K9Ac marks were significantly reduced at 
promoters bound by wtBASP1 at all five target genes examined (AREG, ETS-1, 
REN, VDR and JUNB). At G2A-BASP1 bound sites there is no decrease in H3K9Ac 
marks at any of the gene promoters. In fact, at the AREG and JUNB promoters 
levels of H3K9Ac are higher in the G-K562 than V-K562 cells. This result further 
validates that the implemented ChIP protocol can be used to reproduce previous 
observations.  
To further explore how BASP1-PIP2 mediate changes in chromatin dynamics at 
WT1 target gene promoters, the abundance of other activating histone modifications 
at these sites was examined. The relative fold enrichment of two additional active 
histone marks, H3K36me3 and H3K4me3, at the AREG, ETS-1, REN, VDR and 
JUNB promoters in V-K562, B-K562 and G-K562 cells are shown in Figure 3.9. 
Similarly to H3K9Ac, a significant reduction in H3K36me3 was observed at the REN, 
VDR and JUNB promoters in B-K562 but not G-K562 cells. This was not the same 
for the ETS-1 promoter where there was no significant difference in the abundance 
of H3K36me3 marks in V-K562, B-K562 or G-K562 cells. The AREG promoter also 
showed no significant difference in H3K36me3 marks in V-K562 and B-K562 cells.  
Additionally, like H3K9Ac, at several gene promoters there was in fact an increase 
in H3K36me3 marks in G-K562 compared to V-K562 cells. Furthermore, H3K4me3 
marks were significantly reduced at all target gene promoters only in the B-K562 
compared to V-K562 cells. No reduction in H3K4me3 was observed at any of the 
promoters bound by G2A-BASP1. These data provide evidence that BASP1 
recruitment to WT1 target gene promoters affects multiple activating histone 
modifications, and that myristoylation of BASP1 is required for the WT1/BASP1 




requirement for BASP1 myristoylation to induce the observed changes in histone 
modifications implicates PIP2 in being an essential BASP1 interactor for this 
process. 
In addition to examining activating histone marks, levels of the repressive histone 
marks H3K27me3 and H3K9me3 were also studied. BASP1 has previously been 
connected to the placement of H3K27me3 marks at the WT1 regulated Wnt4 locus 
during differentiation of epicardial cells [69]. It was suggested that loss of BASP1 
resulted in the switching of WT1 genes from a repressed to an active state, and thus 
we hypothesised BASP1 to have a dual role in driving removal of active chromatin 
marks and placement of repressive marks to induce a repressive chromatin state. 
Here it was tested whether BASP1 induces a repressive state at WT1 target genes 
in the K562 cell lines and if this is dependent on the myristoylation of BASP1. V-
K562, B-K562 and G-K562 cells were subjected to ChIP using antibodies against 
H3K27me3 and H3K9me3 (Figure 3.10). A significant increase in the enrichment of 
H3K27me3 marks was detected at the AREG and ETS-1 promoters in B-K562 cells. 
H3K27me3 marks were also significantly increased at the AREG promoter in G-
K562 cells (Figure 3.10A). As a trend, levels of H3K27me3 marks at the REN, VDR 
and JUNB promoters were greater in B-K562 and G-K562 cells than V-K562 cells, 
although not to a statistically significant level. Similarly, increases in H3K9me3 
marks were detected at selected gene promoters (AREG, JUNB) in B-K562 and G-
K562 cells, although only to a statistically significant level in the latter. These results 
suggest that BASP1 could indeed have a role in increasing repressive histone 
modifications at WT1 target gene promoters. It appears that this activity is 
















Figure 3.8. H3K9Ac Marks are Decreased at WT1 Target Genes in Wild Type BASP1 Expressing K562s. The presence 
of H3K9Ac marks at the promoters of the WT1 target genes AREG, ETS-1, REN, VDR and JUNB was examined using 
chromatin immunoprecipitation in V-K562, B-K562 and G-K562 cells. Error bars representative of the standard deviation of 
the mean, n=5. *p<0.05 by Student’s t test comparing B-K562 or G-K562 with control line V-K562. 










Figure 3.9. Active Histone Marks H3K36me3 and H3K4me3 are Decreased at WT1 Target Genes in Wild Type BASP1 Expressing 
K562s. The presence of (A) H3K36me3 marks and (B) H3K4me3 marks at the promoters of AREG, ETS-1, REN, VDR and JUNB was 
examined using chromatin immunoprecipitation in V-K562, B-K562 and G-K562 cells. Error bars representative of the standard deviation 
of the mean, A) n=6, B) n=5. *p<0.05 by Student’s t test comparing B-K562 or G-K562 with control line V-K562. 
AREG REN VDR ETS-1 JUNB 






Figure 3.10. Repressive Histone Marks H3K27me3 and H3K9me3 are Increased at WT1 Target Genes in Wild Type and G2A-
BASP1 Expressing K562s. The presence of (A) H3K27me3 marks and (B) H3K9me3 marks at the promoters of AREG, ETS-1, 
REN, VDR and JUNB was examined using chromatin immunoprecipitation in V-K562, B-K562 and G-K562 cells. Error bars 
representative of the standard deviation of the mean, A) n=7, B) n=6. *p<0.05 by Student’s t test comparing B-K562 or G-K562 with 
control line V-K562. 
AREG REN VDR ETS-1 JUNB 






3.9 BASP1-Dependent Chromatin Immunoprecipitation of EZH2 at WT1 
Target Gene Promoters 
The molecular mechanism behind the observed increase in abundance of 
repressive histone marks H3K27me3 and H3K9me3 at WT1 target gene promoters 
in B-K562 and G-K562 cells was investigated further. Mining of BASP1 interactome 
data obtained via a combination of Tandem Mass Tag (TMT) mass spectrometry 
and standard interactome LC-MS mass spectrometry of BASP1 immunoprecipitates 
identified a number of chromatin modifying enzymes including histone 
methyltransferases and histone demethylases (refer to results chapter 2, Figure 
4.2). Amongst the candidate histone methyltransferases that were found to interact 
with BASP1 in the mass spectrometry data sets was enhancer of zeste 2 polycomb 
repressive complex 2 subunit (EZH2). EZH2 is the enzymatic N-methyltransferase 
component of the Polycomb Repressive Complex 2 (PRC2), a complex well known 
to initiate silencing of genomic regions primarily through methylation of H3K27, but 
also of H3K9 [262-264]. Reports that EZH2 predominantly targets H3K27 
methylation, resulting in H3K27me3 marks, as well as having weaker 
methyltransferase activity towards H3K9me2, forming H3K9me3 marks is consistent 
with ChIP data presented here [265-269]. This data shows an increase in 
H3K27me3 marks, with a more modest increase in H3K9me3 marks at BASP1 
bound promoters and so it was hypothesised that EZH2 could be responsible for 
mediating the increase in these marks in BASP1 expressing cells. To test this, ChIP 
experiments were conducted to examine the recruitment of EZH2 at WT1 target 
gene promoters and assess whether this enzyme could be responsible for the 
observed increase in methylation of H3K27 and H3K9. 
Indeed, upon examination of EZH2 recruitment to WT1 target genes via ChIP, at 
three genes (AREG, REN and JUNB) EZH2 was significantly enriched in B-K562 
and G-K562 with respect to V-K562 cells (Figure 3.11A). At the other two genes 
(ETS-1 and VDR) EZH2 was significantly enriched in G-K562 cells and was also 
elevated in B-K562 cells, although not to a statistically significant level. This result 
indicates that EZH2 is indeed recruited to WT1 target gene promoters in a BASP1-
dependent manner that correlates with the observed increase in BASP1-dependent 
H3K27 and H3K9 trimethylation. Just as the increase in H3K27me3 and H3K9me3 is 
not dependent upon myristoylation (and PIP2 interaction) of BASP1, recruitment of 




hypothesis that BASP1 induces a repressive chromatin environment via the 
recruitment EZH2 to WT1 target gene promoters. 
Next, to validate the BASP1-EZH2 interaction nuclear extracts of V-K562, B-K562 
and G-K562 cells were immunoprecipitated with BASP1 antibodies, western blotted 
and probed for EZH2 (Figure 3.11B). A direct interaction between wtBASP1 or G2A-
BASP1 and EZH2 was not detected. The western blotting technique is not as 
sensitive as mass spectrometry and so it is possible that the affinity of EZH2 for 
BASP1 is below the detection level for western blotting. Probing of the western blot 
membranes with other EZH2 antibodies could be performed to determine whether 
antibody specificity could be at fault. It is also possible that the BASP1-dependent 
recruitment of EZH2 as seen in the ChIP data is the result of wider BASP1 mediated 
effects on the local chromatin environment rather than BASP1 directly interacting 
with EZH2 to recruit it to target sites. It is possible that BASP1 has effects on 
additional histone marks which act as a signal for EZH2 recruitment. The BASP1 
mediated effects that result in EZH2 recruitment are clearly independent of 
myristoylation.  
 
3.10 Chromatin Immunoprecipitation of RNA Polymerase II and CDK7 at WT1 
Target Genes Promoters 
So far, the data has shown the BASP1 repression complex mediates its effect on 
gene transcription through changes to the chromatin environment at WT1 target 
gene promoters. Whether BASP1 mediates effects downstream of chromatin 
alterations had yet to be explored. Here, the recruitment and activation of the 
transcription machinery was analysed through further ChIP experiments. To this 
end, the recruitment of RNA polymerase II to WT1 target gene promoters in V-K562, 
B-K562 and G-K562 cells was examined (Figure 3.12A). Since mRNA expression 
data showed wtBASP1 causes gene repression, whilst G2A-BASP1 does not, it was 
hypothesised that RNA polymerase II recruitment may be reduced by wtBASP1 and 
not by G2A-BASP1.  
No statistically significant differences were identified in the level of recruitment of 
total RNA polymerase II in V-K562, B-K562 and G-K562 cells at three of the five 
examined target gene promoters (ETS-1, REN, JUNB) (Figure 3.12A). At the VDR 
promoter, significantly greater recruitment of RNA polymerase II was identified only 




recruitment of RNA polymerase II significantly reduced in the B-K562 cell line 
compared to V-K562. These results suggested instead that for most target genes 
BASP1 has no effect on the overall recruitment of RNA polymerase II. 
Following this finding, the phosphorylation status of RNA polymerase II at serine 5 
was also examined via ChIP. Serine 5 within the C terminal domain of the large 
subunit of RNA polymerase II is phosphorylated by the CDK7 kinase subunit of  
TFIIH [270]. This phosphorylation event transforms RNA polymerase II from its pre-
initiation state to a transcription initiating state where it is released from the 
promoter and begins to transcribe approximately 30bp of DNA to RNA [271]. Further 
phosphorylation of RNA polymerase II serine 2 by the Ctk1 subunit of the CTDK-1 
complex leads to transcription elongation [272].  As RNA polymerase II recruitment 
to the promoter is unchanged by the presence of BASP1, it was hypothesised that 
perhaps the initiation of transcription via RNA polymerase II serine 5 
phosphorylation is perturbed by the BASP1 repression complex. Indeed, at multiple 
target gene promoters (AREG, REN and ETS-1) phosphorylation of RNA 
polymerase II at serine 5 was reduced specifically in the B-K562 cells, with no 
difference seen between G-K562 and V-K562 cells. At two promoters this trend was 
not observed, there was no significant changes in RNA polymerase II serine 5 
phosphorylation at the JUNB promoter and at the VDR promoter RNA polymerase II 
serine 5 phosphorylation was significantly increased only in the B-K562 cells 
compared to V-K562 cells. 
Next, having seen that at the majority of target gene promoters there was 
significantly less phosphorylation of RNA polymerase II serine 5 the recruitment of 
CDK7, the kinase subunit of TFIIH responsible for RNA polymerase II 
phosphorylation, was examined. In line with the RNA polymerase II serine 5 
phosphorylation data, recruitment of CDK7 was significantly reduced specifically in 
B-K562 cells at the AREG, ETS-1 and REN promoters. No significant change was 













Figure 3.11. BASP1 Recruits EZH2 to the Promoters of WT1 Target 
Genes. A, The presence of EZH2 at the promoters of AREG, ETS-1, 
REN, VDR and JUNB was examined using chromatin 
immunoprecipitation in V-K562, B-K562 and G-K562 cells. Error bars 
representative of the standard deviation of the mean, n=10. *p<0.05 by 
Student’s t test comparing B-K562 or G-K562 with V-K562. B, Nuclear 
extracts of V-K562 (V), B-K562 (B) and G-K562 (G) were 
immunoprecipitated with BASP1 antibodies, western blotted and probed 
for EZH2.  











Figure 3.12. BASP1 Reduces RNA Pol II S5 Phosphorylation and CDK7 Recruitment to WT1 Target Gene Promoters. The presence 
of total RNA polymerase II (A) phospho S5 RNA polymerase II (B) and CDK7 (C) at the promoters of AREG, ETS-1, REN, VDR and JUNB 
was examined using chromatin immunoprecipitation in V-K562, B-K562 and G-K562 cells. Error bars representative of the standard 
deviation of the mean, A) n=5, B) n=5, C) n=6. *p<0.05 by Student’s t test comparing B-K562 or G-K562 with control line V-K562. 
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3.11 Discussion of Results Chapter 1  
3.11.1 Validation of Cell Lines  
The work presented at the beginning of this chapter showed the generation of stable 
K562 cell lines for use throughout this investigation. This was followed by gene 
expression analysis to demonstrate myristoyl-BASP1 mediated repression of WT1 
target genes in these lines, and PMA treatment to demonstrate BASP1 driven 
differentiation towards a neuron-like lineage. Following previous reported effects of 
BASP1 on the differentiation and growth of K562 cells, soft agar assays were 
conducted to assess the effect of BASP1 on tumourigenicity [2]. Cells expressing 
wtBASP1 showed both reduced colony formation and limited colony growth 
compared to control K562 cells, but it was shown here for the first time that 
expression of G2A-BASP1 results in an intermediate cellular phenotype of K562 
cells grown in 3D agar. G-K562 cells had a reduced capacity to form colonies but 
significantly greater colony growth compared to B-K562 cells. This suggests a 
myristoyl-independent function for BASP1 in inhibiting colony formation and a 
myristoyl-dependent role for BASP1 in inhibiting colony growth. The necessity of 
myristoylation for BASP1 function in transcription control has only previously been 
studied by our group and this forms our first evidence of a myristoyl-independent 
function of BASP1 in reducing colony formation. 
3.11.2 BASP1 Regulates Active and Repressive Chromatin Modifications at 
WT1 Target Genes 
Further work presented in this chapter details the careful optimisation of the ChIP 
method. The lab has consistently found that K562 cells need particular finetuning of 
the crosslinking and sonication steps so optimisation was focused in these areas. 
The final method was used to explore the mechanisms of BASP1 mediated 
transcriptional repression at WT1 target genes. Together, the ChIP data suggest the 
BASP1 complex likely mediates gene repression via different molecular 
mechanisms at different genes. As hypothesised, BASP1 mediates a reduction in 
multiple active chromatin marks (Figure 3.9). In addition to the previously reported 
removal of H3K9Ac, BASP1 also decreased H3K4me3 at all target gene promoters 
and H3K36me3 at the majority of target genes in a myristoyl-dependent manner. 
These findings demonstrate that BASP1 modulates the chromatin environment by 




therefore implicates PIP2 as an important regulator of the chromatin environment at 
BASP1 regulated genes.  
Additionally, in agreement with previous work and our hypothesis, the BASP1 
repression complex mediates an increase in repressive H3K27me3 marks (Figure 
3.10) [69]. It has been shown here for the first time that repressive H3K9me3 marks 
are also increased at many wtBASP1 and G2A-BASP1 bound target gene 
promoters (Figure 3.10). G2A-BASP1 doesn’t recruit HDAC1 to remove acetyl 
groups from H3K9 therefore it must be assumed from this data that H3K9me3 marks 
accumulate at non-acetylated H3K9 residues as these modifications cannot both be 
present on the same histone residue. This work implicates BASP1 as a regulator of 
chromatin dynamics that induces compaction of chromatin via the removal of 
activation marks and addition of repressive marks (refer to Figure 3.13 for proposed 
model of BASP1 activity). Here BASP1’s role in placing repressive chromatin marks 
was shown to be independent of myristoylation, and therefore independent of PIP2 
interaction. This work shows for the first time that BASP1 has additional myristoyl-
independent repression inducing function. This provides new insight into BASP1 
mediated transcriptional repression as a multi-step process with both myristoyl-
dependent and myristoyl-independent steps. This further implicates PIP2 as an 
important cofactor specifically for the removal of activation marks.  
Later work showed that the methyltransferase EZH2 is recruited to BASP1 bound 
promoters and is therefore a candidate for executing the methylation of both H3K27 
and H3K9. EZH2 is the enzymatic component of the Polycomb Repressive Complex 
2 (PRC2), a complex associated with inducing silencing of genomic regions 
primarily through methylation of H3K27, but also of H3K9 [262-264]. EZH2 has been 
identified via mass-spec within BASP1 immunoprecipitates, which further implies a 
BASP1-EZH2 interaction (refer to Figure 4.2). Moreover, EZH2 is known to be 
critical for WT1-dependent regulation of the Wnt4 gene during nephrogenesis [70]. 
Recruitment of EZH2 and subsequent upregulation of repressive chromatin marks is 
therefore a potential mechanism through which wtBASP1 may exert its down-
regulation of WT1 target genes. Recruitment of EZH2 by G2A-BASP1 and 
subsequent placement of repressive chromatin marks does not offer explanation as 
to the mechanism by which these sites remain actively transcribed. 
The occurrence of only the myristoyl-BASP1 independent changes to the chromatin 
environment around G2A-BASP1 bound sites results in promoters exhibiting both 




by others, where both activating H3K4me3 and repressive H3K27me3 are present 
[273]. Bivalent domains are usually associated with embryonic stem cells and 
commonly occur at transcription start sites of genes encoding transcription factors 
and developmentally significant genes that establish cell identity. It is thought that 
bivalent modification patterns pause genes in a bipotential state, and an active or a 
repressive state is selected as cells differentiate depending on cell lineage. WT1 is 
an important regulator of development in multiple tissues. Its function is highly 
context specific, acting to both activate and repress transcription of its targets 
depending on the binding of particular cofactors [274, 275]. A recent report 
demonstrated that BASP1 mediated regulation of WT1 blocks pluripotency and is a 
major driver of differentiation [90]. Thus, the WT1/BASP1 complex plays a major 
role in controlling cell fate and it is perhaps unsurprising that WT1/BASP1 regulated 
sites are among those known to be bivalent. Perhaps a lipid regulated switch could 
control the fate of bivalent promoters, whereby the WT1/BASP1 complex is paused 
on bivalent promoters and upon lipid binding the displacement of activation marks is 
triggered, prompting a more repressive chromatin environment. 
H3K9Ac and other active histone marks including H3K14Ac have also previously 
been shown to cluster at sites displaying H3K27me3 marks [276]. It is generally 
accepted that the biological effect of histone marks is additive rather than defined, 
thus it is often the abundance of a range of active and repressive marks that tips the 
balance towards active transcription or repression. Bivalent promoters are usually 
associated with low levels of transcription; however, our work demonstrates that 
bivalent G2A-BASP1 bound promoters do not undergo gene repression [273, 277]. 
Other exceptions have previously been identified where loci in mouse embryonic 
stem cells containing H3K4me3, H3K9Ac and H3K27me3 do undergo active 
transcription [276]. Equally, it appears that a general phenomenon of cancer cells is 
the upregulation of bivalent genes [273, 277]. Therefore, in the context of a K562 
cell, the addition of H3K27me3 and H3K9me3 marks by BASP1/EZH2 without 
removal of any active marks may not be sufficient to ensure gene repression. 
Additionally, many bivalent PRC2 targeted loci marked with both H3K4me3 and 
H3K27me3 have now been identified [278, 279]. This suggests PRC2 could indeed 
be recruited to WT1/BASP1 target genes despite the presence of active marks.  
3.11.3 BASP1 Regulates Transcription Initiation 
The effects of BASP1 binding on transcriptional events downstream of chromatin 




BASP1 reduces the initiation of transcription through different means at different 
promoters. BASP1 can reduce total RNA polymerase II binding (AREG) or inhibit 
CDK7 recruitment thereby limiting RNA polymerase II S5 phosphorylation (ETS-1, 
REN) (Figure 3.12). These data provide the first evidence of BASP1-mediated 
effects on transcription downstream of RNA polymerase II recruitment. The data 
also provide the first evidence that myristoylation of BASP1 is important for this 
function. The myristoyl-dependent nature of this activity implicates PIP2 as an 
important binding partner in BASP1 mediated regulation of transcription initiation. 
Examples of PIP2 involvement in RNA polymerase I driven transcription are already 
known; PIP2 forms a complex with the RNA polymerase I transcription factor UBF, 
interacts with a subset of the Pol I transcription machinery to promote transcription, 
and plays a structural role as an anchor for the RNA polymerase I pre-initiation 
complex [151, 280]. PIP2 has also been shown to aid epigenetic repression of rRNA 
gene transcription [150]. Recent evidence also proposes the formation of PIP2 and 
RNA rich nuclear lipid islets is important to provide a structural platform for RNA 
polymerase II driven transcription [281]. Data here therefore contributes to emerging 





3.11.4 Summary of Results Chapter 1  
A summary of the data presented in this chapter is shown in Figure 3.13 in the form 
of a schematic illustrating chromatin modifications and proteins present at unbound, 
wtBASP1 bound and G2A-BASP1 bound WT1 target gene promoters. A WT1 target 
gene unbound by BASP1 is shown to have H3K4me3, H3K9Ac and H3K36me3 
active chromatin marks, is bound by WT1, and bound by RNA polymerase II which 
is subsequently phosphorylated by CDK7 to initiate transcription. A WT1 target gene 
bound by wtBASP1 is instead shown to have H3K27me3 and H3K9me3 repressive 
chromatin marks, is bound by WT1 and the BASP1 repression complex (including 
established components such as prohibitin and BRG1). H3K4me3 and H3K36me3 
marks are shown as being removed by KDM2B. Removal of these marks by 
KDM2B has not been tested in this study, thus at this stage it is only hypothesised 
as having a role in this process. This prediction is based upon the presence of 
KDM2B in BASP1 immunoprecipitates (discussed in results chapters 2 and 3). The 
wtBASP1 bound gene promoter is either not bound by RNA polymerase II, or the 
bound RNA polymerase II is yet to be phosphorylated by CDK7 and thus 
transcription initiation is prevented. A WT1 target gene promoter bound by WT1 and 
G2A-BASP1 is shown to have both active and repressive chromatin marks present. 
Binding of some repression complex components, such as HDAC1, is known to be 
PIP2-dependent and therefore these factors are not present. G2A-BASP1 bound 
sites recruit RNA polymerase II which can subsequently be phosphorylated by 
CDK7 and thus transcription initiated. Ultimately, despite the presence of repressive 
histone marks, G2A-BASP1 bound sites retain activation marks and retain RNA 
polymerase II binding and S5 phosphorylation and therefore the initiation of 
transcription cannot be prevented. This highlights the necessity for both the removal 
of activation marks and the increase in repressive marks in order to fully induce a 






Figure 3.13. Chapter 1 Summary: Mechanism of BASP1-PIP
2
 Mediated Gene Repression. 
Representation of WT1 target gene promoters. Top promoter; bound by WT1 only. Bottom left promoter; bound by WT1 and wtBASP1. Bottom right 









). Red arrow indicates phosphorylation of serine 5 of RNA polymerase 
II by CDK7. Large black arrow represents active transcription. Smaller black arrow represents reduced levels of transcription. Dashed arrows 









Purple arrow represents previously reported removal of H3K9Ac by HDAC1. Some known components of the BASP1-PIP2 repression complex are 




4 Results Chapter 2: Localisation of the WT1/BASP1/PIP2 Repression 
Complex 
4.1 Introduction 
It has been known for several decades that lipids and the enzymes that regulate 
lipid metabolism are present in the nucleus. Nuclear lipids have been shown to 
associate with protein complexes involved in a diverse range of nuclear processes 
including RNA processing, chromatin remodelling and gene transcription, but the 
mechanisms through which lipids are involved in such processes remain unclear  
[101, 107, 113, 117, 118]. Very little is known about the role of lipids in gene 
regulation and how they affect transcriptional and cellular responses. Nuclear lipids 
are present within the nuclear membrane where their hydrophobic tail is buried 
within the bilayer structure, but lipids are also extensively present within the nuclear 
space [101, 113]. How hydrophobic lipid tails can exist in the nucleoplasm remains 
poorly understood. It has been hypothesised that they could be housed within 
nuclear speckles such as PML bodies, although the structure of such speckles, the 
protein complexes present within them and how they accommodate hydrophobic 
lipid tails is not yet known [127].  
BASP1 interacts directly with phospholipids and cholesterol through the myristoyl 
motif and a cholesterol recognition consensus sequence (CRAC domain) [80, 82, 
83, 282]. As BASP1 is the only myristoylated protein with a confirmed role for the 
myristoyl motif in transcription regulation, it provides a rare opportunity to examine 
the role of nuclear lipids in gene regulation. Although it is known that N-terminal 
myristoylation of BASP1 enables it to associate with membranes it is not yet known 
whether BASP1 mediated repression occurs at the nuclear membrane or within the 
nucleoplasm [3]. The subnuclear localisation of genes and their recruitment to the 
nuclear periphery and incorporation into heterochromatin is now known to play a 
vital role in gene expression [174-177]. Thus, here it was examined whether the 
myristoyl-dependent nature of BASP1 gene repression activity could be due to a 
necessity for interaction with the nuclear membrane and the repressive environment 
of the nuclear periphery.  
In addition to potential roles at the nuclear membrane BASP1 is also found localised 
throughout the cytoplasm and nucleus [3, 282]. Here it was hypothesised that non-
membrane nuclear lipids could be stabilised within the nucleoplasm by lipidated 
proteins such as BASP1. The study of BASP1 in this chapter provides insight into 




mediated gene regulation. Experiments presented in this chapter aimed to explore 
the localisation of nuclear myristoylated BASP1. This includes the use of 
biochemical and immunofluorescence techniques examining BASP1 and lipids 
throughout the nucleus and the nuclear membrane. Association of the 
WT1/BASP1/PIP2 repression complex with protein components of the nuclear 
periphery was examined through imaging, interaction studies and ChIP. These 
experiments were completed with the aim of understanding if interaction with inner 
nuclear membrane (INM) components is important for WT1/BASP1/PIP2 driven 
gene repression.  
4.2 Subnuclear Fractionation of V-K562, B-K562 and G-K562 Nuclei 
First, to explore the importance of BASP1 myristoylation for the subnuclear 
localisation of the WT1/BASP1/PIP2 repression complex biochemical fractionation of 
nuclei isolated from V-K562, B-K562 and G-K562 cells was performed. Nuclei were 
purified using the Nuclei EZ Prep Kit (Sigma) which involved two cycles of 
incubating whole cells in lysis buffer, on ice, and collecting nuclei via centrifugation. 
Initially, validation of this nuclei purification method was conducted (Figure 4.1A). 
Successful isolation of pure nuclei was confirmed via western blotting of whole cells 
and the purified nuclei, followed by probing with antibodies against a marker of the 
golgi apparatus, TGN46. Control protein TGN46 was detected in whole cells of V-
K562, B-K562 and G-K562, but not in purified nuclei. BASP1 expression was 
confirmed in the whole cells and nuclei from B-K562 and G-K562. Secondly, purified 
nuclei were then subjected to biochemical fractionation. The fractionation procedure 
results in the isolation of the soluble, chromatin and matrix fractions. The soluble 
fraction consists of all soluble nuclear proteins, the chromatin fraction consists of 
chromatin itself plus chromatin bound proteins, and the matrix fraction consists of 
nuclear structures including the nuclear membrane, nucleolus, pml bodies, cajal 
bodies as well as the nuclear actin-matrix network itself. Upon isolation of the three 
nuclear fractions samples were western blotted and probed for the presence of 
repression complex components (BASP1, WT1, HDAC1, prohibitin) as well as 
characterised nuclear membrane components (emerin, lamin A/C), negative control 
TGN46 and positive control β-actin (Figure 4.1B).  
Negative control TGN46 was not detected in any of the nuclear fractions, whilst 
positive control β-actin was detected throughout. WT1 was found most abundantly 
in the matrix fraction; a finding consistent with previous experiments from our 




nuclear matrix, including paraspeckles and nucleoli where it is involved in RNA 
processing and splicing, has been well documented [283-287]. A low level of WT1 
protein was also detected in the soluble and chromatin fractions of V-K562 nuclei, 
although WT1 could not be detected in these fractions for B-K562 or G-K562 nuclei. 
This could be due to the lower expression level of WT1 in these cell lines and/or 
poor antibody detection. HDAC1 was evenly distributed through all nuclear fractions 
and Prohibitin was detected in the soluble and chromatin fractions for all cell lines 
[288, 289]. Predictably for a nuclear membrane protein, Lamin A/C was exclusively 
isolated from the nuclear matrix fraction in all cell lines. Emerin was detected 
predominantly in the nuclear matrix, although emerin protein was also present in 
both the soluble and chromatin fractions. This result reflects the evidence that 
emerin is predominantly found in the inner nuclear membrane and supports the 
body of evidence for emerin’s role in chromatin organisation and gene regulation. 
There is very little evidence of soluble emerin being present within the cytoplasm or 
nucleus (only reported for mutant derivatives), thus it is most likely that emerin 
detected here in the soluble fraction is an artificial product of the fractionation 
procedure [290]. Also notable is the doublet of emerin apparent within the nuclear 
matrix. This extra protein band was not pursued here but approximately 40 different 
residues of the emerin protein have been reported to be phosphorylated, many of 
which occur in a cell cycle dependent manner and regulate emerin binding partners 
[237, 291]. The doublet of emerin seen here is speculated to be caused by 
alternatively phosphorylated forms in the matrix. 
The most interesting result from the subnuclear fractionation experiment is the 
discovery that wtBASP1 and G2A-BASP1 distribute differently through the nuclear 
fractions (Figure 4.1B). Both forms of BASP1 protein localise to the soluble and 
chromatin fractions, however only wtBASP1 localised to the nuclear matrix fraction. 
Thus, myristoylation appears essential for BASP1 localisation to the nuclear matrix. 
Myristoylation also appears to affect the level of BASP1 localised to chromatin, as 
G2A-BASP1 is reduced by approximately 66% in comparison to wtBASP1 in this 
fraction. This data suggests that myristoylation is required for BASP1 to localise to 
the matrix, and subsequently that PIP2 interaction could be critical for the 
association of BASP1 with the nuclear matrix. It suggests that the interaction with 
PIP2 is important not only for the WT1/BASP1 repression complex to interact with 






Figure 4.1. Myristoylation is Required for BASP1 to Localise into the Matrix. A, Whole cells and nuclei purified from V-K562 (V), 
B-K562 (B) and G-K562 (G) cell lines were western blotted and probed with antibodies against BASP1, TGN46 and β-actin. B, Purified 
nuclei from V-K562, B-K562 and G-K562 cells were biochemically fractionated into soluble, chromatin and matrix subnuclear fractions 
and western blotted for BASP1 repression complex components, nuclear membrane protein emerin, nuclear matrix protein lamin A/C 
and further negative and positive controls, TGN46 and β-actin, respectively. Molecular weight in kDa shown to left of each blot. 
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4.3 Investigation of BASP1 Interactions with Nuclear Membrane Proteins 
4.3.1 Mining of BASP1 Interactome Proteomic Data Sets 
Previous work in our laboratory included the generation of several proteomic data 
sets of BASP1 interactors. These data sets included BASP1 interactome studies 
achieved through BASP1 immunoprecipitation from V-K562, B-K562, and G-K562 
followed by LC-MS mass spectrometry of immunoprecipitates. In this investigation, 
further tandem mass tag (TMT) mass spectrometry was completed in triplicate on 
BASP1 immunoprecipitates from V-K562, B-K562 and G-K562 cells (see Table 1, 
appendix). Together, these interaction studies reliably and repeatedly predicted a 
number of potential BASP1 interactors. Some interactors that are of particular 
interest to our laboratory have been repeatedly identified across proteomic datasets, 
including within the TMT mass spectrometry dataset gained in this study. Such 
repeatedly identified proteins are summarised in Figure 4.2, divided into four main 
categories; chromatin remodelling proteins, basal transcription proteins, inner 
nuclear membrane (INM) proteins and nuclear actin complexes. Some of these 
BASP1 interactors identified by the proteomics have previously been validated 
(HDAC1, BRG1, Prohibitin) and are known to bind BASP1 in a myristoyl dependent 
manner [3, 96]. Many other interactions have been directly tested and confirmed via 
western blotting [89]. The remaining proteins listed require direct testing to validate 
a specific interaction with BASP1, and whether they could be myristoyl-dependent 
or independent interactions. These proteomic data sets have provided a list of 
candidate interactors that will be explored during further investigation into the 





Figure 4.2. BASP1 Interacting Proteins. Using a combination of direct testing and comparative TMT/Orbitrap Mass Spectrometry several 
BASP1 binding proteins have been repeatedly identified. Categorized interactors are shown (under purple headings). Through analysis of BASP1 
mutant derivatives defective in myristoylation and PIP2-binding (G2A-BASP1) the dependency of this protein interaction on the presence of PIP2 
has been predicted (yellow star indicates known PIP2 dependent BASP1 interactor). BASP1 interactions with HDAC1, BRG1, PHB1 are 
published (black text). Interactions with TFIIH, EMD, LAP2, actin, MYO1C, NPM, GSN, FLI1 have previously been confirmed by western blotting 


































4.3.2 Immunoprecipitation of BASP1 and Nuclear Membrane Proteins 
The proteomic datasets summarised above indicate that BASP1 may interact with a 
number of nuclear membrane and nuclear lamina proteins including emerin, lap2α, 
nesprin, HP1 and barrier-to-autointegration (BAF). Direct testing of an interaction 
between BASP1 and candidate interactors was conducted in order to validate the 
interactions and assess their dependence on BASP1 myristoylation. This was 
achieved via immunoprecipitation of nuclear extracts prepared from V-K562, B-
K562 and G-K562 cells with BASP1 antibody followed by western blotting and 
probing for nuclear membrane proteins. BASP1 protein was successfully harvested 
using the immunoprecipitation method in both B-K562 and G-K562 nuclei (Figure 
4.3Ai). Emerin protein was present in wtBASP1 immunoprecipitates but was absent 
from G2A-BASP1 immunoprecipitates. Additionally, emerin protein was successfully 
immunoprecipitated from V-K562, B-K562 and G-K562 nuclear extracts, but BASP1 
was present only in B-K562 immunoprecipitates (Figure 3.3Aii). This data provides 
evidence of a myristoyl dependent BASP1 and emerin interaction.  
It is not possible to determine the nuclear localisation of the BASP1-emerin 
interaction from this immunoprecipitation data, thus it cannot be concluded that the 
interaction occurs at the nuclear membrane, or within the nucleoplasm. However, 
validation of the emerin interaction does serve to support the hypothesis that 
myristoylation of BASP1 could be a prerequisite for localising the BASP1 repression 
complex to the nuclear periphery. 
BASP1 immunoprecipitates from V-K562, B-K562 and G-K562 cell nuclear extracts 
were also tested for the presence of other nuclear membrane and nuclear lamina 
proteins (Figure 4.3 B). Whilst Lamin A/C, BAF and Lap2α could all be detected in 
K562 nuclear extracts, none could be reliably identified in BASP1 
immunoprecipitates from any of the K562 cell derivatives. A weak protein band in B-
K562 BASP1 immunoprecipitates western blotted and probed for BAF was 
detected, however the molecular weight of this band (approximately 25kDa) is 
significantly larger than the reported molecular weight of the BAF protein (10kDa) 
and therefore was not assumed to be specific. Similarly, weak bands of protein 
around 45kDa were irregularly detected in V-K562, B-K562 and G-K562 BASP1 
immunoprecipitates western blotted and probed for lap2α but were not considered 
to be specific. Positive control β-actin however, an established BASP1 interactor, 
was detected in all nuclear extracts and was present in B-K562 BASP1 




components of the nuclear actin network including β-actin, FLI1, NPM, MYO1C [89]. 
Here, this result confirms our previous finding that β-actin interacts with BASP1 and 
indicates for the first time that the BASP1-β-actin interaction is dependent upon 
myristoylation. It suggests that the interaction of BASP1 and the other established 
nuclear actin complex components could also be myristoyl dependent, although 
direct testing is needed to confirm this. If so, the myristoyl-dependence of these 




















Figure 4.3. Immunoprecipitation of BASP1 and Nuclear Membrane Proteins. A, (i) Nuclear extracts from V-K562 (V), B-K562 (B) and G-K562 (G) 
nuclei were subjected to immunoprecipitation with BASP1 antibodies, and western blotted for BASP1 and emerin. A, (ii) Nuclear extracts from V-K562, 
B-K562 and G-K562 nuclei were subjected to immunoprecipitation with emerin antibodies, and western blotted for BASP1 and emerin. B, Nuclear 
extracts from V-K562, B-K562 and G-K562 nuclei were subjected to immunoprecipitation with BASP1 antibodies and western blotted for other nuclear 
membrane proteins (Lamin A/C, BAF and Lap2α) as well as previously reported interactors of the nuclear actin complex (β-actin). Black arrows point to 
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4.4 Confocal Microscopy of BASP1 in the K562 Cell Derivatives  
Having determined from the biochemical analysis that BASP1 myristoylation is 
essential for localisation to the nuclear matrix fraction and interaction with emerin 
and β-actin, visual methods of examining BASP1 localisation were explored. The 
first approach adopted was confocal microscopy of B-K562 and G-K562 nuclei.  
4.4.1 Immunofluorescence of BASP1 and Repression Complex Components 
Initially validation of the immunofluorescence protocol was conducted to ensure that 
images obtained reliably represented BASP1 nuclear localisation. Whole B-K562 
cells or purified nuclei were subjected to immunostaining in suspension with 
antibodies against BASP1 and TGN46, plus DAPI staining (Figure 4.4A). Cells or 
nuclei were then centrifuged into a pellet, resuspended in a minimum volume of 
mounting media (DABCO, Sigma), pipetted onto slides and mounted with 
coverslips. TGN46 signal was seen in whole cells only, indicating that nuclei 
purification was again successful and able to produce high quality nuclei for 
imaging. Next, BASP1 antibody dilutions of 1:200, 1:300 and 1:500 were tested in 
V-K562 and B-K562 nuclei (Figure 4.4B). Concentrations of both 1:200 and 1:300 
reliably gave BASP1 signal in B-K562, and not in V-K562. The weaker dilution of 
1:500 gave no signal above background levels and thus it was concluded a 1:300 
dilution of BASP1 antibody should be used throughout this study. Finally, a 
secondary antibody only control was performed to ensure the secondary antibody 
used for BASP1 staining (anti Rabbit-488) was specific (Figure 4.4C). No signal was 
detected in this secondary antibody only control in either V-K562 or B-K562 nuclei. 
Having optimised the immunofluorescence protocol for confocal imaging of purified 
nuclei, it was then sought to image BASP1 and other repression complex 
components in B-K562 and G-K562 nuclei. Confocal imaging of B-K562 and G-
K562 nuclei stained for BASP1, Prohibitin, PIP2 and HDAC1 is shown in Figure 4.5. 
All proteins were detected within B-K562 and G-K562 nuclei. Both wtBASP1 and 
G2A-BASP1 appear abundantly throughout the nuclear space. The difference in 
BASP1 staining pattern between Figure 4.5A, and Figure 4.5B and 4.5C is the result 
of the use of two different BASP1 antibodies. The sheep derived BASP1 antibody 
utilised in Figure 4.5A has consistently shown a broader nuclear staining pattern in 
multiple cell types analysed in our laboratory compared to the routinely used rabbit 
BASP1 antibody. This difference is likely caused by recognition of different BASP1 




detect BASP1 throughout the nucleoplasm and at the nuclear periphery in both B-
K562 and G-K562 nuclei. Similarly to BASP1, prohibitin and HDAC1 are also highly 
abundant throughout the nuclei. No substantial difference in their localisation could 
be determined between B-K562 and G-K562 nuclei. PIP2 was also successfully 
detected within the nuclei of both cell types, appearing at the nuclear periphery and 
within intranuclear speckles, consistent with previous reports by us and others [3, 
107, 151, 292]. Whilst all proteins and PIP2 were successfully visualised in B-K562 
and G-K562 nuclei using this immunofluorescence technique, no determinable 
differences in their localisation between the B-K562 and G-K562 derivatives could 
be identified. It was concluded that due to the abundance of these proteins and PIP2 
throughout the nucleus higher resolution imaging techniques combined with 
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Figure 4.4. Optimisation of BASP1 Staining and Nuclei Purification Technique for Immunofluorescence. A, Confocal images of i) whole cells and ii) 
purified nuclei, showing validation of nuclei purification technique. B-K562 cells were immunostained for BASP1 and TGN46, plus DAPI. Scale bar 10µm in 
whole cells (i) and 5µm in purified nuclei (ii). B, Confocal images of V-K562 nuclei (i) and B-K562 nuclei (ii) immunostained with BASP1 antibody at 
dilutions of 1:200, 1:300 and 1:500, and stained with DAPI. Scale bar 5µm. C, Confocal images of V-K562 cells (i) and B-K562 cells (ii) immunostained 
with only Rb-488 secondary antibody at a dilution of 1:500. Scale bar 10µm.  
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Figure 4.5. Confocal Imaging of BASP1, Prohibitin, 
PIP
2
 and HDAC1 in B-K562 and G-K562 Nuclei. 
Purified B-K562 nuclei or G-K562 nuclei subjected to 
immunostaining in suspension with antibodies against; A, 
Prohibitin and BASP1, B, BASP1 and HDAC1, C, BASP1 
and PIP
2
. Scale bar is 5µm. B-K562 nuclei are shown in 
top panels, and G-K562 nuclei in lower panels. 
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4.4.2 Immunofluorescence of BASP1 and Nuclear Membrane Proteins 
Simultaneously to examining the localisation of BASP1 repression complex 
components in B-K562 and G-K562 nuclei, it was sought to examine whether 
wtBASP1 and G2A-BASP1 could be visualised alongside markers of the nuclear 
membrane and nuclear periphery via immunofluorescence. Due to the biochemical 
data previously presented (Figure 4.1, Figure 4.3) it was hypothesised that 
wtBASP1 might be present at the inner nuclear membrane alongside emerin. Based 
on the immunoprecipitation results (Figure 4.3) it was also hypothesised that G2A-
BASP1 would lack membrane association. To examine this, B-K562 and G-K562 
nuclei were subjected to immunostaining in suspension with antibodies against 
BASP1, emerin and lamin A/C, as well as a DAPI stain (Figure 4.6). Points of 
colocalisation between BASP1 and both Lamin A/C and emerin were observed in B-
K562 nuclei, but this was comparable to that observed G-K562 nuclei. As may be 
expected from the biochemical data, greater colocalisation was apparent between 
BASP1 and emerin compared to BASP1 and lamin A/C, evidenced by the greater 
overlap of fluorescent signal in these images. The images provide initial evidence to 
support the presence of both wtBASP1 and G2A-BASP1 at the nuclear periphery. 
This is in contrast to the biochemical data which suggested that G2A-BASP1 could 
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Figure 4.6. Confocal Imaging of BASP1 and Emerin or Lamin A/C in B-K562 and G-K562 Nuclei. Purified B-K562 nuclei and G-
K562 nuclei were subjected to immunostaining in suspension with; A, BASP1 and lamin A/C antibodies, B, BASP1 and emerin 




4.5 Click Chemistry Analysis of BASP1 and Alkyne-Myristic Acid 
Experiments presented so far have used the G2A-BASP1 mutant to infer the 
importance of the myristoyl motif in BASP1 subnuclear localisation and function. 
There are currently no antibodies available that can detect the myristoyl motif 
directly, so it is not possible to employ standard immunoprecipitation or 
immunofluorescence techniques to detect myristoyl. As an alternative method to 
examine the BASP1 myristoyl motif a click chemistry technique was utilised. This 
technique involves incubating cells with an alkyne conjugated myristic acid, which is 
readily incorporated into myristoylated proteins. A cycloaddition reaction of the 
alkyne to an azide molecule is then performed, followed by detection of the azide 
molecule in an assay dependent manner. Two protocols incorporating click 
chemistry were devised; a click chemistry immunoprecipitation method, and a click 
chemistry immunofluorescence method.  
4.5.1 Immunoprecipitation of wtBASP1 via Alkyne-Myristic Acid Pull Down 
A summary of the click chemistry immunoprecipitation process is shown in the 
below diagram. Briefly, V-K562, B-K562 and G-K562 cells pre-incubated with alkyne 
myristic acid were subject to click chemistry reaction with an azide-PEG3-biotin 
conjugate. Nuclear extracts were then incubated with streptavidin conjugated 
magnetic beads to pull down myristoylated proteins (refer to Materials and Methods 
for full protocol).  
 
Western blotting confirmed successful immunoprecipitation of wtBASP1 but not 
G2A-BASP1 (Figure 4.7). Negative control β-actin confirmed specific pull down of 
myristoylated protein from this sample. A further alkyne-free negative control with V-




click chemistry reaction itself does not lead to protein immunoprecipitation. This 
result provides additional evidence to validate the G2A-BASP1 mutant protein as 
lacking the myristoyl modification, i.e. BASP1 is not myristoylated at any other 
residues. This also validates the myristoyl click chemistry protocol as a means of 




4.5.2 Confocal Imaging of BASP1 and Alkyne-Myristic Acid  
Next, to image the myristoyl motif whole MCF7 cells pre-incubated with alkyne 
myristic acid were subject to click chemistry reaction followed by immunostaining in 
suspension. A summary of the click chemistry immunofluorescence process is 
shown in the below diagram. For this method, following the click reaction whole cells 
were incubated with streptavidin conjugated antibody (refer to Materials and 
Methods for full protocol). 
Figure 4.7. Pull Down of wtBASP1 via Click Chemistry of Alkyne-Myristic Acid 
Immunoprecipitation.  V-K562, B-K562 and G-K562 cells incubated with ethanol 
(alkyne-free control) or 10µg/ml alkyne-Myristic acid and subjected to a click 
chemistry reaction. Pull downs using streptavidin beads were then performed on 
nuclear extracts, and western blots used to detect the presence of BASP1, or 
negative control β-actin. Molecular weight marker in kDa shown to left of each blot 
   52- 
   72- 
β-actin 




   52- 




  BASP1 
N.E. Input   BASP1 
   52- 





Two stable MCF7 cell lines were used; shN MCF7 (negative control knockdown 
line) and shB MCF7 (stable BASP1 knockdown line). BASP1 protein was calculated 
to be 63% knocked-down in shB MCF7 compared to shN MCF7 via quantification 
using ImageJ (Figure 4.8Ai). Both negative controls (alkyne-free is cells incubated 
with vehicle only, and azide-free is cells without azide-PEG3-biotin added) revealed 
no streptavidin-594 signal via confocal microscopy (Figure 4.8Aii). BASP1 was 
successfully detected throughout the cytoplasm of the shN MCF7 cells, and only low 
level BASP1 signal was detected in the shB MCF7 cells, as expected in this 
knockdown cell line (Figure 4.8Bi). Like BASP1, in whole cells, the myristoyl signal 
observed is predominantly within the cytoplasm and the cell membrane.  
To more closely examine nuclear BASP1 and myristoyl signal and avoid 
interference from cytoplasmic immunofluorescence signal the click chemistry 
imaging technique was applied to purified nuclei. Therefore, shN MCF7 and shB 
MCF7 cells were incubated with alkyne-myristic acid, then the nuclei were purified 
and the nuclei only were subjected to the click chemistry reaction followed by 
immunostaining in suspension (Figure 4.8Bii). Here, without interference from 
cytoplasmic signal, nuclear BASP1 and myristoyl were successfully visualised in 
shN MCF7 nuclei. Interestingly, in both the whole cell images and the purified nuclei 
images a lower level of myristoyl signal was seen in the shB MCF7 cells than in shN 
MCF7 cells (Figure 4.8Bi and 4.8Bii). It is surprising that knockdown of BASP1 
alone would account for such a loss in observed myristoyl signal.  It is possible that 
either BASP1 alone accounts for a considerable proportion of the myristoylated 
protein is these cells or that BASP1 forms complexes with other myristoylated 
nuclear proteins which are disrupted following BASP1 depletion leading to 




Close study of the nuclear myristoyl signal in MCF7 nuclei suggests that not only is 
myristoyl present at the nuclear periphery, most probably within the nuclear 
membrane, but is also present as speckles within the nuclear space. A proportion of 
intranuclear signal coincides with BASP1 signal, but additional nuclear myristoyl 
signal, including within the nucleolus, is apparent. This imaging therefore 
contributes to evidence that nuclear myristoylated proteins can also be present in 
the nucleoplasm and are not restricted to the nuclear membrane.  
Nuclear BASP1 and myristoyl signal in the K562 cell lines was next explored. Nuclei 
were purified from V-K562, B-K562 and G-K562 cells following incubation with 
alkyne-myristic acid. Purified nuclei were subjected to the click reaction and 
immunostaining in suspension with BASP1 antibodies as previously described. 
Once again both negative controls (alkyne-free and azide-free control) revealed no 
streptavidin-594 signal via confocal microscopy (Figure 4.8C). BASP1 protein was 
present as speckles throughout B-K562 and G-K562 nuclei, and not detected in V-
K562 nuclei (Figure 4.8D). Similar to MCF7 nuclei, myristoyl is localised most 
abundantly around the nuclear membrane of K562 nuclei, however myristoyl is also 
convincingly present throughout the inner nuclear space, including within the 
nucleolus. In K562 cells BASP1 is excluded from the nucleolus, therefore this 
myristoyl signal must be produced by other myristoylated proteins within the 
nucleolus. Once again diminished myristoyl signal is apparent in V-K562 nuclei 
compared to B-K562 nuclei much like that observed in the MCF7 cell lines. This 
again suggests that BASP1 could account for a large proportion of nuclear 
myristoylated protein, or that BASP1 may contribute to the stabilisation of nuclear 
myristoylated protein complexes. 
As well as gaining qualitative imaging data exploring nuclear myristoyl signal, it was 
anticipated that the click chemistry imaging conducted here could provide 
quantitative analysis of colocalisation between wtBASP1 and G2A-BASP1 with 
myristoyl within the nucleus. Colocalisation analysis was performed using both the 
Pearson’s correlation coefficient (PCC) and Manders colocalisation analysis 
methods. Both these approaches are widely accepted as valid approaches to 
analyse complex colocalisation data [293]. The PCC method revealed an average 
correlation coefficient of 0.17 for BASP1 and myristoyl in B-K562 nuclei, and 0.066 
in G-K562 nuclei (Figure 4.8E). This analysis suggests a weak positive correlation 
between wtBASP1 and myristoyl signal, with a statistically significant reduction in 




values obtained here for wtBASP1 and myristoyl is most likely representative of fact 
that there is a large proportion of myristoylated protein in addition to BASP1. This 
finding suggests it is more likely that the diminished myristoyl signal apparent in 
non-BASP1 expressing cells is caused at least in part by BASP1 acting to stabilise 
nuclear myristoylated protein complexes.  
Manders colocalisation analysis examining the overlap of BASP1 and myristoyl 
signals in B-K562 and G-K562 nuclei is also shown in Figure 4.8E. Here, M1 values 
represent the proportion of BASP1 signal that colocalises with myristoyl signal. For  
wtBASP1 this was determined as 20.9%, and for G2A-BASP1 it was 17.9%. M2 
values represent the proportion of myristoyl signal that colocalises with BASP1. For 
wtBASP1 this was 32.1%, and for G2A-BASP1 it was 25.8%. Whilst there is no 
significant difference in the proportion of wtBASP1 and G2A-BASP1 associated with 
myristoyl (M1 values), this analysis suggests significantly less myristoyl associates 
with G2A-BASP1 than with wtBASP1 (M2 values). Once again, these values 
indicate that a significant proportion of nuclear myristoyl signal is accounted for by 
proteins other than BASP1. The apparent similarity between M1 values from B-
K562 and G-K562 could perhaps be indicative that both wtBASP1 and G2A-BASP1 
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Figure 4.8. Click Chemistry Confocal Imaging of Myristoyl in MCF7 Whole Cells, MCF7 Nuclei and K562 Nuclei.  
Click chemistry of shNegative (shN) and shBASP1 (shB) MCF7 cells, and V-K562, B-K562, G-K562 nuclei incubated with 10µg/ml alkyne-Myristic acid. 
Click chemistry reaction was followed by immunofluorescence with BASP1 and streptavidin antibodies, and confocal microscopy. Ai) Expression level of 
BASP1 in shN and shB MCF7s, Aii) MCF7 (shN) Azide-free and alkyne-free controls. Bi) BASP1 and Myristoyl in whole MCF7 cells, Bii), BASP1 and 
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Figure 4.8. Continued: C, Azide-free controls and alkyne-free controls in V-K562, B-K562 and G-K562 nuclei. D, BASP1 and Myristoyl in V-K562, B-K562 
and G-K562 nuclei. Scale bar 10µm. E, Quantification of the colocalisation of BASP1 and Myristoyl in B-K562 and G-K562 nuclei as analysed using the 
Pearson’s correlation coefficient and the Manders’ colocalisation technique. *p<0.05 following students t test comparing M1 values from BK and GK nuclei, 
and M2 values from BK and GK values over 3 independent experiments, n=67. 
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4.6 Electron Microscopy of BASP1 and Emerin in B-K562 Cells 
Completion of the click chemistry imaging of intranuclear BASP1 and myristoyl 
provided quantitative data of the difference in myristoyl association of wtBASP1 and 
G2A-BASP1. It also enabled visualisation of intranuclear myristoyl motifs and gave 
insight into the nuclear localisation of myristoylated proteins. Next, high resolution 
imaging was explored in order to examine the localisation of BASP1 to the nuclear 
periphery. To achieve this B-K562 cells were high pressure frozen, embedded in 
lowicryl resin, sectioned and subjected to immunogold labelling to detect BASP1 
(via HA tag) and emerin. Sections were then imaged via transmission electron 
microscopy to examine BASP1 and emerin localisation in the nucleus (Figure 4.9).  
A significant challenge to the production of high quality immunogold labelled 
sections is the simultaneous preservation of cellular structures and attainment of 
high contrast for TEM imaging. Use of the Leica EM PACT2 high pressure freezing 
system facilitated good preservation of cellular structures although this is 
accompanied with relatively low contrast across the sections (Figure 4.9A and 
4.9B). Antibody penetrance through the embedding resin is an additional technical 
challenge. Immunogold labelling using HA rather than BASP1 antibodies was 
recommended by the Electron Microscopy facility in order to achieve specific 
binding and reliable signal for BASP1. Following optimisation of antibody 
concentrations for the immunogold labelling a concentration of 1:5 HA antibody 
provided the best protein labelling. Using this protocol immunogold labelled particles 
were localised throughout the B-K562 cell and nucleus, indicative of good antibody 
penetration of the lowicryl resin (Figure 4.9B). Examination of HA-BASP1 in the 
nucleus and at the nuclear periphery enabled identification of 6nm gold labels, 
labelling HA-BASP1, throughout the nucleus including at the inner nuclear 
membrane (Figure 4.9C). The labelling of emerin functions as a positive control in 
this assay. Examination of emerin, labelled by 10nm gold particles, identified emerin 
at the nuclear membrane however this labelling was accompanied by emerin 
labelling throughout the cell. It was concluded that the emerin labelling likely 
included some non-specific particles. Subsequently, firm conclusions regarding the 
localisation of HA-BASP1 could not be made from these images. However, the 
images obtained here do support previous evidence to suggest that wtBASP1 is 
present within the nucleoplasm and provide initial evidence that wtBASP1 is also 
localised at the inner nuclear membrane. Further TEM study of wtBASP1 and G2A-
BASP1 localisation is required, accompanied by thorough image analysis, to 





Figure 4.9. Electron Microscopy of Gold-Labelled HA-BASP1 and Emerin in B-K562 Cells. B-K562 cells were high pressure frozen, lowicryl 
embedded, sectioned and subjected to antibody and gold labelling. A, TEM image of B-K562 cell showing preservation of cellular structures. PM, plasma 
membrane, NM, nuclear membrane, N, nucleus, C, cytoplasm, M, mitochondria. B, TEM image of B-K562 cell showing distribution of heterochromatin and 
euchromatin in the nucleus and gold labelling throughout the cell. C, TEM image of B-K562 cell showing nuclear periphery with HA-BASP1 (6nm) and 



















4.7 Click Chemistry Chromatin Immunoprecipitation of Myristoyl at WT1 
Target Gene Promoters 
Previous work from our laboratory demonstrated for the first time that BASP1 
induces gene repression of WT1 target genes in a myristoyl-dependent manner [3]. 
It was shown that PIP2 and HDAC1 were only recruited to gene promoters by 
wtBASP1, and not the G2A-BASP1 myristoyl mutant. At the time, it was not directly 
demonstrated that the BASP1 present at the promoter was myristoylated. Here, the 
click chemistry approach has proven useful in detecting myristoyl for visualisation 
and for protein capture via magnetic beads. Therefore, it was predicted that with 
further optimisation the click chemistry approach could be employed in combination 
with the optimised ChIP protocol to directly test myristoyl-BASP1 recruitment to 
WT1 target genes.  
Indeed, development of a click chemistry combined with chromatin 
immunoprecipitation technique (click-ChIP) identified recruitment of myristoyl to the 
promoter of all examined WT1 target genes (AREG, ETS-1, REN, VDR and JUNB), 
which coincided with the recruitment of wtBASP1 and not G2A-BASP1 (Figure 
4.10). For this method, following incubation with alkyne-myristic acid cells were fixed 
in 4% formaldehyde for 15 mins, subjected to click reaction, then fixed again in 4% 
formaldehyde for 15 mins before cell pellets were lysed, chromatin sheared via 
sonication and lysates incubated with streptavidin beads to capture myristoyl (refer 
to Materials and Methods for full protocol). A summary of the click-ChIP process is 
shown in the below diagram: 
 
Fold enrichment was calculated as enrichment of myristoyl above signal from the 




myristoyl was then compared to a control gene region (18S). Myristoyl was 
significantly enriched only in B-K562 cells compared to V-K562 cells. The G-K562 
line acted as a negative control in this experiment since G2A-BASP1 lacks the vital 
N-terminal glycine acceptor for the myristoyl modification. This result confirms that 
the detected myristoyl signal is indeed dependent on myristoylated BASP1. It 
confirms that the nuclear pool of BASP1 includes an N-terminally myristoylated form 





Figure 4.10. Myristoyl is Present at the Promoters of WT1 Target Genes in wtBASP1 
Expressing K562 Cells. A, DNA gel electrophoresis shows DNA fragment sizes following the 
incubation of V-K562, B-K562 and G-K562 cells with either ethanol (alkyne-free control) or 10ug/ml 
alkyne-Myristic acid, followed by a click chemistry reaction and sonication of the DNA. ChIP 
experiments were performed using a streptavidin-biotin pull down of azide-alkyne-Myristoyl bound 
DNA regions. Base pair markers (bp) are shown at left. B, Fold enrichment of Myristoyl at the AREG, 
ETS-1, REN, JUNB and VDR promoters in V-K562, B-K562 and G-K562 cells compared to the 
alkyne-free control pull down, and control region 18S. Error bars representative of the standard 
deviation of the mean, n=10. *p<0.05, by Student’s t test comparing B-K562 or G-K562 with control 
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4.8 Role of Inner Nuclear Membrane Components in WT1/BASP1/PIP2 
Mediated Gene Repression 
Work from our laboratory and data presented in the first chapter of this study have 
shown that G2A-BASP1 is defective at gene repression [3]. In this chapter 
subnuclear fractionation revealed that unlike wtBASP1, G2A-BASP1 does not 
localise to the nuclear matrix. It has also been shown that wtBASP1 interacts with 
the INM protein emerin in a myristoyl dependent manner. Therefore, it was next 
sought to investigate whether interaction with INM proteins is important for BASP1 
gene repressor function. Here it was reasoned that if BASP1 interacts with INM 
proteins to repress transcription, then the INM components should be recruited to 
the promoters of wtBASP1, but not G2A-BASP1 bound WT1 target genes. It was 
further reasoned that depletion of INM components would relieve BASP1-mediated 
transcriptional repression.  
4.8.1 Chromatin Immunoprecipitation of Nuclear Membrane Proteins at WT1 
Target Gene Promoters 
To examine whether nuclear membrane proteins are recruited to BASP1 repressed 
genes a series of ChIP experiments was conducted with V-K562, B-K562 and G-
K562 cells. Sonicated chromatin samples were subjected to immunoprecipitation 
with emerin, BAF or lap2α antibodies. Strikingly, enrichment of all three proteins 
was apparent at WT1 target gene promoters specifically in wtBASP1 expressing 
cells (Figure 4.11). Emerin and BAF protein were both significantly enriched at the 
promoters of the AREG, ETS-1, VDR and JUNB promoters in B-K562 compared to 
V-K562 control, and not enriched in G-K562 cells. Similarly, lap2α was statistically 
significantly enriched at the promoters of the ETS-1, REN, VDR and JUNB 
promoters in B-K562 compared to V-K562 control, and not enriched in G-K562 cells. 
These results indicate that the expression of wtBASP1, and it’s binding to WT1 
target gene promoters, coincides with the recruitment of multiple INM proteins. The 
binding of these INM components does not occur in G2A-BASP1 expressing cells, 






Figure 4.11. Nuclear Membrane Proteins Emerin, BAF and LAP2α are Bound to WT1 Target Gene Promoters in B-K562 cells. The binding of 
Emerin (A), BAF (B) and LAP2α (C) at the promoters of AREG, ETS-1, REN, VDR and JUNB was examined using chromatin immunoprecipitation in V-
K562, B-K562 and G-K562 cells. Fold enrichment above IgG and compared to control region BAX. Error bars representative of the standard deviation of 
the mean, A) n=8, B) n=8, C) n=8. *p<0.05, by Student’s t test comparing B-K562 or G-K562 with control cell line V-K562. 
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4.8.2 Gene Expression Analysis Following Knockdown of Emerin via siRNA 
The results so far have demonstrated that BASP1 interacts with emerin and that it 
recruits several INM proteins to the promoter region of WT1 target genes. These 
activities of BASP1 are abolished by the G2A mutation suggesting that they are 
dependent on BASP1 myristoylation. To investigate whether INM proteins are 
involved in the mechanism of BASP1 mediated gene repression an siRNA 
knockdown experiment was conducted targeting emerin. The stable shN MCF7 and 
shB MCF7 cell lines were transfected with either a control siRNA sequence or an 
siRNA sequence targeting emerin. Expression levels of WT1 target genes were 
analysed via quantitative PCR 48 hours post transfection (Figure 4.12A). Western 
blots were conducted to confirm emerin protein knockdown (Figure 4.12B). ImageJ 
analysis indicates emerin protein was reduced by ~50%. As expected, in the control 
condition the expression level of all three WT1 target genes examined (AREG, ETS-
1 and VDR) was increased in shB MCF7 cells compared to shN MCF7 cells, 
indicating that loss of BASP1 expression leads to loss of repression of these genes. 
Upon emerin knockdown two effects are seen. Firstly, for AREG and ETS-1 in the 
presence of BASP1 the knockdown of emerin leads to an increase in gene 
expression, but when both BASP1 and emerin are depleted no loss of repression is 
apparent. Secondly, for VDR, in the presence of BASP1 the knockdown of emerin 
leads to a small increase in gene expression, but when both BASP1 and emerin are 
depleted loss of repression is maintained. The fact that emerin depletion has 
different effects in shN and shB MCF7 cells suggests a relationship between BASP1 
and emerin that is important for gene repression. However, it is also clear that 
simultaneous knockdown of Emerin and BASP1 inhibits expression of AREG and 
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Figure 4.12. Knockdown of Emerin via siRNA Reduces BASP1 Mediated Gene Repression. A, Relative expression of (i) AREG, (ii) ETS-1 
and (iii) VDR in MCF7 shN (shNegative control stable MCF7 cells) and shB (shBASP1 stable MCF7 cells) following transfection of either siControl 
or siEmerin. Relative expression normalised to GAPDH. Error bars represent standard deviation across 3 independent experiments for AREG and 
ETS-1 and 5 independent experiments for VDR. *p<0.05 following students t test compared to ShN control sample. B, samples of transfected shB 




4.9 Discussion of Chapter 2 Results 
4.9.1 Myristoylation Affects BASP1 Localisation 
The work presented in this chapter has further explored the importance of 
myristoylation for the transcriptional repression function of BASP1. This included 
examination of the localisation of the BASP1 repression complex, identification of 
myristoyl dependent interaction partners, and investigation into the role of INM 
proteins in BASP1 mediated repression. Biochemical fractionation of the nucleus 
provided the first evidence that the subnuclear localisation of BASP1 is affected by 
the myristoyl modification, whereby lack of myristoylation results in loss of BASP1 
from the nuclear matrix fraction. Furthermore, immunoprecipitation data revealed 
that myristoylation is essential for BASP1 to interact with proteins largely associated 
with the nuclear membrane and nuclear matrix, namely emerin and β-actin. The 
myristoyl dependent nature of these interactions is likely to contribute to loss of 
G2A-BASP1 from the nuclear matrix fraction. The myristoyl dependent nature of 
these interactions also posed the question of whether they play a role in BASP1 
mediated gene repression.  
Having discovered that BASP1 nuclear localisation is affected by the myristoyl 
modification, microscopy approaches were then adopted with the aim of visualising 
wtBASP1 and G2A-BASP1 in the nucleus. Following confocal microscopy of BASP1 
alongside repression complex components prohibitin, HDAC1 and PIP2 it was 
concluded that the abundance of these nuclear components called for higher 
resolution imaging techniques in order to gain meaningful localisation data. 
Preliminary TEM observation of immunogold labelled HA-BASP1 in B-K562 cells 
suggested that wtBASP1 may indeed localise at the inner nuclear membrane, as 
well as throughout the inner nuclear space. Further TEM observation and analysis 
of wtBASP1 and G2A-BASP1 is now required to confirm BASP1 presence at the 
nuclear membrane and examine any differences in the localisation of wtBASP1 and 
G2A-BASP1.  
4.9.2 Nuclear Localisation of BASP1 and Myristoyl 
Next, the development of click chemistry techniques enabled visualisation of the 
nuclear colocalisation of BASP1 and the myristoyl modification. Following validation 
of the click chemistry technique and pull down of wtBASP1 using streptavidin 
beads, confocal images were obtained which provided evidence for the presence of 




nuclear space, including the nucleolus (Figure 4.7 and Figure 4.8). A handful of 
other myristoylated proteins have previously been found in the nucleoplasm and the 
nucleolus and include the tyrosine kinase c-ABL, MARCKS and ARL4 [130, 294-
297]. Myristoyl was observed in the nucleolus of both cell types examined in this 
study, whilst BASP1 was only apparent in the nucleolus of MCF7 cells, suggesting 
that BASP1 contributes to the pool of myristoylated proteins in the nucleolus in 
some cell types. It is possible this difference may be due to the ectopic expression 
of BASP1 protein in K562 cells compared to endogenous MCF7 BASP1 protein. 
The click chemistry imaging of BASP1 and myristoyl has also provided quantitative 
data to show reduced association of G2A-BASP1 with myristoyl. This agrees with 
the click chemistry immunoprecipitation data (Figure 4.7) and is further supported by 
the click-ChIP data which is consistent with myristoylation occurring only at the G2 
residue of BASP1. The presence of the myristoyl modification was detected at all 
wtBASP1 bound sites, confirming that BASP1 is recruited to WT1 target genes in an 
N-terminally myristoylated form. BASP1 remains the only protein known to have a 
function in gene regulation that is dependent upon myristoylation and the click-ChIP 
data presented here directly demonstrates recruitment of myristoylated BASP1 to 
gene promoters for the first time.  
4.9.3 Myristoyl Dependent Interaction of BASP1 and the INM 
Work presented later in this chapter demonstrated that BASP1 interacts with the 
inner nuclear membrane protein, emerin, in a myristoyl dependent manner. BASP1 
immunoprecipitation followed by mass spectrometry also revealed that BASP1 
interacts with a range of other nuclear periphery components. The data collected 
from a series of ChIP experiments described here demonstrate recruitment of 
multiple inner nuclear membrane components (emerin, BAF and lap2α) to BASP1 
bound promoters in a myristoyl dependent manner. This is the first evidence that 
membrane components are recruited to BASP1 bound promoters. Given that 
myristoylation of BASP1 is essential for transcriptional repression, interaction with 
emerin, and recruitment of INM proteins to gene promoters, it was reasoned that 
interaction with INM components may be important for BASP1 gene repressor 
activity.  
The subnuclear localisation of these promoter bound INM components cannot be 
confirmed from the ChIP data, however a role for these factors in inducing gene 




been associated with gene repression through a number of means; firstly through 
the anchoring of transcriptional regulators to the nuclear membrane, such as β-
catenin to downregulate Wnt signalling, the Notch intracellular domain to 
downregulate Notch signalling and Lmo7 which regulates heart and muscle relevant 
genes [298-301]. Secondly, emerin has been implicated in promoting a repressive 
chromatin environment at the nuclear periphery through its association with 
chromatin modifying complexes like the nuclear corepressor (NCoR) complex [189]. 
Emerin directly binds HDAC3, the catalytic subunit of the NCoR complex, resulting 
in its recruitment to the nuclear periphery and enhanced deacetylation of H4K5 and 
adjacent acetyl lysines, leading to gene repression [189]. Similarly, emerin 
activation of HDAC3 activity causes relocalisation of Myf5, MyoD and Pax7 genes to 
the nuclear membrane where they undergo repression during differentiation of 
myogenic progenitors [238]. These findings support a role for emerin in 
repositioning DNA at the nuclear periphery. 
BAF also has functions associated with chromatin reorganisation and gene 
repression at the nuclear periphery, partly in association with emerin. BAF binds to 
the LEM domain of emerin and anchors it in the nuclear membrane [302]. This 
anchoring is essential for emerin function, evidenced by BAF downregulation 
leading to the release of emerin into the cytosol and subsequent upregulation of 
Notch signalling [301]. BAF can also directly bind transcription factors, such as the 
homeodomain transcription factor Crx and related transcription factors and repress 
their transactivation activity [303]. Many groups have demonstrated that BAF also 
dynamically binds other LEM domain containing proteins, including the Lap2 family 
and lamins, which assemble together to govern chromatin organisation and capture 
segregated chromosomes at the nuclear envelope [304, 305]. Furthermore, BAF is 
also associated with heterochromatin formation through epigenetic mechanisms 
including binding to the methyltransferase SETD1A which mediates repression 
through H3K4 methylation [306-308].   
The binding of both BAF and emerin to LAP2 proteins further serves to bridge 
chromosomes to the nuclear lamina [302, 309]. Alongside the other lap2 isoforms 
(β, δ, Ɛ, Ɣ, ξ), lap2α forms an integral structural component of the nuclear lamina 
where it complexes with chromatin, DNA and Lamin A/C [310]. Unlike the other 
Lap2 isoforms, as well as localising in the nuclear lamina and interacting with the 
nuclear membrane, Lap2α also localises throughout the nucleoplasm as part of the 




chromosomes via its chromatin interaction domain, which has been shown to be 
important during dynamic structural organisation of the nucleus in processes such 
as spermiogenesis and post mitotic nuclear reassembly [311-313]. Lap2α is 
therefore a vital collaborative component for chromatin reorganisation.  
Here, emerin knockdown leads to a reduction in BASP1 mediated gene repression 
of multiple targets, supporting the hypothesis that the BASP1-emerin interaction is 
important for the gene repression. One limitation of this experiment is the adverse 
effect of emerin knockdown on cellular health. Loss of emerin is associated with 
severe motor and cardiac defects, as documented in the emerin knockout mouse, 
and mutations in emerin lead to X-linked recessive Emery–Dreifuss muscular 
dystrophy and cardiac abnormalities including cardiomyopathy [314-317]. In vitro, 
emerin knockdown has been shown to cause nuclear shape instability, induce 
changes in gene expression patterns including the MAPK pathway, impair the 
differentiation potential of cells and even to promote metastasis [318-320]. It is 
comprehendible that depleting emerin levels by even 50%, as achieved in our 
emerin knockdown experiment, is sufficient to cause severe loss of cellular fitness 
leading to general adverse effects on the transcription of some gene products. 
Despite this caveat, these data still provide the first suggestion that emerin could be 
important for BASP1 mediated repression of WT1 target genes. Further 
investigation is required before more firm conclusions can be made about the 
requirement for emerin and the other INM proteins in the mechanism of BASP1 
mediated repression. However, given this preliminary transcription data and the 
finding that emerin, BAF and lap2α localise with BASP1 at WT1 target genes, it is 
reasonable to speculate that the interaction of the BASP1 repression complex with 
these components might facilitate recruitment to the nuclear periphery, resulting in 
relocalisation of target genes and subsequent gene repression.  
As discussed following findings from results chapter 1, BASP1 assembly at a gene 
promoter coincides with recruitment of EZH2 and an increase in repressive 
H3K27me3 and H3K9me3 chromatin marks. It is therefore speculated that BASP1 
recruits EZH2 and the PRC2 complex to gene promoters which contributes to the 
induction of a repressive chromatin environment around these genes. The PRC2 
complex also already has a well-defined role in mediating the repression of specific 
targets at the nuclear periphery through laying down of H3K27me3 marks and 
heterochromatin formation. PRC2 recruitment to the nuclear periphery is essential 




levels of H3K27me3 are also found on target chromatin following PRC2 recruitment 
to the INM by the YY1 transcription factor [232]. Such PRC2 activity is vital for 
development and differentiation. The recruitment of PRC2 by BASP1 provides 
another mechanism through which gene repression could be mediated at the 
nuclear periphery. 
4.9.4 Myristoyl Dependent Interaction of BASP1 and β-actin 
In addition to the myristoyl-dependent interaction of BASP1 with emerin, it was also 
demonstrated in this chapter that the BASP1-β-actin interaction is myristoyl 
dependent (Figure 4.3). As well as being a crucial architectural component of the 
nucleus, β-actin is a vital component of many chromatin remodelling complexes 
including members of the SWI/SNF family and the BAF complex [322]. β-actin binds 
directly to the BRG1 ATPase subunit, stabilises the complex and facilitates the 
binding of the BAF complex to chromatin and the nuclear matrix [118, 322]. We 
have previously shown that BRG1 is recruited to WT1 target gene promoters in a 
BASP1 and prohibitin-dependent manner [96]. The importance of β-actin interaction 
for BASP1 repression function was not pursued here, but it would be interesting to 
establish whether a BASP1-β-actin interaction is important for recruiting BRG1 to 
BASP1 bound promoters and whether it could have a role in linking the BASP1 
repression complex to chromatin and/or the nuclear matrix. Furthermore, PIP2 has 
also been shown to be important in enhancing the association of the BAF complex 
with the nuclear matrix and with chromatin [118]. It would be interesting to examine 
whether the myristoyl-dependent BASP1-β-actin interaction is due to a requirement 
for PIP2 to link the BASP1 complex with chromatin and the nuclear matrix. 
Nuclear actin is increasingly thought to be important for transcription initiation and 
elongation and has been copurified from preinitiation complexes at RNA polymerase 
I and II transcribed genes [323-325]. Two models of actin’s contribution to 
transcription elongation have been proposed; firstly through an actomyosin motor 
which helps the transcription machinery move along DNA, and secondly through 
recruitment of histone modifiers including HATs to RNA polymerase II transcribed 
genes [323]. These functions of actin are of direct interest to this study as it was 
shown here for the first time that BASP1 regulates RNA polymerase II recruitment in 
a myristoyl-dependent manner. Although not pursued here, it would be interesting to 
establish whether β-actin plays a role in recruiting histone modifiers to BASP1 
regulated genes, and in Ser5 phosphorylation of RNA polymerase II by CDK7 at 




Nuclear actin is also known to play a vital role in the reorganisation of gene 
positioning as they undergo expression changes. Expression of mutant actin or 
nuclear myosin IC with actin binding and polymerisation defects inhibits intranuclear 
repositioning of genes upon transcriptional activation [326, 327]. These results 
highlight the importance of actin dynamics for gene repositioning and large-scale 
chromatin rearrangement. Given the working hypothesis that BASP1 mediates 
transcriptional repression through interaction with the nuclear membrane and 
relocalisation of WT1 target genes to the nuclear periphery, it would be interesting 
to investigate whether the lack of gene repression function of G2A-BASP1 could be 
related to deregulated gene positioning due to lack of actin binding capacity.  
Furthermore, it is interesting that myosin IC has been implicated in gene 
repositioning, as we have also previously identified a BASP1-Myosin IC interaction 
[89, 326]. An emerin-myosin IC interaction has also been shown to anchor myosin 
IC at the nuclear membrane [300]. Proteomic examination of emerin complexes has 
led to the proposal that emerin forms architectural complexes with nuclear actin, 
myosin IC and lamin proteins that are entirely distinct from its gene regulatory 
complexes with binding partners such as histone 1, histone 3, BAF, HDAC1, 
HDAC3 and actin [300]. Although it remains unclear, it has been suggested that 
these architectural complexes function to facilitate actin motor activity [300]. This 
highlights the need for further investigation to establish how the presence of emerin 
at WT1/BASP1 target genes contributes to repression; it may be through 
contributing to an architectural complex to anchor BASP1 to the membrane or 






4.9.5 Summary of Chapter 2  
A summary of the data presented in this chapter is shown in Figure 3.13 in the form 
of a schematic depicting the hypothesis that BASP1 recruits WT1 target genes to 
the nuclear periphery to mediate gene repression. The figure demonstrates a WT1 
target gene unbound by BASP1, with active histone marks present at the gene 
promoter and transcription initiated by the phosphorylation of RNA polymerase II 
Serine 5 by CDK7. In line with the hypothesis this gene is shown in a central 
euchromatic region. Conversely a wtBASP1 bound gene is shown with repressive 
histone marks present at the gene promoter, and repression complex components 
including HDAC1 present. The complex is depicted interacting with INM proteins 







Figure 4.13. Chapter 2 Summary: Membrane Localisation of BASP1-PIP
2 
Complex Plays a Role in WT1 Target Gene Repression. 
Representation of hypothesised localisation of WT1 target genes. A promoter bound only by WT1 is located within euchromatin in the centre of the nucleus 




). Black arrow indicates phosphorylation of serine 5 of RNA 
polymerase II by CDK7. Large black arrow represents active transcription. A promoter bound by wtBASP1 is located within heterochromatin at the nuclear 




). Small black arrow represents reduced levels of 
transcription. HDAC1 is shown to represent previously established components of the repression complex. Emerin and candidate BASP1 interactors 




5 Results Chapter 3: The Role of Cholesterol in WT1/BASP1 Mediated Gene 
Repression 
5.1 Introduction 
BASP1 is a unique transcriptional regulator which is known to require an interaction 
with lipids, specifically PI(4,5)P2 (PIP2), to mediate gene repression. Our laboratory 
showed for first time that BASP1 recruits PIP2 to target gene promoters, where the 
lipid subsequently recruits additional repression complex components and 
chromatin modifiers (HDAC1, BRG1, prohibitin) to mediate gene repression [2, 3, 
96]. The work presented in the previous chapters of this study has provided further 
insight into the mechanism of WT1/BASP1/PIP2 mediated gene repression and how 
lipidation of BASP1 contributes to the intranuclear localisation of the repression 
complex. In addition to PIP2, BASP1 also has the capacity to interact with 
cholesterol through a cholesterol recognition amino acid consensus (CRAC) motif 
[82, 83, 328]. As a role for PIP2 in WT1/BASP1 mediated gene regulation is 
becoming increasingly clear, here an investigation into a potential role for 
cholesterol in WT1/BASP1 mediated gene regulation was initiated. Current 
knowledge of cholesterol’s role in gene regulation is limited, thus examination of the 
BASP1-cholesterol interaction provides an excellent means by which to explore this 
poorly understood topic. 
The aim in this chapter was to examine the effect of expressing a cholesterol 
binding mutant BASP1 protein on the expression of WT1 target genes in K562 cells. 
The contribution of cholesterol to BASP1 gene repression activity was assessed 
through a variety of assays including gene expression analysis, differentiation 
assays and confocal imaging of intranuclear BASP1 and cholesterol. ChIP of 
BASP1 and cholesterol at target gene promoters was utilised to examine 
recruitment of the cholesterol binding mutant BASP1 protein and of cholesterol itself 
to WT1 target genes. Further ChIP assessed the contribution of the BASP1-
cholesterol complex to levels of active histone modifications and RNA polymerase II 






5.2 Validation of Y12L-BASP1 Mutant 
5.2.1 Generation of Stable Y12L-BASP1 K562 Cell Line 
A stable K562 cell line expressing a tyrosine-12 to leucine (Y12L) mutant BASP1 
protein (hereafter referred to as Y12L-BASP1) was generated in the same way as 
previously described in chapter 1 for G-K562 cells (results chapter 1, Figure 3.2). 
The Y12 residue is the critical tyrosine of the CRAC motif, its substitution for leucine 
removes the sole aromatic amino acid, eliminating cholesterol binding [88]. 
Transfection into K562 cells was followed by selection with 2µg/ml G418. Western 
blotting confirmed expression of BASP1 in this Y-K562 cell line at a similar level to 
that of the B-K562 stable line (Figure 5.1A). Further, visualisation of BASP1 
expression in B-K562 and Y-K562 cells via immunofluorescence and confocal 
microscopy confirmed similar expression levels and nuclear localisation of wtBASP1 
and Y12L-BASP1 in the K562 cells (Figure 5.1B).  
To confirm that the Y12L mutation of BASP1 results in the loss of cholesterol 
binding, recombinant wtBASP1 or Y12L-BASP1 was incubated with a membrane 
dot blotted with increasing concentrations of cholesterol, followed by detection with 
BASP1 antibodies (Figure 5.1C). Recombinant wtBASP1 and the mutant derivative 
Y12L were generated using E. coli engineered to express N-myristoyl transferase. 
Quantification of wtBASP1 and Y12L-BASP1 binding to cholesterol confirmed a 
statistically significant decrease in cholesterol binding by the Y12L-BASP1 mutant 
protein. This work and the data presented in Figure 5.1 was generated by 






Figure 5.1. Generation and Validation of Stable Y12L-BASP1 Expressing K562 Cell Line. A, K562 cells were stably transfected with 
pcDNA3-Y12L-BASP1 vector, selected with 2µg/ml G418 and tested for BASP1 expression via western blotting. B, Confocal microscopy images 
of wtBASP1 and Y12L-BASP1 expression in K562 nuclei. C, recombinant wtBASP1 and Y12L-BASP1 were generated (i) and incubated with 
increasing concentrations of cholesterol via dot blot assay (ii). +, positive control sheep BASP1 antibody and -, negative control vehicle (ethanol) 
only. Cholesterol binding by wtBASP1 and Y12L-BASP1 is quantified in C (iii). **represents p<0.005, following students t test comparing 
wtBASP1 and Y12L-BASP1 binding. Error bars representative of the standard deviation across 3 independent experiments. Work carried out 
by Samantha Carrera. 



















































5.2.2 Immunoprecipitation of wtBASP1 via Alkyne-Cholesterol Pull Down 
A click chemistry immunoprecipitation technique was previously developed in this 
study to pull down the myristoyl motif (refer to Chapter 2, Figure 4.7). As secondary 
validation that the Y12L-BASP1 protein is defective at cholesterol binding the click 
chemistry immunoprecipitation technique was applied using alkyne-cholesterol. 
Briefly, V-K562, B-K562 and Y-K562 cells pre-incubated with alkyne-cholesterol 
were subject to click chemistry reaction with an azide-PEG3-biotin conjugate. 
Nuclear extracts were then incubated with streptavidin conjugated magnetic beads 
to pull down cholesterol and cholesterol interacting proteins (refer to Materials and 
Methods for full protocol).  
Western blotting confirmed successful pull down of wtBASP1 but not Y12L-BASP1 
using this technique (Figure 5.2). β-actin served as a negative control. A further 
alkyne-free negative control with V-K562, B-K562 and Y-K562 cells incubated with 
vehicle (ethanol) alone confirmed that the click chemistry reaction itself does not 
lead to BASP1 protein pull down. These results provide additional evidence to 
validate that the Y12L-BASP1 protein lacks cholesterol binding activity, and that the 





Figure 5.2. Pull Down of wtBASP1 via Click Chemistry of Alkyne-Cholesterol 
Immunoprecipitation. V-K562, B-K562 and Y-K562 cells incubated with either vehicle 
(alkyne-free control) or 10µg/ml alkyne-Cholesterol and subjected to a click chemistry 
reaction. Pull downs using streptavidin beads were then performed on nuclear extracts, 
and western blots used to detect the presence of BASP1, or negative control β-actin.  
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5.3 Confocal Imaging of BASP1 and Alkyne-Cholesterol  
Earlier work presented in this study involved the imaging of alkyne-myristoyl in K562 
nuclei via click chemistry immunofluorescence. Using the same technique, following 
the incubation of K562 cells with alkyne-cholesterol, confocal imaging of nuclear 
cholesterol was performed. Briefly, V-K562, B-K562 and Y-K562 cells with 
incubated with alkyne-cholesterol and subjected to the click chemistry reaction 
followed by immunostaining in suspension. For this method, following the click 
reaction either whole cells or intact purified nuclei were incubated with streptavidin 
conjugated antibody (refer to Materials and Methods for full protocol).  
The alkyne-cholesterol imaging was initially conducted in whole MCF7 derivative 
cells and nuclei as described earlier (Figure 5.3A). Azide-free and alkyne-free 
negative controls are shown in Figure 5.3C and demonstrate that no fluorescence 
signal is obtained without incubation with alkyne-cholesterol and completion of the 
click reaction. In whole cells, the cholesterol signal observed is most abundant 
within the cytoplasm, most likely the golgi body, and in the cell membrane. Nuclear 
BASP1 was also successfully visualised in purified nuclei from shN MCF7 and shB 
MCF7 cells, where BASP1 signal was markedly diminished in shB MCF7 nuclei as 
expected. In the nuclei, cholesterol is present not only around the nuclear periphery, 
presumably within the nuclear membrane, but also speckled throughout the nuclear 
space. Interestingly, similar to the observations with alkyne-myristoyl, the level of 
cholesterol signal was lower in the shB MC7 cell line compared to the shN MC7 line 
in both whole cells and in nuclei. This suggests that downregulation of BASP1 
expression coincides with a decrease in total cellular cholesterol levels. This 
suggests BASP1 could contribute to the stabilisation of cholesterol and/or 
cholesterol containing complexes in the cell. 
To further examine a potential relationship between nuclear cholesterol and BASP1, 
imaging of alkyne-cholesterol was next conducted in nuclei from the K562 cell lines. 
V-K562, B-K562 and Y-K562 cells were incubated with alkyne-cholesterol, then 
purified nuclei from these cell lines were subjected to the click reaction and 
immunostaining in suspension with BASP1 and streptavidin antibodies. BASP1 
protein was present throughout B-K562 and Y-K562 nuclei, and not detected in the 
negative control V-K562 nuclei (Figure 5.3B). Like in MCF7 nuclei, expression of 
BASP1 coincided with greater nuclear cholesterol signal. Cells expressing both 
wtBASP1 and Y12L-BASP1 appear to have a greater abundance of cholesterol in 




levels or stabilising cholesterol complexes. In the nuclei of all cell types cholesterol 
can be seen localised to the nuclear membrane, but also speckled throughout the 
intranuclear space, often in large distinct puncta. These images suggest that 
cholesterol is present throughout the nucleoplasm.  
Mander’s colocalisation analysis examining the overlap of BASP1 and cholesterol 
signals in B-K562 and Y-K562 nuclei is shown in Figure 5.3D. Here, M1 values 
represent the proportion of BASP1 signal that colocalises with cholesterol signal. 
The proportion of wtBASP1 colocalising with cholesterol was determined as 37.0%, 
and the proportion of Y12L-BASP1 colocalising with cholesterol was determined as 
16.9%. This difference reveals a statistically significant decrease in the proportion of 
Y12L-BASP1 associated with cholesterol compared to wtBASP1. This provides 
further quantitative data to support the lack of cholesterol binding activity by Y12L-
BASP1. These results also suggest that only a proportion of BASP1 in the cell is 
interacting with cholesterol at any one time, or that the alkyne-cholesterol visualised 
here does not necessarily represent the entire pool of nuclear cholesterol. M2 
values generated from the Mander’s colocalisation analysis represent the proportion 
of nuclear cholesterol signal that colocalises with BASP1. This was determined as 
3.15% for wtBASP1 11.2% for Y12L-BASP1. These M2 values suggest that there is 
a large amount of nuclear cholesterol which is not associated with BASP1. 
Surprisingly, the values also indicate a statistically significant increase in the 
proportion of cholesterol coinciding with Y12L-BASP1 signal than wtBASP1 signal. 
Although this result could suggest that Y12L-BASP1 associates with cholesterol to a 
greater extent than wtBASP1 through other cholesterol binding proteins, an 
alternative is that the lower abundance of cholesterol in the Y-K562 cells causes the 
association between Y12L-BASP1 and cholesterol to appear artificially raised. Like 
all colocalisation data, the values from the Mander’s colocalisation analysis should 
be carefully interpreted. False positive and false negative associations can easily be 
gained depending on the exact analysis parameters. Although the colocalisation 
analysis cannot provide clear quantitative evidence regarding the association of 
nuclear BASP1 and cholesterol, it has suggested a difference between wtBASP1 
and Y12L-BASP1 cholesterol interaction and importantly has provided evidence to 





Figure 5.3. Click Chemistry Confocal Imaging of Alkyne-Cholesterol in MCF7 Whole Cells, MCF7 Nuclei and K562 Nuclei. Click chemistry of 
shNegative (shN) and shBASP1 (shB) MCF7 or V-K562/B-K562/Y-K562 cells incubated with 10µg/ml alkyne-Myristoyl. Click chemistry reaction was 
followed by immunofluorescence with BASP1 and streptavidin antibodies. A i), Cholesterol in whole MCF7 cells, A ii), Cholesterol in purified MCF7 
nuclei. Scale bar 10µm. B, BASP1 and Cholesterol in V-K562, B-K562 and Y-K562 nuclei. Scale bar 5µm. C, Azide-free control MCF7 (shN) and 
alkyne-free controls MCF7 (shN), V-K562, B-K562 and Y-K562. Scale bar 10µm. D, Quantification of the colocalisation of BASP1 and alkyne-
cholesterol in B-K562 and Y-K562 nuclei as analysed using the Mander’s colocalisation technique. **represents p<0.005, ***represents p<0.0005 
following Students t test comparing M1 values from B-K562 and Y-K562 nuclei, and M2 values from B-K562 and Y-K562 nuclei over two 
independent experiments, n=35. 
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5.4 Gene Expression Analysis of WT1 Target Genes in V-K562, B-K562 and 
Y-K562  
The V-K562, B-K562 and Y-K562 cell lines were next tested for their expression 
levels of a selection of WT1 target genes. Total RNA was extracted, cDNA samples 
were prepared and RNA expression levels determined using real time quantitative 
PCR. Three WT1 target genes AREG, ETS-1 and REN, were examined and 
confirmed to be repressed by BASP1 (Figure 5.4) [2, 3, 96]. Transcriptional 
repression of AREG and ETS-1 was not observed in Y-K562 cells but was still 
observed for REN. This result indicates that Y12L-BASP1 lacks gene repression 
activity towards select WT1 target genes and implicates cholesterol as an important 
BASP1 binding partner. Data presented in Figure 5.4 was generated by Samantha 
Carrera. 
  
Figure 5.4. WT1 Target Genes are Selectively Repressed in Y12L-BASP1 
Expressing K562 Cells. The relative expression of WT1 target genes in V-K562, B-K562 
and Y-K562 cell lines was analysed, compared to control gene GAPDH. The expression 
levels of three target genes; AREG (amphiregulin), ETS-1 and REN are shown. Error bars 
representative of the standard deviation across 3 independent experiments. *p<0.05, 
***p<0.0005 by Student’s t test comparing B-K562 or Y-K562 with V-K562. Work carried 




































5.5 Investigating the Differentiation of V-K562, B-K562 and Y-K562 Cells 
In order to further investigate the importance of the BASP1-cholesterol interaction, 
V-K562, B-K562 and Y-K562 cells were subjected to PMA treatment to induce their 
differentiation. As seen in previous reports treatment of V-K562 cells with PMA 
leads to their differentiation towards a megakaryocyte lineage [2, 256, 257]. V-K562 
cells adhered to the culture dish and retained a round morphology (Figure 5.5). 
PMA-treated V-K562 cells upregulated expression of megakaryocyte markers DAB2 
and ITGA2 (Figure 5.6). PMA treated B-K562 cells differentiated into neuron-like 
cells, as previously reported (Figure 5.5), and upregulated expression of neuronal 
markers MAO-A and ENC1 instead of the megakaryocyte markers (Figure 5.6) [2]. 
PMA treated Y-K562 cells also adhered to the culture dish, however arborisation 
was limited (Figure 5.5B). The gene expression profile of PMA treated Y-K562 cells 
shows that limited arborisation of these cells is likely due to the upregulation of both 
the megakaryocyte and neuronal markers (Figure 5.6). DAB2 was upregulated in Y-
K562 cells to a level similar to that observed in V-K562 cells, and ITGA2 was 
upregulated in Y-K562 cells to approximately 50% the level seen in V-K562 cells. 
Neuronal marker MAO-A was not upregulated in Y-K562 cells, but ENC1 was 
upregulated to a similar level observed in differentiating B-K562 cells. These 
observations suggest that mutation of the cholesterol binding domain of BASP1 
results in partial BASP1 function in both gene regulation and differentiation. 
To further examine whether cholesterol interaction is important for BASP1 mediated 
differentiation of K562 cells to a neuronal phenotype, V-K562, B-K562 and Y-K562 
cells were pre-treated for 12 hours with mevinolin and then subjected to PMA 
treatment for 72 hours. Mevinolin is a statin that inhibits the HMG-CoA reductase 
enzyme which is required for cholesterol biosynthesis [329]. The depletion of 
cholesterol by mevinolin caused a reduction in arborisation of B-K562 cells upon 
PMA treatment. Mevinolin treatment also lead to increased clumping of V-K562 and 
Y-K562 cells in suspension, and limited adherence of these cell lines to the culture 
dish. This suggests that cholesterol is broadly required for differentiation, and 
depletion of total cholesterol levels leads to diminished differentiation for all cell 
lines. It cannot therefore be reliably concluded from this data how depletion of 
cholesterol affects BASP1 driven differentiation of K562 cells. (50% of the data 
presented in Figure 5.5 and all data presented in Figure 5.6 was generated by 
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Figure 5.5. Y12L-BASP1 is Partially Functional in Differentiation. A, Top Panel: V-K562, B-K562 and Y-K562 cells were treated with 
200nm PMA for 72 hours in 6 well plates and examined for the presence of differentiating cells. Lower Panel: V-K562, B-K562 and Y-K562 
cells were pre-treated with 10µg mevinolin for 12 hours, and then treated with 200nm PMA for 72 hours, and examined for the presence of 
differentiating cells. B, Quantification of arborised cells following PMA treatment. Error bars representative of the standard deviation across 3 
independent experiments. **p<0.005, ***p<0.0005 by Student’s t test comparing B-K562 and Y-K562 with V-K562 cells. p value following 






























Figure 5.6. Y12L-BASP1 Upregulates Expression of Megakaryocyte Markers and Neuronal Genes During K562 Differentiation. The 
relative expression of megakaryocyte markers (DAB2, ITGA2) and neuronal markers (MAO-A, ENC1) in V-K562, B-K562 and Y-K562 cell 
lines was analysed, compared to control gene GAPDH following either vehicle control treatment, or 72 hour 100nm PMA treatment. Error bars 
representative of the standard deviation across 5 independent experiments. *p<0.05, **p<0.005, ***p<0.0005  by Student’s t test comparing B-













































































































5.6 The Role of Cholesterol in Chromatin Modification at WT1 Target Gene 
Promoters 
The data presented so far in this chapter has shown that the cholesterol binding 
mutant, Y12L-BASP1, is selectively defective at gene repression. This mutant is 
also defective at inducing the neuron-like differentiation of K562 cells. To further 
examine how the interaction of BASP1 with cholesterol may be important for the 
mechanism of WT1/BASP1 mediated gene repression, a series of ChIP and click-
ChIP experiments were conducted.  
5.6.1 Chromatin Immunoprecipitation of BASP1 and WT1 at WT1 Target 
Gene Promoters in V-K562, B-K562 and Y-K562 Cells 
Detection of BASP1 and WT1 at the promoters of WT1 target genes in V-K562, B-
K562 and Y-K562 cells was performed (Figure 5.7). Both wtBASP1 and Y12L-
BASP1 were found to localise at the AREG, ETS-1, REN, VDR and JUNB 
promoters. The fold enrichment of BASP1 signal at these gene promoters was 
significantly greater in B-K562 and Y-K562 cells than in V-K562 cells (with the 
exception of Y12L-BASP1 at the VDR promoter) as determined using a student’s t 
test (Figure 5.7A). The enrichment of BASP1 at these sites was also statistically 
significantly higher than background from the IgG control. These findings show that 
Y12L-BASP1 is equally capable of binding to WT1 target gene promoters as 
wtBASP1. 
WT1 was also found to be bound at the AREG, ETS-1, REN, VDR and JUNB 
promoters, and binding was statistically significantly greater than the level of 
background signal (IgG) in all three cell lines, indicating that WT1 was bound to its 
target gene promoters regardless of wtBASP1 or Y12L-BASP1 expression (Figure 
5.7B). There was no statistically significant difference in the binding of WT1 at these 
promoters between V-K562, B-K562 and Y-K562 cells, as determined using a 
student’s t test, showing that WT1 is equally capable of binding to its target genes in 







Figure 5.7. Recruitment of BASP1 and WT1 to AREG, ETS-1, REN, VDR and JUNB Promoters in K562 Cells. The presence of BASP1 (A) and 
WT1 (B) at the promoters of AREG, ETS-1, REN, VDR and JUNB was examined using chromatin immunoprecipitation in V-K562, B-K562 and Y-K562 
cells. Error bars representative of the standard deviation of the mean, A) n=8, B) n=7. *p<0.05 by Student’s t test comparing B-K562 or Y-K562 with 
control line V-K562. 
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5.6.2 Click Chemistry Chromatin Immunoprecipitation of Cholesterol at WT1 
Target Gene Promoters 
Following successful detection of wtBASP1, Y12L-BASP1 and WT1 bound to target 
gene promoters by ChIP, the presence of cholesterol itself at these promoters was 
next examined. A click-ChIP technique was developed in the previous chapter. 
Using this same technique with alkyne-cholesterol enabled detection of cholesterol 
binding at target genes in V-K562, B-K562 and Y-K562 cells (Figure 5.8). For this 
method, following incubation with alkyne-cholesterol cells were fixed in 4% 
formaldehyde for 4 hours, subjected to click reaction, then fixed again in 4% 
formaldehyde for 15 mins before cell pellets were lysed, chromatin sheared via 
sonication and lysates incubated with streptavidin beads to capture cholesterol 
(refer to Materials and Methods for full protocol). Fold enrichment was calculated as 
enrichment of cholesterol above signal from the alkyne-free negative control ChIP 
from each cell line. Fold enrichment of cholesterol was then compared to a control 
gene region (18S).  
Cholesterol was enriched at multiple target gene promoters, coinciding with 
wtBASP1 recruitment, and not Y12L-BASP1 recruitment (Figure 5.8). When 
compared with the V-K562 cells BASP1-dependent recruitment of cholesterol only 
occurred to a statistically significant level at the VDR promoter. Although not to a 
significant level, cholesterol enrichment is raised in B-K562 compared to V-K562 
and Y-K562 cells at all the remaining gene promoters, except REN. This indicates 






Figure 5.8. Cholesterol Detection at the Promoters of WT1 Target Genes in wtBASP1 Expressing K562 Cells. V-K562, B-K562 
and Y-K562 cells were incubated with either ethanol (alkyne-free control) or 10ug/ml alkyne-Cholesterol, followed by a click chemistry 
reaction and sonication of the DNA. ChIP experiments were performed using a streptavidin-biotin pull down of azide-alkyne-
cholesterol bound DNA regions. Fold enrichment of alkyne-Cholesterol at the AREG, ETS-1, REN, JUNB and VDR promoters in V-
K562, B-K562 and Y-K562 cells compared to the alkyne-free control pull down, and control region 18S is shown. Error bars 
representative of the standard deviation of the mean, n=9. *p<0.05, by Student’s t test comparing B-K562 or Y-K562 with control cell 
line V-K562. 




5.6.3 Chromatin Immunoprecipitation of Active Chromatin Marks and RNA 
Polymerase II at WT1 Target Gene Promoters in V-K562, B-K562 and Y-
K562 Cells 
As previously described, our lab has demonstrated a decrease in activating H3K9Ac 
marks at BASP1 bound sites in a PIP2-dependent manner [3]. Work completed in 
results chapter 1 of this study revealed that BASP1 causes the removal of several 
other activating histone marks including H3K4me3 and affects RNA polymerase II 
recruitment and phosphorylation in a myristoyl-dependent manner. Here, following 
the detection of Y12L-BASP1 at WT1 target gene promoters, and the detection of 
cholesterol at multiple wtBASP1 bound promoters, the potential contribution of 
cholesterol to the removal of active marks at WT1/BASP1 target genes was 
assessed through ChIP. ChIP was conducted in V-K562, B-K562 and Y-K562 cells 
using antibodies targeting H3K9Ac, H3K4me3 and total RNA polymerase II (Figure 
5.9). Two genes were selected for examination, one gene that appears regulated by 
cholesterol in our analysis thus far (AREG) and one gene that does not appear to be 
regulated by cholesterol (REN). 
In agreement with previous findings H3K9Ac marks were significantly reduced by 
wtBASP1 at both the AREG and REN promoters [3]. At the AREG promoter Y12L-
BASP1 did not lead to a decrease in H3K9Ac marks. Similarly, a decrease in 
H3K4me3 was observed in B-K562 cells compared to V-K562 cells, but Y-K562 cells 
do not show diminished H3K4me3 marks at the AREG promoter. Total RNA 
polymerase II recruitment was also specifically reduced in B-K562 cells and not V-
K562 or Y-K562 cells. This demonstrates that the Y12 residue is critical for BASP1 
mediated removal of both H3K9Ac and H3K4me3 marks and blocking RNA 
polymerase II recruitment at the AREG promoter.  
At the REN promoter in Y-K562 cells H3K9Ac marks appear at an intermediate level 
between that of V-K562 and B-K562 cells (Figure 5.9). Furthermore, no difference in 
H3K4me3 was seen at the REN promoter in Y-K562 compared to V-K562 cells, 
again suggesting Y12L-BASP1 has no capacity to remove H3K4me3 marks at this 
site. It is important to note that although a decrease in H3K4me3 marks was 
observed in B-K562 compared to V-K562 cells the abundance of H3K4me3 at this 
promoter in all cell lines is substantially lower than at AREG (or any of the other 
genes) when compared to H3K9Ac and control IgG. A fold enrichment/control of 
only 1.10 in V-K562 cells suggests that H3K4me3 does not play a significant role in 




marginally reduced at the REN promoter when either wtBASP1 or Y12L-BASP1 are 
present. This suggests that RNA polymerase II recruitment is not significantly 
regulated by BASP1 at this gene. These data again indicate that BASP1 elicits 
distinct effects at the AREG and REN promoters and further highlights that the role 
of cholesterol in transcription regulation is promoter specific. All data presented in 
Figure 5.9 was generated by Samantha Carrera. 
As mentioned in results chapter 2, our laboratory has undertaken a number of 
approaches to analyse BASP1 interactors, including TMT/multiplexing of BASP1 
immunoprecipitates to identify differences in wtBASP1 and G2A-BASP1 
interactomes (Figure 4.2). The same approach was also used to examine Y12L-
BASP1 interactors and revealed that BASP1-PIP2 and BASP1-cholesterol interact 
with both distinct and overlapping protein complexes. BASP1 interactions with 
HDAC1, BRG1 and emerin are known to require PIP2 but not cholesterol, whereas 
prohibitin requires both lipids [3, 54, 96]. Conversely, a BASP1-Lysine demethylase 
2B (KDM2B) interaction was identified and appears to be solely reliant on 
cholesterol. H3K4me3 is the major substrate of KDM2B suggesting that the BASP1-
cholesterol interaction may function to remove H3K4me3 activation marks through 
this enzyme [330]. Furthermore, given that Y12L-BASP1 interacts with HDAC1 but 
fails to support deacetylation of H3K9Ac it can be speculated that the removal of 





Figure 5.9. Y12L-BASP1 is Selectively Defective in Histone Modification at WT1 Target Genes. The presence of 
H3K9Ac, H3K4me
3
 and RNA polymerase II (total) at the promoters of the WT1 target genes AREG and REN was examined 
using chromatin immunoprecipitation in V-K562, B-K562 and Y-K562 cells. Error bars representative of the standard 
deviation of the mean, n=4. *p<0.05, by Student’s t test comparing B-K562 or Y-K562 with control cell line V-K562. Work 






































































5.7 Discussion of Chapter 3 Results 
5.7.1 Validation of Y12L-BASP1 Cholesterol Binding Mutant  
The work presented in this chapter builds upon our previous studies identifying the 
role of PIP2 in WT1/BASP1 mediated gene repression. Having previously 
characterised PIP2-dependent transcriptional regulation by BASP1, here the 
previously unexplored contribution of cholesterol to WT1/BASP1 mediated gene 
repression was investigated. Firstly, a K562 cell line was generated to stably 
express a cholesterol binding mutant BASP1 protein via Y12L mutation to disrupt 
the critical tyrosine residue in the CRAC domain. Others have previously reported 
disruption of cholesterol interaction through mutation of the central tyrosine within a 
CRAC domain [331] and this has also previously been reported for BASP1 [88]. 
Confirmation of the lack of cholesterol binding by Y12L-BASP1 was achieved 
through an in vitro cholesterol binding assay and cholesterol click-ChIP. This 
analysis confirms that cholesterol cannot interact with BASP1 through any other 
means.  
5.7.2 Imaging Intranuclear BASP1 and Cholesterol 
Previously, the study of nuclear cholesterol has been limited by lack of tools to 
reliably distinguish membrane cholesterol from intranuclear cholesterol [332]. 
Application of the click chemistry imaging technique developed earlier in this study 
has provided a reliable method to examine the localisation and abundance of 
BASP1 and cholesterol in the K562 cell lines. Images collected here support 
biochemical evidence in the literature that cholesterol is present throughout the 
nucleus; in the membrane, in intranuclear pools and within the nucleolus (Figure 
5.3). This data also provides further quantitative evidence of reduced cholesterol 
binding by Y12L-BASP1 compared to wtBASP1. 
Here cholesterol was observed throughout the nucleus, often within puncta in the 
nucleoplasm. This fits with the evidence that nuclear cholesterol forms complexes 
with sphingomyelin and nuclear proteins that are not just restricted to the nuclear 
membrane [333]. Other intranuclear cholesterol complexes containing 
sphingomyelin and phosphatidylcholine have functional roles in transcription, 
including the stabilisation of newly transcribed RNA and the activation of signalling 
pathways such as STAT3 during cell proliferation [122, 334, 335]. It would be 
interesting to assess in more detail whether cholesterol interacts with the 




our knowledge of the subnuclear localisation of the cholesterol that contributes to 
gene regulation. This is important as cholesterol-sphingomyelin-phosphatidylcholine 
complexes are known to interact with chromatin and have been shown to associate 
with lamin B, suggesting these complexes could also potentially contribute to the 
linking of chromatin and the inner nuclear membrane [334]. Throughout results 
chapter 2 it was hypothesised that PIP2 binding is important for WT1/BASP1 
complex localisation to the nuclear periphery to induce gene repression; it would be 
interesting to establish whether cholesterol is also important for localisation of the 
complex to the nuclear periphery, and what effect this has on the repression of WT1 
target genes.  
It is interesting that expression of BASP1 coincides with increased cholesterol signal 
within the nucleus in both MCF7 and K562 cells. This implies that BASP1 may 
stabilise cholesterol levels and/or intranuclear cholesterol complexes. WT1 is 
already known to regulate the SREBP genes and can therefore affect the 
cholesterol/fatty acid synthesis pathway, plus cholesterol itself is involved in a 
feedback loop for its own synthesis and uptake [336, 337]. It is possible that, as a 
cofactor of WT1, BASP1 binding could alter cholesterol regulation.  
Alternatively, the lower levels of cholesterol detected in shB-MCF7 and V-K562 
could also be reflective of the increased tumourigenicity of these cells [89]. The role 
of cholesterol in cancer is complex and it is not yet known if changes in cholesterol 
regulation are a consequence of, or actually contribute to, cellular transformation. 
However, cholesterol is increasingly thought to actively alter the progression and 
severity of multiple cancer types, with both hypocholesterolaemia and 
hypercholesterolaemia implicated in tumour progression [166-168]. Interestingly, 
hypocholesterolaemia has been proposed as a biomarker for severe leukaemia, 
where cells with lower cholesterol levels express higher levels of cell proliferation 
genes including RNA polymerase II, STAT3, PKCz and Cyclin D1, and 
consequently a greater rate of growth [167]. It would be interesting to assess 
whether the tumour suppressor function of BASP1 extends to modulating these cell 
proliferation genes through cholesterol regulation.  
5.7.3 The Role of Cholesterol in the Mechanism of BASP1/WT1 Mediated 
Gene Regulation 
Further experiments presented in this chapter looked at whether the BASP1-
cholesterol interaction could be important for the role of BASP1 in differentiation. 




differentiation pathway of K562 cells away from a megakaryocytic lineage towards a 
neuron-like lineage [2]. Here Y12L-BASP1 expressing cells differentiated into an 
intermediate cell-type, expressing markers of both megakaryocytes and neurons 
(DAB2, ITGA2, ENC1), implicating cholesterol binding as important for the 
regulation of a selection of WT1/BASP1 targets through differentiation. The mixed 
gene expression profile likely explains the intermediate arborisation and morphology 
phenotype of these cells. Mevinolin treatment appeared to block the differentiation 
of all K562 derivatives, indicative of a vital requirement for cholesterol during 
differentiation of this cell line. In many cell types cholesterol depletion activates 
signalling proteins such as extracellular signal-regulated kinase (ERK), human 
epidermal growth factor receptor 2 (HER2) or epidermal growth factor receptor 
(EGFR) which are known to affect differentiation [338, 339]. Cholesterol depletion is 
also known to activate the Wnt/beta-catenin pathway to enhance myogenic 
differentiation and activate p38α/β which alters gene expression of the keratinocyte 
differentiation marker involucrin during the early stages of keratinocyte 
differentiation [338, 340].  
The molecular basis of the observed inhibition of differentiation following mevinolin 
treatment in this study was not investigated. More thorough study through gene 
expression analysis may provide greater insight into the role of cholesterol during 
K562 differentiation. It must also be acknowledged that depletion of total cholesterol 
in this manner could diminish overall cellular health thus the observed block of 
differentiation in K562 following cholesterol depletion could be an artefact of poor 
cell viability. Different doses of mevinolin, treatment with other statins (atorvastatin), 
or use of siRNA targeting HMG-CoA reductase should be trialled to optimise the 
cholesterol depletion. Subsequent protein and gene expression analysis would 
provide thorough assessment of the effect of cholesterol depletion on K562 
differentiation. 
The mechanism by which cholesterol contributes to WT1/BASP1 mediated 
transcriptional repression was next investigated. Firstly, the binding of Y12L-BASP1 
to WT1 target genes was confirmed via ChIP assays with V-K562, B-K562 and Y-
K562 cells. This demonstrated that the BASP1-cholesterol interaction is not required 
for BASP1 to bind promoters. Following this, using the click-ChIP technique 
previously developed in this study, cholesterol was detected at select wtBASP1 
bound promoters. Unlike other WT1 targets, the REN promoter does not undergo 




analysis conducted earlier in this chapter indicated that the repression of REN by 
BASP1 occurs through a cholesterol-independent mechanism. This click-ChIP data 
forms the first evidence for the direct recruitment of cholesterol to gene promoters 
and raises the possibility that cholesterol plays a role in BASP1 mediated repression 
at selected WT1 target genes. 
It should be noted that there was large variability in cholesterol signal detected in 
the click-ChIP assay, particularly when compared to the myristoyl-click-ChIP and 
signal gained from standard ChIP assays in this study. This is likely due to the 
difficulty in cross linking cholesterol. As cholesterol lacks formaldehyde targeted 
structures such as primary amines or tyrosine rings the crosslinking of cholesterol is 
reliant upon its capture within protein complexes. Further optimisation of the 
crosslinking and fixing stages would be beneficial to conduct further repeats of the 
click-ChIP assay and validate these findings.  
Combined with the gene expression data showing that Y12L-BASP1 is defective at 
inducing gene repression at the same select target genes, the click-ChIP data 
provides powerful evidence for the role of cholesterol in gene repression by BASP1. 
Previously cholesterol has only been shown to directly interact with nucleosomes, 
binding to multiple key histone amino acids in the H4 tail and the docking domain 
between the histone clusters H3-H4 and H2A-H2B [139]. Cholesterol’s interaction 
with nucleosomes is thought to contribute to chromatin compaction by promoting the 
formation of 10nm and 30nm chromatin fibres [139]. Data presented here provides 
evidence that cholesterol also contributes to gene repression through binding 
transcriptional complexes on DNA at specific sites. 
Others have shown that cholesterol-sphingomyelin-protein complexes interact with 
chromatin and dynamically change in composition during the transcription process, 
such as during liver regeneration [122, 133]. As BASP1 has an established role in 
mediating changes to chromatin modifications, work presented towards the end of 
this chapter examined how cholesterol interaction may contribute to BASP1 
mediated removal of activating histone marks and the recruitment of RNA 
polymerase II. Through the examination of H3K9Ac, H3K4me3 and total RNA 
polymerase II at WT1 target genes via ChIP it was revealed here for the first time 
that BASP1 mediated reduction in H3K9Ac and H3K4me3 and reduction of RNA 
polymerase II recruitment is dependent upon a functional CRAC domain in BASP1. 




chromatin modifications and the initiation of transcription at a subset of BASP1 
regulated WT1 targets.  
Identification of KDM2B as a candidate BASP1-cholesterol interactor provides a 
potential mechanism through which BASP1 and cholesterol mediate changes in 
chromatin marks at targeted genes. The KDM2B enzyme predominantly targets 
H3K4me3 for demethylation, but also shows activity towards H3K36me3, a mark 
shown in results chapter 1 of this study to be down regulated in a BASP1-myristoyl 
dependent manner (Figure 3.9A) [330, 341]. Validation of a BASP1-KDM2B 
interaction, and the recruitment of KDM2B to WT1 target genes is required to 
confirm whether this mechanism may account for the observed downregulation of 
H3K4me3 in this study. Interestingly, KDM2B is known to upregulate EZH2 
expression and subsequently contribute to the progression of ovarian cancer in vitro 
and in vivo [341]. Furthermore, the KDM2B-EZH2 interaction has been shown to 
promote demethylation of H3K36me2 and H3K4me3 at the Ink4a/Arf locus in mouse 
embryonic fibroblasts [342]. Demethylation of these marks at the Ink4a/Arf locus 
then interferes with RNA polymerase II binding, leading to transcriptional silencing 
[342]. This KDM2B-EZH2 based gene silencing mechanism is similar to the 
observations at BASP1-bound sites described in this study. It would therefore be of 
great interest to examine whether a BASP1-KDM2B-EZH2 interaction at WT1 target 
genes may contribute to the removal of H3K4me3 and H3K36me2, upregulation of 
H3K27me3 and H3K9me3, and decrease in RNA polymerase II recruitment and 
activation, as demonstrated in results chapter 1 (Figures 3.10-3.12). Validation that 
the BASP1-KDM2B interaction is cholesterol-dependent would solidify a role for 
cholesterol in the molecular mechanism of gene silencing by the BASP1 repression 
complex. 
Interestingly, although repression of the AREG gene has been shown to be 
dependent on the BASP1-cholesterol interaction, H3K9Ac is not deacetylated at the 
AREG promoter when Y12L-BASP1 is present. Our BASP1-interactome proteomic 
analysis showed that Y12L-BASP1 can still interact with HDAC1, and it therefore 
could be recruited with Y12L-BASP1 to the AREG promoter. ChIP analysis to 
examine HDAC1 recruitment in V-K562, B-K562 and Y-K562 cells could confirm 
this. If indeed HDAC1 is recruited, this raises the possibility that H3K4me3 
demethylation is a prerequisite for HDAC1 to deacetylate H3K9. Interestingly, the 
HDAC Rpd3L has recently been shown to be targeted to active promoters marked 




repression in yeast [343]. A functional link between H3 acetylation and H3K4me3 
has further been reported whereby the inhibition of HDACs leads to the upregulation 
of H3K4 methylation, resulting in transcriptional activation of genes including 
KLF4 and E-cadherin in prostate cancer cells [344, 345]. The exact nature of the 
functional connection between H3 acetylation and H3K4 methylation remains to be 
explored but it would be interesting to investigate whether a specific sequence of 
chromatin modifications is required at BASP1 regulated target genes. 
The gene specific requirement for cholesterol in the WT1/BASP1 repression 
mechanism has consistently been identified throughout this chapter. REN, a gene 
repressed in both B-K562 and Y-K562 cells, did not show cholesterol recruitment at 
the promoter via click-ChIP, displayed endogenously low levels of H3K4me3 and 
shows no determinable difference in RNA polymerase II recruitment. Conversely, 
AREG, a gene repressed only in B-K562 cells and not Y-K562 cells recruited 
cholesterol to the promoter via click-ChIP, displayed clear removal of active histone 
marks H3K9Ac and H3K4me3 and showed reduced RNA polymerase II recruitment. 
Together these findings suggest that cholesterol is selectively required for 
WT1/BASP1 mediated gene repression and is important for the mechanism of 
BASP1 mediated gene silencing. The low abundance of H3K4me3 marks at the 
REN promoter even in V-K562 cells may explain why a BASP1-cholesterol based 
repression mechanism is not apparent at this gene, as there is limited scope for 
further demethylation and therefore limited scope to alter the chromatin environment 
through removal of this mark. Evidence from results chapter 1 showed that at the 
REN promoter RNA polymerase II Ser5 phosphorylation and CDK7 recruitment was 
reduced by wtBASP1. The observed repression of REN by Y12L-BASP1 signifies 
that these BASP1 functions are cholesterol independent. It would be interesting to 
assess RNA polymerase II Ser5 phosphorylation and CDK7 recruitment in Y-K562 
cells via ChIP to test this. One further explanation as to why the repression 
mechanism of REN may differ to that of other genes could be that the WT1 binding 
site for REN is located within an enhancer sequence, rather than within the proximal 
promoter region like the majority of WT1 targets [346-349]. WT1 binds within the 
human renin conserved region (hRENc), part of a highly conserved enhancer 
sequence approximately 11kb upstream of the promoter [346, 350]. BASP1 may 
therefore require a different mechanism of repression to influence chromatin 





5.7.4 Summary of Results Chapter 3 
A summary of the data presented in this final chapter is shown in Figure 5.10. The 
schematic illustrates the hypothesis that, like PIP2, cholesterol is an important 
component of the WT1/BASP1 repression complex but is recruited to selected 
target gene promoters. The figure demonstrates that cholesterol is present and is 
important for the recruitment of further chromatin modifying components, which 
ultimately reduce active histone marks H3K9Ac and H3K4me3 and contribute to 
reduced RNA polymerase II recruitment and repression of transcription. The histone 
lysine demethylase enzyme KDM2B is shown as a candidate for mediating the 
removal of H3K4me3 marks. Ultimately, these cholesterol-dependent changes at 
select WT1 target genes have been shown to lead to altered gene expression 
profiles and an altered differentiation pathway in K562 cells.  
  
Figure 5.10. Chapter 3 Summary: A Role for Cholesterol in Selective 
Transcriptional Repression by BASP1. 
Representation of WT1 target gene promoters in wtBASP1 expressing cells, with bound 
cholesterol. Cholesterol is shown as part of the WT1/BASP1 repression complex. 
Dashed black arrows represent HDAC1 removal of H3K9Ac, an established mechanism 
of gene repression for this complex. Dashed black arrow also indicates removal of 
H3K4me
3
 marks by KDM2B, the hypothesised cholesterol-dependent activity. 
Subsequently, RNA polymerase II is displaced from DNA (indicated by green arrow), and 
transcription is downregulated (red cross). This cholesterol-dependent activity ultimately 




6 Final Discussion 
6.1 The Role of BASP1 Lipidation in WT1/BASP1 Mediated Gene Regulation 
This study has generated several new findings about the activity of BASP1 and 
provided molecular evidence that demonstrates the importance of lipid interactions 
for BASP1 transcription regulation function. This includes evidence that 
myristoylation of BASP1 is important for the removal of the histone methylation 
marks H3K36me3 an H3K4me3. This is in addition to previous evidence 
demonstrating BASP1-mediated removal of H3K9Ac [3]. Together, this now shows 
that the WT1/BASP1/PIP2 complex mediates the removal of multiple histone 
modifications associated with transcription activation in order to facilitate gene 
repression. Further, it was demonstrated that BASP1 recruits EZH2 to target gene 
promoters, which correlated with an increase in H3K27 and H3K9 trimethylation. 
This implicates BASP1 as a mediator of repressive histone modifications for the first 
time, possibly through recruitment of the PRC2 complex. Gene repression by the 
WT1/BASP1/PIP2 complex was also accompanied by reduced CDK7 recruitment 
and reduced RNA pol II phosphorylation suggesting BASP1 can additionally 
contribute to gene repression through the inhibition of transcription initiation. These 
findings expand our understanding of the mechanism of action of the 
WT1/BASP1/PIP2 complex in modifying the chromatin environment at its target 
genes and inhibiting transcription initiation. 
Additional findings in this study demonstrated for the first time that the mechanism 
of action of the BASP1 transcription repression complex is also dependent on an 
interaction with cholesterol at select target genes. Cholesterol was shown to be 
directly recruited to BASP1 bound gene promoters and binding of BASP1 to 
cholesterol was required for the removal of H3K9Ac and H3K4me3. The importance 
of the cholesterol interaction for BASP1 function in transcription and cell response 
was further demonstrated through the defective differentiation of Y12L-BASP1 
expressing cells. This work shows a direct role for cholesterol in BASP1-mediated 
gene regulation for the first time and implicates cholesterol as an important regulator 
of chromatin modifications at select target genes.  
Work in this thesis demonstrates that myristoylation of BASP1 affects its 
interactions with multiple proteins of the inner nuclear membrane (INM), its 
association with the nuclear matrix as well as its subnuclear localisation. This further 
implicates a critical role for lipids in controlling the subnuclear localisation of the 




complex carries out its regulation of WT1 target genes at the nuclear periphery, 
associated with the nuclear membrane, or within chromatin bodies in the nuclear 
matrix. Results from this study show that emerin, BAF and LAP2α can all bind to 
BASP1 bound promoters in a myristoyl-dependent manner and suggest that emerin 
may contribute to the mechanism of gene repression. Fluorescence Recovery After 
Photobleaching (FRAP) and Fluorescence Loss In Photobleaching (FLIP) analysis 
has demonstrated that emerin is present at the nuclear membrane and is relatively 
immobile [351]. Similarly, transmission electron microscopy and fluorescence 
microscopy have also provided evidence that emerin is restricted to the nuclear 
membrane [352, 353]. Emerin has been observed in the nuclear space, bound to 
BAF, but only for a very restricted period during the two minutes immediately 
following mitosis, after which time both proteins promptly recolocalise at the nuclear 
periphery [353]. Furthermore, Fluorescence Resonance Energy Transfer (FRET) 
results using fluorescent tagged proteins have shown that BAF associates directly 
with emerin at the INM of living cells [351]. It is possible that the established 
bridging activity of BAF also applies to BASP1 regulated genes, such that BAF 
contributes to the linking of BASP1 regulated chromatin and the nuclear lamina 
[184, 187, 188]. Such evidence supports the proposal that emerin and BAF binding 
to WT1/BASP1 bound promoters could facilitate localisation of the 
WT1/BASP1/PIP2 complex and target genes at the nuclear periphery. This proposal 
aligns with the body of evidence that suggests the nuclear periphery is frequently a 
site of gene repression.  
However, in stark contrast to other INM components (such as emerin, LAP2β and 
MAN1), FRAP and FLIP analysis of BAF showed that whilst it is present at the 
nuclear membrane it also diffuses rapidly throughout the nuclear space [351]. This 
raises the question of whether BAF binds chromatin at the nuclear lamina, in the 
nuclear interior, or both. For some genomic regions, even including many genes 
within lamina associated domains (LADs), detachment from the nuclear membrane 
does not always lead to strong transcriptional activation [227]. Like BAF, lamin A is 
located at the INM and partially within the nucleoplasm [351]. Binding of lamin A to 
gene promoters has an established association with gene repression, and 
downregulation of lamin A results in an increase in the active histone mark 
H3K4me3 [354, 355]. Furthermore, LAP2α also resides in the nuclear lamina and 
throughout the nucleoplasm and has an established role in the structural 
organisation of the nucleus and gene regulation in the nuclear matrix [311, 356]. It is 




LAP2α could facilitate the maintenance of a repressive state of WT1/BASP1 
targeted promoters in the nucleoplasm. BASP1, WT1, PIP2 are after all also known 
to reside in nuclear speckles [3, 222]. 
If the WT1/BASP1 transcription repression complex does function in the nuclear 
space the complex must somehow facilitate the binding of lipids in a biochemically 
feasible manner. The assembly of large protein complexes that shield PIP2 and 
cholesterol is one possible mechanism. A large number of BASP1 repression 
complex components including prohibitin, BRG1, HDAC1 in addition to those 
implicated in this study, emerin, LAP2α and BAF, EZH2, KDM2B and components 
of nuclear actin complexes β-actin, Myosin 1C, nucleophosmin, gelsolin and 
flightless, are already known suggesting that BASP1 can indeed participate in large 
complexes [3, 89, 96]. Previous gel filtration analysis has also evidenced that 
BASP1 is contained within high-molecular-weight complexes of ∼700 kDa [85]. 
Furthermore, given the evidence that BASP1 forms oligomeric structures, it is 
reasonable to speculate that multimers of BASP1 could also potentially shield 
hydrophobic lipid tails and stabilise intranuclear lipid complexes [123, 124]. The 
contribution of lipids to the functional segregation of membrane proteins and 
interactors is well established, perhaps it is also possible that lipids act as a 
molecular glue to facilitate the organisation and formation of different nuclear bodies 
and complexes, including the BASP1 repression complex. 
Although debated for some time, it has now been shown using confocal and 
electron microscopy that nuclear lipid droplets are localised within the nucleoplasm 
of a range of human and mammalian cell lines [127]. Interestingly, nuclear lipid 
droplets were found to be closely associated with protrusions of the inner nuclear 
envelope and with PML bodies [357]. PML-II, one PML protein isoform found in PML 
bodies, appears to be closely linked to the formation of nuclear lipid droplets. PML-II 
correlated with the presence of nuclear lipid droplets and overexpression of mutant 
PML-II, which does not distribute along the nuclear envelope, failed to increase the 
number of nuclear lipid droplets seen after overexpression of the wild type protein 
[357]. This suggests that the binding of PML-II to the nuclear membrane may be 
involved in the formation of nuclear lipid droplets. Interestingly, BASP1 has already 
been identified in the proteome of cholesterol rich nuclear lipid droplets [358]. It is 
possible that BASP1, as a lipid binding protein which is also found in both PML 
bodies and the nuclear membrane, could also contribute to the formation of nuclear 




Nuclear lipid droplets contribute to the newly accepted phase separation of nuclear 
content. The emulsion of phase separated droplets of DNA and protein that forms 
the basis of the nucleoplasm is thought to aid the compartmentalisation of 
chromosomes, the assembly of nuclear bodies, and the regulation of gene 
expression [247, 250, 251]. The importance of phase separation for gene 
regulation has so far predominantly focused on its effect on gene activation, where 
it has been linked to the clustering of coactivated genes and enhancers [359]. 
More recent evidence, however, has shown that phase separation could also be 
important for heterochromatin formation as HP1α was shown to induce the 
formation of liquid droplets containing known components of heterochromatin, 
including nucleosomes [249, 253]. Studying the structure and function of nuclear 
lipid droplets is a means to better understand how phase separation of nuclear 
content controls nuclear structure and function including the activation and 
repression of gene expression. It is possible that BASP1, as a lipid binding protein 
that associates with the nuclear membrane and PML bodies could also contribute 
to the formation nuclear lipid droplets. Further, the formation of nuclear lipid 
droplets could be a further means by which BASP1 interfaces the INM with 
chromatin modification and gene regulation. 
In conclusion, data presented in this study shows that PI(4,5)P2 and cholesterol play 
critical roles in the mechanism of transcriptional repression by the WT1/BASP1 
complex. Myristoylation of BASP1 and the BASP1-cholesterol interaction are now 
known to be important for the recruitment of repression complex components, in 
mediating changes to the chromatin environment at WT1/BASP1 target gene 
promoters and in regulating the subnuclear localisation of BASP1. This evidence 
supports a model whereby an interaction between BASP1 and INM proteins is 
important for mediating transcriptional repression, and implicate PI(4,5)P2 as a linker 
between BASP1 and INM proteins. These findings provide insight into the molecular 
mechanisms through which nuclear lipids contribute to transcriptional regulation. 
Further study of BASP1 and nuclear lipid complexes could give important insights 
into the nature of nuclear protein-lipid complexes, their regulation of gene 






6.2 Future Directions  
6.2.1 BASP1 Recruitment of EZH2/PRC2 Complex 
It was demonstrated here for the first time that BASP1 exhibits myristoyl-
independent addition of repressive chromatin marks to WT1 target genes. It is now 
important to establish whether the observed increase in H3K27me3 and H3K9me3 is 
indeed performed by EZH2 as part of the PRC2 complex, and whether repression of 
WT1 target genes is dependent upon this activity. Firstly, validation of the BASP1-
EZH2 interaction should be completed through BASP1 immunoprecipitation 
(wtBASP1 and G2A-BASP1) and immunoblotting for EZH2, as well as other PRC2 
components (Suz12, Eed and RbAp48). The dependence on EZH2 for BASP1 
mediated repression should be assessed through siRNA depletion of EZH2 followed 
by gene expression analysis of WT1 target genes in the K562 cell lines. ChIP 
should also be conducted to assess changes in chromatin marks at these sites 
following siRNA depletion of EZH2. It is predicted that EZH2 depletion will affect the 
placement of H3K27me3 and H3K9me3 marks at promoters in both B-K562 and G-
K562 cells. As a consequence, it is predicted that repression of WT1 target genes 
would be relieved in the B-K562 cell line. Gene expression analysis of WT1 targets 
and ChIP of chromatin marks following PRC2 inhibitor treatment inhibitor would 
further support the above proposed experiments. These experiments will establish 
EZH2 as an essential cofactor for myristoyl independent function of BASP1. 
Furthermore, completion of these proposed experiments also in Y12L-BASP1 
expressing cells would allow assessment of whether cholesterol is required for 
these BASP1 functions at select WT1 targets. 
6.2.2 WT1/BASP1 Mediated Gene Repression at the Nuclear Periphery 
Data presented in results chapter 2 suggest that BASP1 regulates chromatin 
dynamics and represses transcription through myristoyl-dependent interactions with 
INM proteins. To experimentally examine this proposal high resolution Stimulated 
Emission Depletion (STED) imaging and cryogenic electron microscopy should now 
be conducted followed by colocalisation analysis to study the subnuclear 
localisation of wtBASP1, G2A-BASP, emerin, BAF and lap2α. High resolution 
imaging and colocalisation of BASP1 and PRC2 components would also 
complement findings from results chapter 1 and further implicate PRC2 as a partner 
in BASP1 mediated repression. Imaging studies should be complemented by in 




wtBASP1, G2A-BASP, emerin, BAF and lap2α. Isolation of the nuclear membrane 
domains, including lipid microdomains, and internal nuclear compartments can be 
achieved following sucrose gradient fractionation and centrifugation [122, 360]. 
Immunoblotting of BASP1 repression complex components, chromatin remodelling 
interactors and INM proteins could then determine their subnuclear localisation and 
enable understanding of how BASP1 localisation and repression function is 
controlled by its interaction with lipids.  
Additionally, RNA analysis experiments utilising siRNA targeting emerin should be 
repeated and extended to include RNA analysis following siRNA depletion of BAF 
and lap2α. Expression levels of multiple WT1 target genes (AREG, ETS-1, JUNB, 
VDR, REN) should be examined in V-K562, B-K562 and G-K562 to determine the 
roles of INM proteins in transcriptional repression and the myristoyl-dependence of 
this activity. Greater insight into the role of INM proteins in BASP1 mediated gene 
repression could also be gained from ChIP analysis of histone marks present at 
WT1 target genes in V-K562, B-K562 and G-K562 cells following siRNA depletion of 
emerin, BAF and lap2α.  
Ultimately the gold-standard to determine the localisation of BASP1 bound 
promoters would be to perform Fluorescence in Situ Hybridisation (FISH) to localise 
specific promoters of WT1 target genes in V-K562, B-K562 and G-K562 (plus other 
stably expressing CML cell lines). Using this approach would enable direct 
visualisation of WT1 target genes in wtBASP1 and G2A-BASP1 expressing cells to 
determine if BASP1 (and its myristoylation) causes the relocalisation of gene 
promoters to the nuclear periphery. The proposed experiments would also identify 
the subnuclear location of components of the BASP1 repressor complex and 
determine how the myristoyl-dependent repressor function of BASP1 is related to 
target gene localisation. These results would provide new insights into the 
organisation of repressed genes in the nucleus and how this is regulated by protein-
lipid interactions. 
6.2.3 Role of Cholesterol in WT1/BASP1 Mechanism of Gene Regulation 
Proteomic analysis of wtBASP1 and Y12L-BASP1 immunoprecipitates revealed 
KDM2B as a candidate cholesterol-dependent BASP1 interactor. Validation of this 
interaction via wtBASP1 and Y12L-BASP1 immunoprecipitation followed by western 
blotting and probing for KDM2B is now required. Recruitment of KDM2B to BASP1 




Y-K562. In addition, siRNA depletion of KDM2B followed by gene expression 
analysis of WT1 targets would assess the requirement for KDM2B in the 
WT1/BASP1 repression mechanism. Further ChIP to examine the presence of 
histone modifications at WT1 target genes following siRNA depletion of KDM2B 
would reveal whether removal of H3K4me3 marks is a mechanism by which BASP1 
and cholesterol mediate gene repression. These experiments could also be 
conducted following depletion of cholesterol via statin treatment (Mevinolin, 
Atorvastatin), or blocking of cholesterol synthesis via siRNA targeting HMG-CoA 
reductase to further assess the contribution of cholesterol to BASP1 mediated gene 
repression. 
It would also be interesting to complete the proposed experiments examining 
WT1/BASP1 mediated gene repression at the nuclear periphery in Y12L-BASP1 
expressing cells to assess the contribution of cholesterol to the localisation of the 
BASP1 repression complex, interaction with INM proteins, and the regulation of 
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Table 1. V-K562, B-K562, G-K562 Interactome as Identified by TMT Mass Spectrometry. Triplicates of BASP1 immunoprecipitates from V-K562, B-K562 
and G-K562 were labelled using TMT isobaric mass tags and pooled together prior to high performance liquid chromatography (HPLC) separation. Peptides 
were analysed using SEQUEST to generate a score for each protein. The dataset was filtered to include only proteins identified with >95% confidence, as 
assessed via false discovery rate (FDR) estimation following comparison to the human reverse decoy database. The relative abundance of each identified 
protein in the replicates of V-K562, B-K562 and G-K562 compared to replicate 1 of B-K562 was calculated. The average relative abundance for V-K562, B-
K562 and G-K562 was then calculated. The dataset was filtered to include only proteins with relatively greater abundance in the B-K562 replicates compared 
to V-K562 (negative control).  
Accession Description Score Coverage 
# Unique  Average Relative Abundance 
Peptides B-K562 G-K562 V-K562 
P78527 DNA-dependent protein kinase catalytic subunit 1291.72 61.89 233 0.894 1.280 0.714 
P09874 Poly [ADP-ribose] polymerase  355.32 64.00 68 0.848 1.228 0.700 
Q15149 Plectin  339.00 27.75 108 1.499 1.160 0.910 
P35580 Myosin-10 336.57 43.78 64 1.265 0.750 0.174 
P13010 X-ray repair cross-complementing protein 5 314.50 70.63 44 0.786 1.221 0.587 
P11388 DNA topoisomerase 2-alpha  313.34 48.01 59 0.984 1.727 0.559 
P35579 Myosin-9  309.42 39.95 58 0.971 1.210 0.268 
P12956 X-ray repair cross-complementing protein 6 248.72 61.41 42 0.811 1.241 0.547 
A2VCL5 FLOT1 protein (Fragment) 7.50 9.70 2 2.546 1.422 0.542 
Q5JQC4 Cancer/testis antigen 47A  4.64 8.33 2 0.827 0.305 0.178 
P19338 Nucleolin 226.77 54.51 43 0.700 1.402 0.350 
H6VRF8 Keratin 1  224.27 64.29 34 0.517 0.135 0.106 
Q6NTA2 HNRNPL protein (Fragment)  199.77 67.48 25 0.668 0.748 0.534 
O14980 Exportin-1 194.54 43.32 37 0.922 1.116 0.817 
P35527 Keratin, type I cytoskeletal 185.58 68.54 28 0.392 0.056 0.083 




Accession Description Score Coverage 
# Unique  Average Relative Abundance 
Peptides B-K562 G-K562 V-K562 
Q02880 DNA topoisomerase 2-beta  183.43 30.87 32 0.897 1.174 0.595 
I3L192 Basigin (Fragment)  4.24 9.32 2 1.703 0.757 0.452 
Q8WVW5 Putative uncharacterized protein (Fragment) 174.10 61.71 5 1.035 0.736 0.587 
Q8N5A0 Eukaryotic translation initiation factor 5B  171.54 36.80 41 0.771 1.094 0.483 
P09496 Clathrin light chain A 7.46 9.27 3 0.886 0.523 0.274 
P08670 Vimentin 169.05 73.18 32 2.031 1.776 0.799 
Q9P258 Protein RCC2  166.96 73.75 32 0.695 0.747 0.353 
Q00610 Clathrin heavy chain 1 165.68 28.78 39 0.801 0.431 0.264 
P80723 Brain acid soluble protein 1  157.32 89.43 17 2.255 1.352 0.123 
C9J3L8 Translocon-associated protein subunit alpha 5.07 7.17 2 1.163 0.687 0.419 
Q99543 DnaJ homolog subfamily C member 2 4.77 4.67 2 0.996 0.985 0.377 
Q9UQ80 Proliferation-associated protein 2G4 132.10 62.18 21 1.238 2.202 0.414 
A8K7S5 Katanin p60 ATPase-containing subunit A1  3.74 3.87 2 1.418 2.483 0.558 
P05771 Protein kinase C beta type  10.26 4.32 3 0.976 0.607 0.386 
Q8NE71 ATP-binding cassette sub-family F member 1  123.84 40.83 30 0.791 1.149 0.525 
A0A024R3R7 HEAT repeat containing 1, isoform CRA_b 122.75 19.74 30 1.215 1.184 0.772 
P55060 Exportin-2  122.37 36.35 28 0.958 1.383 0.860 
H0UID5 AP complex subunit beta 121.44 38.44 15 0.595 0.679 0.368 
P36578 60S ribosomal protein L4  115.09 59.48 30 0.764 1.193 0.669 
Q9H0A0 RNA cytidine acetyltransferase  111.41 33.95 8 1.129 1.278 0.499 
P39023 60S ribosomal protein L3  108.72 61.54 6 0.786 1.232 0.664 
P07900 Heat shock protein HSP 90-alpha  105.84 36.34 12 0.835 1.284 0.650 
A9Z1X7 Serine/arginine repetitive matrix protein 1  102.31 33.95 24 0.805 0.710 0.703 
P05198 Eukaryotic translation initiation factor 2 subunit 1  96.40 65.08 17 0.796 1.554 0.469 
Q6P2E9 Enhancer of mRNA-decapping protein 4  96.31 24.41 23 0.785 1.126 0.601 
B2R5W2 Heterogeneous nuclear ribonucleoproteins C1/C2 96.22 57.24 21 0.561 0.485 0.493 




Accession Description Score Coverage 
# Unique  Average Relative Abundance 
Peptides B-K562 G-K562 V-K562 
O95782 AP-2 complex subunit alpha-1  89.23 33.67 18 0.598 0.649 0.456 
Q14008 Cytoskeleton-associated protein 5  89.04 17.47 27 0.679 0.910 0.430 
A8K4Z4 60S acidic ribosomal protein P0 88.97 61.83 17 0.796 1.247 0.577 
B2R7F8 Plasminogen 11.38 2.96 2 1.073 1.833 0.495 
Q9P2P1 Protein NYNRIN 1.85 1.32 2 0.914 1.834 0.433 
P63241 Eukaryotic translation initiation factor 5A-1  88.25 51.95 6 1.195 3.091 0.658 
Q14258 E3 ubiquitin/ISG15 ligase TRIM25  87.31 41.11 20 0.564 0.767 0.450 
Q9Y2X3 Nucleolar protein 58 86.75 43.86 19 0.904 1.045 0.755 
Q5JSL3 Dedicator of cytokinesis protein 11  85.63 14.76 27 0.644 0.737 0.372 
O75330 Hyaluronan mediated motility receptor  85.13 39.23 6 0.575 1.023 0.517 
P62906 60S ribosomal protein L10a 82.96 63.13 16 0.774 1.152 0.595 
P05387 60S acidic ribosomal protein P2  81.72 92.17 7 0.898 1.551 0.654 
Q9Y608 Leucine-rich repeat flightless-interacting protein 2  19.01 9.15 5 0.771 0.876 0.403 
P19474 E3 ubiquitin-protein ligase TRIM21  7.50 6.95 3 1.097 0.849 0.577 
O76021 Ribosomal L1 domain-containing protein 1  78.52 36.73 21 0.698 0.847 0.609 
O43776 Asparagine--tRNA ligase, cytoplasmic  9.98 7.48 3 0.648 0.620 0.348 
P46777 60S ribosomal protein L5  77.62 67.34 19 0.817 1.250 0.658 
Q9NZI8 Insulin-like growth factor 2 mRNA-binding protein 1  76.16 41.25 20 0.695 0.901 0.555 
O60832 H/ACA ribonucleoprotein complex subunit 4  74.19 42.02 20 0.853 1.003 0.680 
P41091 Eukaryotic translation initiation factor 2 subunit 3 73.55 54.66 19 0.785 1.347 0.378 
A0A024R2V0 Microtubule-associated protein  73.53 48.14 7 1.232 1.700 0.802 
P16403 Histone H1.2  72.93 42.72 5 0.739 1.299 0.469 
D3DRH1 Dedicator of cytokinesis 8, isoform CRA_a 7.89 2.22 2 0.573 0.669 0.320 
Q9NX58 Cell growth-regulating nucleolar protein  71.22 51.19 2 0.866 1.034 0.517 
Q9P016 Thymocyte nuclear protein 1  1.95 9.33 2 0.938 1.492 0.529 
P48668 Keratin, type II cytoskeletal 6C  70.69 37.23 8 0.581 0.227 0.209 




Accession Description Score Coverage 
# Unique  Average Relative Abundance 
Peptides B-K562 G-K562 V-K562 
P08779 Keratin, type I cytoskeletal 16 69.85 42.28 8 0.652 0.378 0.324 
P62917 60S ribosomal protein L8  69.05 59.14 16 0.784 1.197 0.672 
Q5F1R6 DnaJ homolog subfamily C member 21  11.97 7.16 2 0.723 0.662 0.420 
Q5VYK3 Proteasome-associated protein ECM29 homolog  68.99 12.09 16 0.775 0.767 0.675 
P18124 60S ribosomal protein L7 65.71 47.98 15 0.784 1.185 0.592 
Q96BS4 FBL protein (Fragment)  65.70 69.23 15 0.965 1.094 0.863 
Q9UHB9 Signal recognition particle subunit SRP68  64.48 33.81 16 0.982 1.324 0.853 
E9PFH4 Transportin-3 63.26 28.24 17 0.866 0.917 0.770 
P32969 60S ribosomal protein L9  63.02 61.46 12 0.816 1.146 0.645 
M0R0Y2 Alpha-soluble NSF attachment protein  6.35 8.98 2 1.480 1.370 0.878 
M0R3D6 60S ribosomal protein L18a (Fragment) 62.92 55.32 9 0.797 1.133 0.603 
A0A0D9SFL2 Bifunctional polynucleotide phosphatase/kinase 14.38 8.25 3 1.127 3.763 0.672 
P13647 Keratin, type II cytoskeletal 5  61.94 29.49 7 0.761 0.377 0.312 
A0A0C4DGS1 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit  11.83 9.11 3 1.506 1.233 0.900 
Q6FG43 FLOT2 protein  8.54 9.50 3 1.272 1.073 0.760 
F1JVV5 EWSR1/ATF1 fusion protein type 1 11.51 8.94 3 0.870 2.376 0.523 
A0A0A0MS07 Ig gamma-1 chain C region (Fragment)  6.37 5.08 2 1.039 0.873 0.630 
B2R7C5 DNA helicase 60.02 22.28 14 0.765 1.072 0.681 
P43487 Ran-specific GTPase-activating protein  6.88 9.95 2 0.994 0.753 0.606 
A0A0D9SFK2 Unconventional myosin-XVIIIa  58.81 12.32 16 0.933 1.064 0.599 
Q14554 Protein disulfide-isomerase A5  7.85 5.59 2 0.778 1.197 0.484 
H0Y465 Neurofibromin (Fragment) 22.30 4.28 6 1.046 1.510 0.653 
B2RAM6 Kinesin-like protein  58.77 18.75 15 0.727 1.105 0.638 
O76094 Signal recognition particle subunit SRP72 58.20 31.30 19 0.850 1.129 0.698 
Q7Z3Z9 L1 cell adhesion molecule (Fragment)  2.50 1.67 2 0.732 0.582 0.459 
H3BPZ1 Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 3  2.19 5.64 2 1.176 1.041 0.737 




Accession Description Score Coverage 
# Unique  Average Relative Abundance 
Peptides B-K562 G-K562 V-K562 
A0A087WXM6 60S ribosomal protein L17 (Fragment) 56.22 59.17 10 0.950 1.468 0.726 
Q02878 60S ribosomal protein L6 56.00 52.43 20 0.770 1.115 0.607 
O75475 PC4 and SFRS1-interacting protein 55.69 28.49 14 0.714 0.930 0.325 
Q7Z3N6 Putative uncharacterized protein DKFZp686A01173 (Fragment)  16.64 3.82 4 1.104 1.835 0.699 
A0A087WY71 AP-2 complex subunit mu 55.01 43.09 15 0.611 0.725 0.469 
O00567 Nucleolar protein 56  54.46 32.83 19 0.973 1.007 0.690 
P16402 Histone H1.3  53.18 33.03 2 0.716 1.824 0.635 
A0A024RC67 Protein regulator of cytokinesis 1, isoform CRA_e  53.03 24.68 16 0.772 1.093 0.626 
O60814 Histone H2B type 1-K  52.32 62.70 2 0.976 2.193 0.624 
Q8WYA6 Beta-catenin-like protein 1  51.57 28.95 14 0.756 0.884 0.679 
Q5SWX3 Calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma, isoform CRA_n 10.34 5.81 3 0.600 0.693 0.386 
P06899 Histone H2B type 1-J  51.50 62.70 2 0.976 2.187 0.560 
P62805 Histone H4  49.22 58.25 7 1.226 3.821 0.714 
O43684 Mitotic checkpoint protein BUB3  48.50 43.60 12 0.596 0.750 0.505 
P62888 60S ribosomal protein L30 48.04 77.39 9 0.825 1.179 0.538 
Q9NSY1 BMP-2-inducible protein kinase 22.43 9.22 5 0.643 0.672 0.421 
P62753 40S ribosomal protein S6  46.87 33.33 11 0.797 1.267 0.706 
G3V1D0 Echinoderm microtubule associated protein like 3, isoform CRA_f  12.88 7.76 4 0.763 0.948 0.502 
Q9BSQ6 RPL13A protein (Fragment)  45.85 49.75 15 0.799 1.184 0.610 
Q99848 Probable rRNA-processing protein EBP2 45.56 42.48 11 0.771 0.902 0.570 
G3V203 60S ribosomal protein L18 45.33 43.90 8 0.820 1.217 0.593 
Q08ES8 Cell growth-inhibiting protein 34 45.21 37.85 8 0.788 1.190 0.641 
Q04695 Keratin, type I cytoskeletal 17  45.12 29.17 4 0.712 0.175 0.142 
P46781 40S ribosomal protein S9  44.48 51.03 15 0.806 1.286 0.709 
Q12771 P37 AUF1 43.51 34.97 9 0.758 1.233 0.618 
P20042 Eukaryotic translation initiation factor 2 subunit 2 43.22 43.84 13 0.795 1.520 0.356 




Accession Description Score Coverage 
# Unique  Average Relative Abundance 
Peptides B-K562 G-K562 V-K562 
O94973 AP-2 complex subunit alpha-2  42.20 14.27 3 0.559 0.613 0.355 
P62081 40S ribosomal protein S7 41.74 48.45 9 0.979 1.457 0.854 
Q9Y490 Talin-1  30.62 4.92 6 1.089 2.079 0.758 
P26373 60S ribosomal protein L13 41.67 48.82 13 0.791 1.105 0.586 
A0RZB8 Diaphanous-1 40.99 13.79 11 0.943 1.373 0.833 
Q8IU60 m7GpppN-mRNA hydrolase  7.83 7.14 3 0.737 1.373 0.516 
P61011 Signal recognition particle 54 kDa protein  40.89 32.94 12 0.860 1.084 0.719 
A0A0A0MR02 Voltage-dependent anion-selective channel protein 2 (Fragment) 40.87 41.13 8 1.043 0.488 0.262 
Q15717 ELAV-like protein 1  40.57 32.52 8 0.656 0.759 0.577 
O75934 Pre-mRNA-splicing factor SPF27  40.46 44.44 9 0.794 0.927 0.713 
Q15019 Septin-2 39.55 37.12 9 0.555 0.947 0.465 
Q96HI4 Glycylpeptide N-tetradecanoyltransferase (Fragment) 39.11 21.46 8 1.146 0.872 0.243 
P62750 60S ribosomal protein L23a  39.07 55.13 11 0.895 1.413 0.637 
Q9UHB7 AF4/FMR2 family member 4 5.66 2.58 3 0.782 0.684 0.558 
E7EXA6 Chromosome transmission fidelity protein 18 homolog 7.18 3.38 2 0.904 1.259 0.650 
Q15061 WD repeat-containing protein 43  5.27 5.17 3 0.775 0.986 0.559 
P18754 Regulator of chromosome condensation 39.06 37.53 9 0.693 0.885 0.402 
Q96SB8 Structural maintenance of chromosomes protein 6  20.29 8.62 8 0.929 1.190 0.672 
A8K9K1 Calcium-transporting ATPase  8.99 3.61 3 0.856 1.075 0.620 
B5BUB5 Autoantigen La (Fragment) 38.51 33.33 13 0.761 1.338 0.630 
P46778 60S ribosomal protein L21  37.96 49.38 11 0.794 1.211 0.622 
A6NHN7 Zinc finger MYM-type protein 3  37.67 10.39 11 0.952 1.075 0.800 
P60891 Ribose-phosphate pyrophosphokinase 1 37.41 31.45 5 0.409 0.307 0.110 
P02008 Hemoglobin subunit zeta 36.54 76.76 9 0.814 1.031 0.704 
E4W6B6 RPL27/NME2 fusion protein (Fragment) 35.75 57.14 8 0.796 1.150 0.561 
O43670 BUB3-interacting and GLEBS motif-containing protein ZNF207  17.13 8.16 4 0.620 0.802 0.456 




Accession Description Score Coverage 
# Unique  Average Relative Abundance 
Peptides B-K562 G-K562 V-K562 
Q8N9V7 Testis- and ovary-specific PAZ domain-containing protein 1  3.49 0.95 2 0.762 0.694 0.563 
Q96P70 Importin-9 20.39 9.13 4 0.866 1.161 0.641 
D6R9P3 Heterogeneous nuclear ribonucleoprotein A/B  34.86 37.50 8 0.687 0.832 0.574 
Q5SSJ5 Heterochromatin protein 1-binding protein 3 34.54 22.78 12 0.770 0.819 0.667 
Q8TED0 U3 small nucleolar RNA-associated protein 15 homolog 34.42 16.41 8 0.928 0.926 0.687 
P16104 Histone H2AX  34.00 64.34 4 0.925 1.622 0.592 
Q9BW19 Kinesin-like protein KIFC1  33.74 21.25 11 0.816 1.246 0.644 
Q8TDN6 Ribosome biogenesis protein BRX1 homolog 33.53 28.90 11 0.743 0.878 0.503 
D3YTB1 60S ribosomal protein L32 (Fragment)  33.18 56.39 10 0.815 1.278 0.613 
A0A0J9YWM9 U3 small nucleolar RNA-associated protein 4 homolog (Fragment) 14.46 9.20 4 1.100 1.202 0.825 
Q9UG63 ATP-binding cassette sub-family F member 2 32.91 19.10 11 0.936 1.373 0.795 
Q9NW13 RNA-binding protein 28  32.79 16.60 10 0.734 1.308 0.643 
P31942 Heterogeneous nuclear ribonucleoprotein H3  31.65 25.72 7 0.645 0.572 0.433 
J3QR09 Ribosomal protein L19  30.38 44.56 11 0.783 1.123 0.679 
Q9Y6M1 Insulin-like growth factor 2 mRNA-binding protein 2  30.11 17.53 6 0.697 1.033 0.592 
P15924 Desmoplakin  2.80 0.84 2 0.653 0.822 0.499 
P27824 Calnexin 29.97 16.39 9 2.007 0.869 0.720 
B7Z7P8 Eukaryotic peptide chain release factor subunit 1  29.79 22.22 8 0.784 1.375 0.671 
Q96F86 Enhancer of mRNA-decapping protein 3 29.65 22.83 8 0.724 0.877 0.510 
Q16777 Histone H2A type 2-C 29.58 55.04 2 0.769 2.297 0.571 
Q9UKD2 mRNA turnover protein 4 homolog 29.55 36.82 9 0.871 1.248 0.709 
H3BN98 Uncharacterized protein (Fragment) 29.33 26.58 2 1.178 1.078 0.762 
Q96PK6 RNA-binding protein 14 28.25 16.59 9 0.677 0.817 0.601 
A0A024RDA1 Exocyst complex component 1, isoform CRA_a 28.04 11.83 7 0.643 0.832 0.572 
E7EQV9 Ribosomal protein L15 (Fragment)  27.97 56.32 11 0.803 1.231 0.614 
C9J0I9 Nuclear-interacting partner of ALK 27.86 17.65 5 0.794 0.727 0.712 




Accession Description Score Coverage 
# Unique  Average Relative Abundance 
Peptides B-K562 G-K562 V-K562 
P46779 60S ribosomal protein L28 27.79 48.91 8 0.829 1.210 0.577 
B4DUD5 cDNA FLJ58787 26.62 15.01 5 0.616 0.839 0.528 
P50914 60S ribosomal protein L14  26.34 43.72 12 0.757 1.141 0.552 
P53999 Activated RNA polymerase II transcriptional coactivator p15 26.27 68.50 8 1.135 0.783 0.183 
B2R860 cDNA, FLJ93752 25.94 23.58 4 0.465 0.510 0.277 
P46063 ATP-dependent DNA helicase Q1 25.66 16.49 9 0.637 1.393 0.399 
E7EU96 Casein kinase II subunit alpha 25.49 19.74 5 1.099 1.443 0.951 
Q9UES0 SNARE protein Ykt6 (Fragment)  25.38 37.70 7 0.900 0.804 0.631 
P63173 60S ribosomal protein L38  25.19 50.00 4 1.098 1.559 0.913 
O75531 Barrier-to-autointegration factor 24.98 73.03 6 1.351 2.093 0.795 
P46087 Probable 28S rRNA (cytosine(4447)-C(5))-methyltransferase  24.57 13.18 7 0.947 1.565 0.662 
Q9H8H0 Nucleolar protein 11  24.57 11.40 9 0.859 0.972 0.659 
O75569 Interferon-inducible double-stranded RNA-dependent protein kinase activator A  24.08 29.07 7 0.658 1.086 0.578 
P18077 60S ribosomal protein L35a 23.96 58.18 8 0.766 1.117 0.556 
Q5QPL9 RNA-binding protein Raly (Fragment)  23.77 44.30 10 0.607 0.611 0.517 
Q9NQT5 Exosome complex component RRP40  23.66 30.91 6 0.782 0.832 0.690 
P61513 60S ribosomal protein L37a  23.42 45.65 5 0.809 1.195 0.624 
F8VZJ2 Nascent polypeptide-associated complex subunit alpha  23.27 51.47 5 1.645 2.749 0.757 
P61254 60S ribosomal protein L26  23.13 40.00 10 0.880 1.331 0.703 
A0A024QYZ6 Exocyst complex component 3, isoform CRA_a  22.92 13.56 7 0.762 0.947 0.672 
Q6FI30 Nuclear factor 1 7.63 6.81 2 0.639 0.896 0.519 
Q96HX3 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 1 22.72 16.20 8 1.371 0.954 0.563 
F5H018 GTP-binding nuclear protein Ran (Fragment)  22.58 28.14 5 0.713 0.993 0.581 
Q8WXA9 Splicing regulatory glutamine/lysine-rich protein 1 22.43 17.13 2 0.803 1.079 0.694 
P62854 40S ribosomal protein S26 22.10 49.57 5 0.853 1.251 0.747 
Q92608 Dedicator of cytokinesis protein 2  32.20 6.23 9 0.750 0.362 0.611 




Accession Description Score Coverage 
# Unique  Average Relative Abundance 
Peptides B-K562 G-K562 V-K562 
F8VQE1 LIM domain and actin-binding protein 1  21.83 12.21 6 0.974 0.726 0.639 
Q0EFC6 HSR1 protein  4.32 2.94 2 0.901 1.060 0.738 
P51692 Signal transducer and activator of transcription 5B  21.41 12.07 8 0.719 1.150 0.639 
Q92522 Histone H1x  21.16 37.09 9 0.737 1.031 0.511 
J3QSY4 H/ACA ribonucleoprotein complex subunit 2  21.04 42.22 3 1.004 1.302 0.756 
P08240 Signal recognition particle receptor subunit alpha  6.25 5.96 2 1.000 0.995 0.824 
P62306 Small nuclear ribonucleoprotein F 21.02 24.42 3 0.759 1.120 0.665 
Q8IW76 EIF2AK2 protein (Fragment) 11.17 7.41 2 1.160 2.309 0.957 
M0QXD6 General transcription factor IIF subunit 1 (Fragment)  20.52 22.40 6 0.672 0.738 0.421 
P37108 Signal recognition particle 14 kDa protein  20.17 36.03 7 0.698 1.063 0.596 
Q00688 Peptidyl-prolyl cis-trans isomerase FKBP3 19.46 37.05 9 1.156 2.171 0.490 
H0Y4R1 Inosine-5'-monophosphate dehydrogenase 2 (Fragment)  19.37 16.38 5 0.450 0.202 0.132 
Q9UID3 Vacuolar protein sorting-associated protein 51 homolog 6.23 4.35 2 0.743 1.701 0.617 
B4DVE4 cDNA FLJ56793 19.15 16.30 6 0.828 1.126 0.719 
Q16643 Drebrin  18.93 13.56 7 1.182 0.769 0.611 
Q92979 Ribosomal RNA small subunit methyltransferase NEP1  18.70 29.51 6 0.693 0.588 0.532 
Q8IY33 MICAL-like protein 2 21.37 8.63 7 0.642 0.726 0.535 
A8K4B4 cDNA FLJ78441 9.81 8.62 3 0.620 0.928 0.517 
Q4VB87 EPB41 protein 18.64 12.36 4 1.599 0.589 0.387 
P21796 Voltage-dependent anion-selective channel protein 1  18.32 24.03 5 1.011 0.614 0.457 
P46776 60S ribosomal protein L27a  18.07 36.49 7 0.810 1.281 0.724 
Q7L576 Cytoplasmic FMR1-interacting protein 1  24.10 6.38 7 0.764 1.044 0.639 
Q9Y266 Nuclear migration protein nudC  17.68 25.08 8 1.160 2.506 1.017 
Q7Z524 HUMEEP  17.46 12.80 4 0.995 1.638 0.663 
P41223 Protein BUD31 homolog 17.19 41.67 5 0.818 1.332 0.680 
F8VYY9 5'-AMP-activated protein kinase subunit gamma-1  17.02 13.21 3 0.750 0.822 0.555 




Accession Description Score Coverage 
# Unique  Average Relative Abundance 
Peptides B-K562 G-K562 V-K562 
P14618 Pyruvate kinase PKM 16.48 16.57 5 0.884 0.937 0.795 
A0A024RAC0 Leucine zipper protein 1, isoform CRA_a 13.92 6.04 5 0.818 1.005 0.691 
P61221 ATP-binding cassette sub-family E member 1  16.10 12.69 6 0.833 0.936 0.713 
P0C0S5 Histone H2A.Z  16.09 53.91 3 0.979 1.565 0.440 
P49207 60S ribosomal protein L34  15.88 41.88 6 0.783 1.201 0.587 
P61927 60S ribosomal protein L37 15.49 41.24 7 0.849 1.295 0.700 
P60953 Cell division control protein 42 homolog 15.49 26.18 3 0.896 0.653 0.486 
A0A0S2Z5K3 DCP1 decapping enzyme-like protein A isoform 3 (Fragment)  15.02 11.72 5 0.828 1.231 0.602 
Q8WV22 Non-structural maintenance of chromosomes element 1 homolog  14.99 27.44 5 0.834 0.987 0.668 
B3KSJ3 cDNA FLJ36409 6.14 4.89 2 0.723 1.125 0.615 
E9PL38 26S proteasome non-ATPase regulatory subunit 13 (Fragment)  8.14 9.51 2 0.713 0.504 0.606 
Q8IVI9 Nostrin  14.96 12.65 4 0.782 1.018 0.338 
P39880 Homeobox protein cut-like 1 28.06 7.44 10 0.665 1.058 0.566 
Q9NPQ8 Synembryn-A  14.70 12.24 5 0.854 0.842 0.718 
I3L1K6 Myosin light chain 4 (Fragment) 14.56 30.81 5 0.975 1.128 0.763 
A0A0S2Z476 Proteasome 26S subunit non-ATPase 12 isoform 2  14.13 10.13 3 0.803 0.693 0.706 
P55010 Eukaryotic translation initiation factor 5 13.64 12.53 4 1.299 2.133 0.617 
P53680 AP-2 complex subunit sigma  13.25 28.17 5 0.608 0.784 0.524 
H3BQN4 Fructose-bisphosphate aldolase  13.10 16.62 5 1.063 1.641 0.713 
P49458 Signal recognition particle 9 kDa protein  12.95 40.70 4 0.778 1.262 0.536 
Q9BRZ2 E3 ubiquitin-protein ligase TRIM56 17.92 8.34 5 0.673 0.831 0.578 
Q13131 5'-AMP-activated protein kinase catalytic subunit alpha-1  6.51 9.66 4 0.718 0.846 0.619 
P07355 Annexin A2  12.49 13.57 4 0.850 1.003 0.745 
O60732 Melanoma-associated antigen C1  8.68 4.03 4 0.687 1.330 0.593 
Q96GW1 Endoplasmin  11.95 13.65 3 1.292 1.168 0.878 
Q0VDF9 Heat shock 70 kDa protein 14  11.56 10.02 5 0.752 1.210 0.606 




Accession Description Score Coverage 
# Unique  Average Relative Abundance 
Peptides B-K562 G-K562 V-K562 
C9J9W2 LIM and SH3 domain protein 1 (Fragment) 10.91 22.29 4 0.450 0.425 0.362 
A0A024R326 Ribosomal protein L29, isoform CRA_a 10.76 31.21 6 0.806 1.433 0.655 
Q5U071 High-mobility group box 2  10.28 12.50 2 1.706 2.773 0.386 
Q9Y3U8 60S ribosomal protein L36  10.15 40.95 4 0.785 1.216 0.671 
Q4LE74 MYO9B variant protein (Fragment)  14.05 1.97 3 0.602 0.851 0.523 
P0DMU6 Cancer/testis antigen family 45 member A4  9.94 21.69 4 0.602 0.848 0.352 
P61224 Ras-related protein Rap-1b  9.59 17.93 3 1.675 0.882 0.708 
A0A024R5H8 RAB6A, member RAS oncogene family, isoform CRA_b 9.44 16.35 2 1.206 0.925 0.761 
P09429 High mobility group protein B1 9.06 32.09 6 1.522 3.261 0.665 
Q5T6U8 High mobility group AT-hook 1  8.89 41.67 5 0.975 1.575 0.405 
Q86TJ2 Transcriptional adapter 2-beta 10.98 8.81 3 0.927 1.632 0.810 
Q5HYL6 Putative uncharacterized protein DKFZp686E1899 8.63 14.49 3 0.806 1.174 0.670 
P35244 Replication protein A 14 kDa subunit 8.39 25.62 2 0.810 1.251 0.569 
P13984 General transcription factor IIF subunit 2  8.16 14.86 3 0.749 0.862 0.635 
H3BMH2 Ras-related protein Rab-11A (Fragment)  7.84 20.65 3 0.898 0.911 0.734 
A0A075BPP5 Methyl CpG binding protein 2 (Fragment) 7.66 11.74 3 0.853 1.908 0.662 
Q9H444 Charged multivesicular body protein 4b 7.51 11.61 2 1.837 1.479 0.969 
Q5HY57 Emerin 7.45 12.33 2 1.143 0.802 0.476 
F2Z2Y6 U6 snRNA-associated Sm-like protein LSm8 7.34 38.81 2 0.763 1.287 0.685 
B3GQE6 DEAD box polypeptide 27  12.53 6.67 5 0.802 1.142 0.704 
A4UCT1 Glyceraldehyde 3-phosphate dehydrogenase (Fragment) 7.29 16.27 2 0.794 0.970 0.431 
A0A024RAC6 Transcription elongation factor B  13.38 6.87 3 0.800 1.222 0.704 
K7EJ44 Profilin 1, isoform CRA_b 7.19 21.15 2 1.069 1.057 0.526 
F8VPF3 Myosin light polypeptide 6 (Fragment)  7.02 25.38 3 0.821 1.368 0.673 
A0A024R5L7 Phosphatidylinositol binding clathrin assembly protein, isoform CRA_c 10.05 4.10 2 1.013 1.588 0.891 
P31151 Protein S100-A7  7.00 31.68 2 2.913 6.875 1.885 




Accession Description Score Coverage 
# Unique  Average Relative Abundance 
Peptides B-K562 G-K562 V-K562 
E9PI77 Baculoviral IAP repeat-containing protein 2 (Fragment) 6.72 20.14 2 0.573 0.620 0.478 
D3DU05 Tousled-like kinase 2, isoform CRA_a  25.16 7.33 2 0.673 0.883 0.595 
P62820 Ras-related protein Rab-1A 6.58 18.05 2 1.694 1.534 0.996 
P51571 Translocon-associated protein subunit delta 6.11 13.87 2 1.078 1.003 0.586 
C9IZZ0 Ras-related protein Rab-7a (Fragment)  5.98 20.69 2 1.117 1.391 0.860 
P12318 Low affinity immunoglobulin gamma Fc region receptor II-a 5.81 11.99 3 1.663 0.711 1.325 
Q5G0E1 2-5-3p (Fragment) 5.71 11.20 3 0.892 1.318 0.758 
Q32NB1 RRBP1 protein (Fragment)  5.57 22.84 2 0.730 0.970 0.630 
J3KND1 Protein SAAL1 8.87 8.03 3 1.050 1.288 0.934 
P43362 Melanoma-associated antigen 9  5.41 13.65 2 0.658 0.708 0.561 
Q96MX6 WD repeat-containing protein 92 6.58 8.12 2 0.759 0.980 0.677 
B1AKQ8 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (Fragment)  5.36 19.44 2 1.476 0.807 0.618 
P19105 Myosin regulatory light chain 12A  5.33 17.54 3 0.858 0.707 0.301 
B7Z4K8 cDNA FLJ52869 11.70 9.41 3 0.898 1.421 0.803 
Q6R327 Rapamycin-insensitive companion of mTOR 14.14 3.69 5 0.669 0.976 0.600 
Q01469 Fatty acid-binding protein, epidermal  4.83 21.48 3 0.616 0.722 0.508 
B4DWF4 cDNA FLJ55404 4.70 12.50 2 0.590 0.692 0.490 
Q06210 Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 1  16.61 6.29 3 0.803 1.200 0.721 
A0A0A0MRQ5 Peroxiredoxin-1 4.69 18.56 2 0.819 0.735 0.597 
B2R5H5 cDNA, FLJ92476 4.36 19.61 2 0.904 1.406 0.755 
P62273 40S ribosomal protein S29 3.49 35.71 3 0.932 1.298 0.792 
B4DJK4 cDNA FLJ54005, highly similar to Transcription elongation factor SPT5  2.19 2.84 2 0.811 0.945 0.729 
F5H1S8 Malectin (Fragment)  2.14 13.70 2 1.075 1.086 0.761 
Q15084 Protein disulfide-isomerase A6  5.53 6.14 2 0.936 1.186 0.843 
Q9NTA6 Putative uncharacterized protein DKFZp761I2124 (Fragment)  9.05 4.87 3 0.717 0.856 0.646 
Q7Z5Y0 EIF4B protein (Fragment)  5.91 7.45 2 1.231 1.819 1.114 




Accession Description Score Coverage 
# Unique  Average Relative Abundance 
Peptides B-K562 G-K562 V-K562 
D6W5C0 Spectrin, beta, non-erythrocytic 1, isoform CRA_b  13.15 2.33 3 0.844 1.562 0.769 
B4DVN5 cDNA FLJ55372 13.88 9.56 5 0.742 1.067 0.678 
Q96IB4 DIP2B protein (Fragment)  8.83 4.59 3 0.632 0.916 0.577 
Q0MQR4 Poly (ADP-ribose) glycohydrolase  12.73 4.71 4 0.751 1.332 0.687 
Q96MG7 Non-structural maintenance of chromosomes element 3 homolog  8.28 8.88 3 0.857 1.186 0.785 
O43747 AP-1 complex subunit gamma-1  10.16 4.50 4 0.834 1.268 0.764 
A8K8N3 cDNA FLJ78740 15.20 5.70 5 0.769 1.187 0.705 
A0A024R1Y2 ATP-citrate synthase  6.40 2.84 3 0.668 0.989 0.615 
A8K4P8 cDNA FLJ75337  6.75 1.84 2 0.893 1.011 0.824 
Q9UPU5 Ubiquitin carboxyl-terminal hydrolase 24 5.91 2.75 4 0.793 1.306 0.733 
O75529 TAF5-like RNA polymerase II p300/CBP-associated factor- 65 kDa subunit 5L 9.88 7.30 3 0.972 1.387 0.898 
B7ZKN7 BLM protein  6.14 2.78 3 0.933 1.135 0.865 
B9ZVT1 RNA-binding protein 12B  4.76 2.16 2 0.669 0.653 0.621 
O94874 E3 UFM1-protein ligase 1  5.52 2.90 2 0.910 1.036 0.848 
Q14566 DNA replication licensing factor MCM6 16.18 8.40 5 0.948 0.834 0.885 
Q5TIG5 Afadin  6.82 2.64 4 0.705 0.910 0.658 
Q8IYI6 Exocyst complex component 8  4.17 2.21 2 0.663 0.802 0.621 
Q05DA9 SFRS17A protein (Fragment)  4.75 6.16 2 0.886 1.045 0.831 
Q13595 Transformer-2 protein homolog alpha 4.72 8.16 2 0.666 0.951 0.627 
Q9H4H8 Protein FAM83D  10.14 8.89 3 0.678 0.825 0.638 
O75177 Calcium-responsive transactivator  7.96 9.60 2 0.802 0.882 0.760 
A4QPB0 IQ motif containing GTPase activating protein 1 32.49 6.88 9 0.830 1.402 0.787 
Q92888 Rho guanine nucleotide exchange factor 1  18.65 7.24 4 0.798 1.046 0.757 
A8K9S3 Coronin OS=Homo sapiens PE=2 SV=1 - [A8K9S3_HUMAN] 3.98 3.43 2 1.129 1.194 1.072 
O14578 Citron Rho-interacting kinase  35.18 7.10 13 0.699 0.869 0.664 
Q92973 Transportin-1  18.65 8.80 3 1.038 1.587 0.990 




Accession Description Score Coverage 
# Unique  Average Relative Abundance 
Peptides B-K562 G-K562 V-K562 
Q9H2G2 STE20-like serine/threonine-protein kinase 5.68 1.54 2 0.773 1.137 0.741 
A0A024DAK3 RNA-specific adenosine deaminase 23.87 7.67 9 0.648 0.729 0.622 
Q53H75 Chromosome 14 open reading frame 133 variant (Fragment)  5.23 4.67 3 0.772 2.665 0.741 
Q14692 Ribosome biogenesis protein BMS1 homolog  8.84 3.35 4 0.688 0.832 0.665 
O60673 DNA polymerase zeta catalytic subunit 2.52 0.61 2 0.686 1.059 0.664 
Q9H2K8 Serine/threonine-protein kinase TAO3  19.38 8.91 7 0.745 1.107 0.721 
Q99856 AT-rich interactive domain-containing protein 3A  12.17 5.40 3 0.881 1.747 0.856 
E9PBF6 Lamin-B1  8.38 8.01 2 0.813 1.722 0.791 
Q96BN2 Transcriptional adapter 1  5.04 6.27 2 0.932 1.146 0.907 
Q8IWQ7 Non-specific serine/threonine protein kinase 5.30 1.34 2 0.792 1.015 0.772 
A0A0C4DFL8 Lysine-specific demethylase 4B  3.00 4.01 2 0.675 1.089 0.660 
Q15042 Rab3 GTPase-activating protein catalytic subunit  6.74 4.28 3 1.031 1.613 1.013 
P26038 Moesin 9.48 6.24 2 0.869 1.317 0.854 
Q15050 Ribosome biogenesis regulatory protein homolog  9.15 9.04 3 0.586 0.687 0.578 
P85037 Forkhead box protein K1  5.11 3.55 3 0.635 1.151 0.628 
P57772 Selenocysteine-specific elongation factor  7.24 3.69 3 0.665 1.448 0.659 
Q15058 Kinesin-like protein KIF14  41.70 9.04 14 0.808 1.037 0.802 
Q14677 Clathrin interactor 1 11.69 7.52 4 0.898 1.108 0.894 
Q15555 Microtubule-associated protein RP/EB family member 2 8.79 9.48 2 0.718 1.049 0.716 
Q9H5Z1 Probable ATP-dependent RNA helicase DHX35 10.72 5.83 3 0.786 1.078 0.785 
E7EQZ4 Survival motor neuron protein 6.14 6.46 2 0.617 0.654 0.616 
 
